



B1

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup> :

C12Q 1/68, C07H 21/04, C12P 19/34

A1

(11) International Publication Number:

WO 99/10536

(43) International Publication Date:

4 March 1999 (04.03.99)

(21) International Application Number: PCT/US98/17284

(22) International Filing Date: 21 August 1998 (21.08.98)

(30) Priority Data:

60 056,844

22 August 1997 (22.08.97)

US

(71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YERRAMILLI, Subrahmanyam, V. [IN/US]; Apartment 103, 18453 Lost Knife Circle, Montgomery Village, MD 20886 (US). PRASHAR, Yatindra [IN/US]; 15 Mountain Lake Court, Germantown, MD 20874 (US). NEWBURGER, Peter [US/US]; 165 Winsor Road, Waban, MA 02468 (US). GOGUEN, Jon [US/US]; 237 Brattle Street, Holden, MA 01520 (US). WEISSMAN, Sherman, M. [US/US]; 459 Saint Ronan Street, New Haven, CT 06511 (US).

(74) Agent: ADLER, Reid, G.; Morgan, Lewis &amp; Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).

(81) Designated States: AU, CA, IL, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

**Published***With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN GRANULOCYTIC CELLS

## (57) Abstract

The present invention comprises a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen or in a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen or isolated from a subject having a sterile inflammatory disease and comparing that profile to a profile prepared from quiescent granulocytic cells. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules. The invention also includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a granulocyte population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

## A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN GRANULOCYTIC CELLS

This application is related to application serial No. 08/510,032, serial No. 60/056,844 and application serial No. 08/688,514, all of which are herein incorporated by reference in their entirety. All published articles, patents and other publications cited throughout this application are herein incorporated by reference in their entirety.

### 5 Technical Field

This invention relates to compositions and methods useful to identify agents that modulate the response of granulocytes to inflammatory and infectious conditions.

### Background of the Invention

Granulocytes (*i.e.*, neutrophils, eosinophils and basophils) are involved in the  
10 immune response elicited by inflammation and infection.

#### *Inflammation*

Inflammation is a localized protective response elicited by injury or destruction of tissues which serves to destroy, dilute or wall off both the injurious agent and the injured tissue. It is characterized by fenestration of the microvasculature, leakages of  
15 the elements of blood into the interstitial spaces, and migration of leukocytes into the inflamed tissue. On a macroscopic level, this is usually accompanied by the familiar clinical signs of erythema, edema, tenderness (hyperalgesia), and pain. During this complex response, chemical mediators such as histamine, 5-hydroxytryptamine, various chemotactic factors, bradykinin, leukotrienes, and prostaglandins are released locally.  
20 Phagocytic cells migrate into the area, and cellular lysosomal membranes may be ruptured, releasing lytic enzymes. All of these events may contribute to the inflammatory response.

-2-

Inflammation is initiated by, among other things, trauma, tissue necrosis, infection or immune reactions. The immediate response is temporary vasoconstriction. Vasoconstriction is followed within seconds by the acute vascular response resulting in increased blood flow (hyperemia) and edema. The acute phase is also characterized by

5 the margination of polymorphonuclear white blood cells (neutrophils) next to endothelial cells, followed by emigration of neutrophils into the adjacent tissue. Margination is recognized by the lining up of neutrophils along the endothelium of vessels. Emigration occurs by passage of the inflammatory cells between endothelial cells.

#### 10 *Neutrophils*

Neutrophils are the first wave of cellular attack on invading organisms and are the characteristic cells of acute inflammation. The appearance of neutrophils in areas of inflammation may be caused by chemicals released from bacteria, factors produced nonspecifically from necrotic tissue or antibody reacting with antigen. Neutrophils use

15 an actin-rich cytoskeleton to move in a directed manner along a chemotactic gradient from the bloodstream to an inflammatory site where they ingest particles (*e.g.*, bacteria) and immune complexes bearing IgG (via FcR) and/or breakdown products of the complement component C3.

Neutrophils belong to a category of white blood cells known as

20 polymorphonuclear white blood cells. The blood cells with single nuclei (mononuclear cells) form the white blood cell population that includes macrophages, T and B cells. White blood cells that contain segmented nuclei are broadly classified as polymorphonuclear. Polymorphonuclear white blood cells (or "granulocytes") are further subdivided into three major populations on the basis of the staining properties of

25 their cytoplasmic granules in standard hematologic smears or tissue preparations: neutrophils staining pink, eosinophils staining red and basophils staining blue.

-3-

Neutrophils (also referred to as polymorphonuclear neutrophils-PMNs) make up 50% to 70% of the white blood cells (WBCs) of the peripheral blood and may be found scattered diffusely in many tissues, although they are most frequently found in areas of acute inflammation or acute necrosis. Like other WBCs, neutrophils are produced from precursor cells in the bone marrow and released into the blood when mature. After entering the circulation, neutrophils are thought to last only 1 or 2 days.

Neutrophils are characterized by numerous cytoplasmic granules that contain highly destructive enzymes that must be kept isolated from the cytoplasm. These granules contain a number of oxygen-independent enzymes as well as oxygen-dependent mechanisms of killing. Upon attraction to sites of inflammation, neutrophils attempt to engulf and digest bacteria coated with antibody and complement. Phagocytosis by neutrophils is also usually accompanied by release of the lysosomal enzymes into the tissue spaces, particularly if the organism is difficult for the neutrophil to digest

At least three cytoplasmic granules are identifiable in neutrophils: specific granules containing lactoferrin, B cytochrome, the complement receptor CR3 and  $\beta_2$ -integrin; azurophilic granules containing acid hydrolases and other enzymes; and a third granule containing gelatinase.

In addition to the role neutrophils and other granulocytic cells play in immune response to pathogens, including bacterial infection, neutrophils and other granulocytic cells play an unwanted role in many chronic inflammatory diseases. There are many disease states in which excessive or unregulated granulocytic cell infiltration and activation are implicated in exacerbating and/or causing the disease. For instance, many inflammatory diseases are characterized by massive neutrophil infiltration, such as psoriasis, inflammatory bowel disease, Crohn's disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, rheumatoid arthritis, thrombosis and glomerulonephritis. All of these diseases are associated with increased IL-8

-4-

production which may be responsible for the chemotaxis of neutrophils into the inflammatory site.

While the role of neutrophil infiltration and activation in inflammation is well known, the biosynthetic responses of neutrophils to pathogens, chemotactic agents, 5 proinflammatory molecules, etc. are not as well understood. Neutrophils were once thought to be in a state of terminal differentiation, thereby lacking biosynthetic ability. This view is consistent with the relative scarcity in mature circulating neutrophils of ribosomes and endoplasmic reticulum and with the ability of neutrophils to ingest particles when RNA and/or protein synthesis has been inhibited. More recently it has 10 been demonstrated that neutrophils perform more active roles in their response to environmental stimuli.

It has thus recently been established that neutrophils synthesize *de novo* important macromolecules including, but not limited to interleukin (IL) 1, IL-6, IL-8, tumor necrosis factor (TNF $\alpha$ ), granulocyte and macrophage colony-stimulating factors, 15 interferon  $\alpha$  (IFN $\alpha$ ), intercellular adhesion molecule (ICAM-1) and membrane and cytoskeletal molecules, such as major histocompatibility class I antigens and actin (Beaulieu et al (1992) *J. Biolog. Chem.* 267(1):426-432; Arnold et al. (1993) *Infect. Immun.* 61(6):2545-2552; and Elsner et al. (1995) *Immunobiol* 193:456-464). No study, however, has taken a systematic approach to assess the transcriptional response 20 during neutrophil activation via contact with a pathogen or from neutrophils isolated from a subject with a sterile inflammatory disease.

### *Eosinophils and Basophils*

Eosinophils are another granulocytic or polymorphonuclear white blood cell that are involved in the inflammatory response. Eosinophils are found predominately in 25 two types of inflammation: allergy and parasite infections.

The role of eosinophils in the host response to parasites is thought to be mediated through the components of the eosinophilic granules. Eosinophils are

-5-

cytotoxic to schistosome larvae through an antibody-dependent cell-mediated mechanism. Eosinophil cationic proteins are highly toxic for schistosomes and may be responsible for binding of eosinophils to parasitic worms as well as fragmentation of the parasite.

5       The role of eosinophils in acute inflammation is not fully understood. On one hand, there is evidence that enzymes in eosinophils may serve to limit the extent of inflammation by neutralizing mediators of anaphylaxis, such as LTC<sub>4</sub>, histamine and platelet-activating factor. On the other hand, there is increasing evidence that cationic proteins in eosinophilic granules are mediators of acute inflammation. Eosinophil  
10 activation is associated with acute tissue injury and cause an intense vasoconstriction in lung microvasculature, followed by increased pulmonary vascular permeability and pulmonary edema.

Basophils or mast cells are the other major cell type characterized as a granulocytic or polymorphonuclear white blood cell. Mast cells contain granules with a  
15 variety of biologically active agents which, when released extracellularly (degranulation), cause dilation of the smooth muscle of arterioles (vasodilation), increased blood flow, and contraction of endothelial cells, thereby opening up vessel walls to permit egress of antibodies, complement or inflammatory cells into tissue spaces.

## 20 Summary of the Invention

While the role of neutrophils and other granulocytic cells in inflammation and/or the immunological response to infection has been the subject of intense study, little is known about the global transcriptional response of granulocytes during cell activation. The present inventors have devised an approach to systematically assess the  
25 transcriptional response from granulocytic cells activated through contact with a pathogen or from granulocytic cells isolated from a subject with a sterile inflammatory disease.

-6-

The present invention includes a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen and comparing that profile to a profile prepared from quiescent granulocytic cells. cDNA species, and therefore genes, which are expressed *de novo* upon neutrophil contact with a pathogen are thereby identified. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules.

The present invention also includes a method to identify granulocytic cell genes that are differentially expressed in response to a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population isolated from a subject exhibiting the symptoms of a sterile inflammatory disease and comparing that profile to a profile prepared from granulocytic cells isolated from a normal granulocytic cell population. cDNA species, and therefore genes, which are differentially expressed in the granulocytic cells of a subject exhibiting the symptoms of a sterile inflammatory disease are thereby identified.

The present invention also includes a method to identify granulocytic cell genes that are differentially expressed upon exposure of a granulocytic cell population to an agonist (pro-inflammatory molecule) by preparing a gene expression profile of a granulocytic cell population contacted with an agonist and comparing that profile to a profile prepared from noncontacted granulocytic cells, thereby identifying cDNA species, and therefore genes, which are expressed *de novo* in the granulocytic cells contacted with the agonist are thereby identified.

The present invention further includes a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte population to a pathogen, comprising the steps of preparing a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to a pathogen, treating said exposed granulocyte



-7-

population with the agent, preparing a third gene expression profile of the treated granulocyte population, comparing the first, second and third gene expression profiles and identifying agents that modulate the response of a granulocyte population to the pathogen.

- 5 Another aspect of the invention is a method to identify a therapeutic agent that modulates the expression of genes in a granulocyte population found in a subject having
- Another aspect of the invention includes a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte cell population in a subject having a sterile inflammatory disease, comprising the steps of preparing a first
- 10 gene expression profile of a granulocyte population in a subject having a sterile inflammatory disease, treating the granulocyte population with the agent, preparing a second gene expression profile of the treated granulocyte population, comparing the first and second gene expression profiles with the gene expression profile of a normal granulocyte population and identifying agents that modulate the expression of genes
- 15 whose transcription levels are altered in the granulocyte population of the subject as compared with normal granulocyte population.

- A further aspect of the present invention is a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocytic population to an agonist (pro-inflammatory molecule), comprising the steps of preparing a first gene
- 20 expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to an agonist, treating the exposed granulocyte population with the agent, preparing a third gene expression profile of the treated granulocyte population, comparing the first, second and third gene expression profiles and identifying agents that modulate the response of a granulocytic
- 25 population exposed to an agonist.

The present invention also includes a method of diagnosing the exposure of a subject to a pathogen, comprising the steps of preparing a first gene expression profile of a granulocyte population from the subject, comparing the first gene expression

-8-

profile to a second gene expression profile of a granulocyte population exposed to that pathogen and to a third gene expression profile of a normal granulocyte preparation and diagnosing whether the subject has been exposed to a pathogen.

Another aspect of the invention includes a method of diagnosing a sterile  
5 inflammatory disease in a subject, comprising the steps of preparing a first gene expression profile of a granulocyte population from the subject, comparing the first gene expression profile to at least one second gene expression profile from a granulocyte population from a subject having a sterile inflammatory disease and to a third gene expression profile of a normal granulocyte preparation and thereby  
10 determining if the subject has a sterile inflammatory disease.

The present invention also includes a method of identifying new bacterial virulence factor genes by preparing a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to a virulent or avirulent bacterial strain, preparing a third gene  
15 expression profile from a granulocyte population exposed to a bacterial strain with a mutation in a putative bacterial virulence factor gene, comparing the first, second and third gene expression profiles and identifying a bacterial virulence factor gene.

Another aspect of the invention is a composition comprising a grouping of nucleic acids that correspond to at least a part of one or more of the genes whose  
20 expression levels are modulated in a granulocyte population that has been exposed to a pathogen, these nucleic acids being affixed to a solid support.

Lastly, an aspect of the invention is a composition comprising a grouping of nucleic acids that correspond to at least part of one or more genes whose expression levels are modulated in a granulocyte population found in a subject having a sterile  
25 inflammatory disease, these nucleic acids being affixed to a solid support.

#### **Brief Description of the Drawings**

-9-

Fig. 1 Figure 1 is an autoradiogram of the expression profile generated from cDNAs made with RNA isolated from neutrophils exposed to avirulent *Escherichia coli* and virulent and avirulent *Yersinia pestis*.

Fig. 2 Figure 2 is an autoradiogram of the expression profile generated from  
5 cDNAs made with RNA isolated from neutrophils exposed to virulent and avirulent *E. coli*, virulent and avirulent *Y. pestis*, LPS, GM-CSF, TNF $\alpha$ , or  $\gamma$ IFN.

Fig. 3 Figure 3 is an autoradiogram of the expression profile generated from cDNAs made with RNA isolated from neutrophils exposed to avirulent *E. coli* and virulent and avirulent *Y. pestis*. All possible 12 anchoring oligo d(T)n1, n2 were used  
10 to generate a complete expression profile for the enzyme *Bgl*II.

Fig. 4 Figure 4 represents a summary of genes which are differentially expressed in neutrophils upon exposure to virulent and avirulent *E. coli* and *Y. pestis*.

Fig. 5 Figure 5 is an autoradiogram of the expression profile generated from cDNAs made with RNA isolated from neutrophils exposed to avirulent *E. coli* and  
15 virulent and avirulent *Y. pestis*. All possible 12 anchoring oligo d(T)n1, n2 were used to generate a complete expression profile for the enzyme *Bam*HI.

Fig. 6 is a section of an autoradiogram showing the differences in band intensity for 2 mRNA species when neutrophils are exposed to avirulent *E. coli* and virulent and avirulent *Y. pestis*.

## 20 Modes of Carrying Out the Invention

### General Description

The response of neutrophils to pathogens, including bacterial pathogens, is a subject of primary importance in view of the need to find ways to modulate the immune response to infection. Similarly, the response of neutrophils to agonists (pro-  
25 inflammatory molecules) is a subject of primary importance in view of the need to find better ways of controlling inflammation in various disease states. One means of assessing the response of neutrophils to pathogens and agonists is to measure the ability

-10-

of neutrophils to synthesize specific RNA *de novo* upon contact with the pathogen or agonist.

The following discussion presents a general description of the invention as well definitions for certain terms used herein.

## 5 Definitions

Granulocytic cells, also known as polymorphonuclear white blood cells, include neutrophils, also known as polymorphonuclear neutrophils or peripheral blood neutrophils, eosinophils, and basophils, also referred to as mast cells.

The term "pathogen" refers to any infectious organism including bacteria, viruses,  
 10 parasites, mycoplasma, protozoans, and fungi (including molds and yeast). Pathogenic bacteria include, but are not limited to Staphylococci (e.g. aureus), Streptococci (e.g. pneumoniae), Clostridia (e.g. perfringens), Neisseria (e.g. gonorrhoeae), Enterobacteriaceae (e.g. coli as well as Klebsiella, Salmonella, Shigella, Yersinia and Proteus), Helicobacter (e.g. pylori), Vibrio (e.g. cholerae), Campylobacter (e.g. jejuni),  
 15 Pseudomonas (e.g. aeruginosa), Haemophilus (e.g. influenzae), Bordetella (e.g. pertussis), Mycoplasma (e.g. pneumoniae), Ureaplasma (e.g. urealyticum), Legionella (e.g. pneumophila), Spirochetes (e.g. Treponema, Leptospira and Borrelia), Mycobacteria (e.g. tuberculosis, smegmatis), Actinomyces (e.g. israelii), Nocardia (e.g. asteroides), Chlamydia (e.g. trachomatis), Rickettsia, Coxiella, Ehrlichia, Rochalimaea,  
 20 Brucella, Yersinia, Francisella, and Pasteurella.

The term "sterile inflammatory disease" refers to any inflammatory disease caused by immune or nonimmune mechanisms not directly linked to infection (see Stewart *et al.*). Examples of sterile inflammatory diseases include, but are not limited to psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury,  
 25 thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and periodontal disease.

-11-

The phrase "solid support" refers to any support to which nucleic acids can be bound or immobilized, including nitrocellulose, nylon, glass, other solid supports which are positively charged and nanochannel glass arrays disclosed by Beattie (WO 95/1175).

The phrase "gene expression profile", also referred to as a "differential expression  
5 profile" or "expression profile" refers to any representation of the expression of at least one mRNA species in a cell sample or population. For instance, a gene expression profile can refer to an autoradiograph of labeled cDNA fragments produced from total cellular mRNA separated on the basis of size by known procedures. Such procedures include slab gel electrophoresis, capillary gene electrophoresis, high performance liquid  
10 chromatography, and the like. Digitized representations of scanned electrophoresis gels are also included as are two and three dimensional representations of the digitized data.

While a gene expression profile encompasses a representation of the expression level of at least one mRNA species, in practice, the typical gene expression profile represents the expression level of multiple mRNA species. For instance, a gene expression profile  
15 useful in the methods and compositions disclosed herein represents the expression levels of at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population. Particularly preferred are gene expression profiles or arrays affixed to a solid support that contain a sufficient representative number of mRNA species whose expression  
20 levels are modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In some instances a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100.

Gene expression profiles can be produced by any means known in the art, including, but not limited to the methods disclosed by: Liang *et al.* (1992) *Science* 257:967-971;  
25 Ivanova *et al.* (1995) *Nucleic Acids Res.* 23:2954-2958; Guilfoyl *et al.* (1997) *Nucleic Acids Res.* 25(9):1854-1858; Chee *et al.* (1996) *Science* 274:610-614; Velculescu *et al.* (1995) *Science* 270:484-487; Fischer *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92(12):5331-5335; and Kato (1995) *Nucleic Acids Res.* 23(18):3685-3690. Preferably,

-12-

gene expression profiles are produced by the methods of Prashar *et al.* (WO 97/05286) and Prashar *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663.

As an example, gene expression profiles as described herein are made to identify one or more genes whose expression levels are modulated in a granulocytic cell population  
5 exposed to a pathogen or isolated from a subject having a sterile inflammatory disease. The assaying of the modulation of gene expression via the production of a gene expression profile generally involves the production of cDNA from polyA RNA (mRNA) isolated from granulocytes as described below.

The mRNAs are isolated from a granulocytic cell source. The cells may be obtained  
10 from an *in vivo* source, such as a peripheral blood. As is apparent to one skilled in the art, any granulocytic cell type may be used, however, neutrophils are preferred. Furthermore, the peripheral blood cells that are initially obtained may be subjected to various separation techniques (*e.g.*, flow cytometry, density gradients).

mRNAs are isolated from cells by any one of a variety of techniques. Numerous  
15 techniques are well known (*see e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Approach*, Cold Spring harbor Press, NY, 1987; Ausubel *et.*, *Current Protocols in Molecular Biology*, Greene Publishing Co. NY, 1995). In general, these techniques first lyse the cells and then enrich for or purify RNA. In one such protocol. Cells are lysed in a Tris-buffered solution containing SDS. The lysate is extracted with  
20 phenol/chloroform, and nucleic acids are precipitated. Purification of poly(A)-containing RNA is not a requirement. The mRNAs may, however, be purified from crude preparations of nucleic acids or from total RNA by chromatography, such as binding and elution from oligo(dT)-cellulose or poly(U)-Sephadex®. As stated above, other protocols and methods for isolation of RNAs may be substituted.

25 The mRNAs are reverse transcribed using an RNA-directed DNA polymerase, such as reverse transcriptase isolated from AMV, MoMuLV or recombinantly produced. Many commercial sources of enzyme are available (*e.g.*, Pharmacia, New England Biolabs, Stratagene Cloning Systems). Suitable buffers, cofactors, and conditions are well

-13-

known and supplied by manufacturers (*see also*, Sambrook *et al.*, *supra*; Ausubel *et al.*, *supra*).

Various oligonucleotides are used in the production of cDNA. In particular, the methods utilize oligonucleotide primers for cDNA synthesis, adapters, and primers for amplification. Oligonucleotides are generally synthesized as single strands by standard chemistry techniques, including automated synthesis. Oligonucleotides are subsequently de-protected and may be purified by precipitation with ethanol, chromatographed using a sized or reversed-phase column, denaturing polyacrylamide gel electrophoresis, high-pressure liquid chromatography (HPLC), or other suitable method. In addition, within certain preferred embodiments, a functional group, such as biotin, is incorporated preferably at the 5' or 3' terminal nucleotide. A biotinylated oligonucleotide may be synthesized using pre-coupled nucleotides, or alternatively, biotin may be conjugated to the oligonucleotide using standard chemical reactions. Other functional groups, such as fluorescent dyes, radioactive molecules, digoxigenin, and the like, may also be incorporated.

Partially-double stranded adaptors are formed from single stranded oligonucleotides by annealing complementary single-stranded oligonucleotides that are chemically synthesized or by enzymatic synthesis. Following synthesis of each strand, the two oligonucleotide strands are mixed together in a buffered salt solution (*e.g.*, 1 M NaCl, 20 100 mM Tris-HCl pH.8.0, 10 mM EDTA) or in a buffered solution containing  $Mg^{2+}$  (*e.g.*, 10 mM  $MgCl_2$ ) and annealed by heating to high temperature and slow cooling to room temperature.

The oligonucleotide primer that primes first strand DNA synthesis comprises a 5' sequence incapable of hybridizing to a polyA tail of the mRNAs, and a 3' sequence that hybridizes to a portion of the polyA tail of the mRNAs and at least one non-polyA nucleotide immediately upstream of the polyA tail. The 5' sequence is preferably a sufficient length that can serve as a primer for amplification. The 5' sequence also preferably has an average G+C content and does not contain large palindromic

-14-

sequence; some palindromes, such as a recognition sequence for a restriction enzyme, may be acceptable. Examples of suitable 5' sequences are

CTCTCAAGGATC:TACCGCT (SEQ ID No. \_\_\_\_\_),

CAGGGTAGACGACGCTACGC (SEQ ID No. \_\_\_\_\_), and

5 TAATACCGCGCCACATAGCA (SEQ ID No. \_\_\_\_\_).

The 5' sequence is joined to a 3' sequence comprising sequence that hybridizes to a portion of the polyA tail of mRNAs and at least one non-polyA nucleotide immediately upstream. Although the polyA-hybridizing sequence is typically a homopolymer of dT or dU, it need only contain a sufficient number of dT or dU bases to hybridize to polyA  
10 under the conditions employed. Both oligo-dT and oligo-dU primers have been used and give comparable results. Thus, other bases may be interspersed or concentrated, as long as hybridization is not impeded. Typically, 12 to 18 bases or 12 to 30 bases of dT or dU will be used. However, as one skilled in the art appreciates, the length need only be sufficient to obtain hybridization. The non-polyA nucleotide is A, C, or G, or a  
15 nucleotide derivative, such as inosinate. If one non-polyA nucleotide is used, then three oligonucleotide primers are needed to hybridize to all mRNAs. If two non-polyA nucleotides are used, then 12 primers are needed to hybridize to all mRNAs (AA, AC, AG, AT, CA, CC, CG, CT, GA, GC, GG, GT). If three non-poly A nucleotides are used then 48 primers are needed (3 X 4 X 4). Although there is no theoretical upper  
20 limit on the number of non-polyA nucleotides, practical considerations make the use of one or two non-polyA nucleotides preferable.

For cDNA synthesis, the MRNAs are either subdivided into three (if one non-polyA nucleotide is used) or 12 (if two non-polyA nucleotides are used) fractions, each containing a single oligonucleotide primer, or the primers may be pooled and contacted  
25 with a mRNA preparation. Other subdivisions may alternatively be used. Briefly, first strand cDNA is initiated from the oligonucleotide primer by reverse transcriptase (RTase). As noted above, RTase may be obtained from numerous sources and protocols are well known. Second strand synthesis may be performed by RTase

**SUBSTITUTE SHEET (RULE 26)**



-15-

(Gubler and Hoffman, *Gene* 25: 263, 1983), which also has a DNA-directed DNA polymerase activity, with or without a specific primer, by DNA polymerase I in conjunction with RNaseH and DNA ligase, or other equivalent methods. The double-stranded cDNA is generally treated by phenol:chloroform extraction and ethanol  
5 precipitation to remove protein and free nucleotides.

Double-stranded cDNA is subsequently digested with an agent that cleaves in a sequence-specific manner. Such cleaving agents include restriction enzymes. Restriction enzyme digestion is preferred; enzymes that are relatively infrequent cutters (*e.g.*,  $\geq 5$  bp recognition site) are preferred and those that leave overhanging ends are  
10 especially preferred. A restriction enzyme with a six base pair recognition site cuts approximately 8% of cDNAs, so that approximately 12 such restriction enzymes should be needed to digest every cDNA at least once. By using 30 restriction enzymes, digestion of every cDNA is assured.

The adapters for use in the present invention are designed such that the two strands  
15 are only partially complementary and only one of the nucleic acid strands that the adapter is ligated to can be amplified. Thus, the adapter is partially double-stranded (*i.e.*, comprising two partially hybridized nucleic acid strands), wherein portions of the two strands are non-complementary to each other and portions of the two strands are complementary to each other. Conceptually, the adapter is "Y-shaped" or "bubble-  
20 shaped." When the 5' region is non-paired, the 3' end of other strand cannot be extended by a polymerase to make a complementary copy. The ligated adapter can also be blocked at the 3' end to eliminate extension during subsequent amplifications. Blocking groups include dideoxynucleotides or any other agent capable of blocking the 3'-OH. In this type of adapter ("Y-shaped"), the non-complementary portion of the  
25 upper strand of the adapters is preferably a length that can serve as a primer for amplification. As noted above, the non-complementary portion of the lower strand need only be one base, however, a longer sequence is preferable (*e.g.*, 3 to 20 bases; 3 to 15

-16-

bases; 5 to 15 bases; or 14 to 24 bases). The complementary portion of the adapter should be long enough to form a duplex under conditions of ligation.

For "bubble-shaped" adapters, the non-complementary portion of the upper strand is preferably a length that can serve as a primer for amplification. Thus, this portion is  
5 preferably 15 to 30 bases. Alternatively, the adapter can have a structure similar to the Y-shaped adapter, but has a 3' end that contains a moiety that a DNA polymerase cannot extend from.

Amplification primers are also used in the present invention. Two different amplification steps are performed in the preferred aspect. In the first, the 3' end  
10 (referenced to mRNA) of double stranded cDNA that has been cleaved and ligated with an adapter is amplified. For this amplification, either a single primer or a primer pair is used. The sequence of the single primer comprises at least a portion of the 5' sequence of the oligonucleotide primer used for first strand cDNA synthesis. The portion need only be long enough to serve as an amplification primer. The primer pair consists of a  
15 first primer whose sequence comprises at least a portion of the 5' sequence of the oligonucleotide primer as described above; and a second primer whose sequence comprises at least a portion of the sequence of one strand of the adapter in the non-complementary portion. The primer will generally contain all the sequence of the non-complementary portion, but may contain less of the sequence, especially when the non-  
20 complementary portion is very long, or more of the sequence, especially when the non-complementary portion is very short. In some embodiments, the primer will contain sequence of the complementary portion, as long as that sequence does not appreciably hybridize to the other strand of the adapter under the amplification conditions employed. For example, in one embodiment, the primer sequence comprises four bases  
25 of the complementary region to yield a 19 base primer, and amplification cycles are performed at 56°C (annealing temperature), 72°C (extension temperature), and 94°C (denaturation temperature). In another embodiment, the primer is 25 bases long and has 10 bases of sequence in the complementary portion. Amplification cycles for this

-17-

primer are performed at 68°C (annealing and extension temperature) and 94°C (denaturation temperature). By using these longer primers, the specificity of priming is increased.

The design of the amplification primers will generally follow well-known guidelines, such as average G-C content, absence of hairpin structures, inability to form primer-dimers and the like. At times, however, it will be recognized that deviations from such guidelines may be appropriate or desirable.

After amplification, the lengths of the amplified fragments are determined. Any procedure that separate nucleic acids on the basis of size and allows detection or identification of the nucleic acids is acceptable. Such procedures include slab gel electrophoresis, capillary gel electrophoresis, high performance liquid chromatography, and the like.

Electrophoresis is technique based on the mobility of DNA in an electric field. Negatively charged DNA migrates towards a positive electrode at a rate dependent on their total charge, size, and shape. Most often, DNA is electrophoresed in agarose or polyacrylamide gels. For maximal resolution, polyacrylamide is preferred and for maximal linearity, a denaturant, such as urea is present. A typical gel setup uses a 19:1 mixture of acrylamide:bisacrylamide and a Tris-borate buffer. DNA samples are denatured and applied to the gel, which is usually sandwiched between glass plates. A typical procedure can be found in Sambrook et al (*Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989) or Ausubel et al. (*Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995). Variations may be substituted as long as sufficient resolution is obtained.

Capillary electrophoresis (CE) in its various manifestations (free solution, isotachopheresis, isoelectric focusing, polyacrylamide gel, micellar electrokinetic "chromatography") allows high resolution separation of very small sample volumes. Briefly, in capillary electrophoresis, a neutral coated capillary, such as a 50  $\mu$ m X 37 cm column (eCAP neutral, Beckman Instruments, CA), is filled with a linear

-18-

- polyacrylamide (*e.g.*, 0.2% polyacrylamide), a sample is introduced by high-pressure injection followed by an injection of running buffer (*e.g.*, 1X TBE). the sample is electrophoresed and fragments are detected. An order of magnitude increase can be achieved with the use of capillary electrophoresis. Capillaries may be used in parallel
- 5 for increased throughput (Smith *et al.* (1990) *Nuc. Acids. Res.* 18:4417; Mathies and Huang (1992) *Nature* 359:167). Because of the small sample volume that can be loaded onto a capillary, sample may be concentrated to increase level of detection. One means of concentration is sample stacking (Chien and Burgi (1992) *Anal. Chem* 64:489A). In sample stacking, a large volume of sample in a low concentration buffer is introduced to
- 10 the capillary column. the capillary is then filled with a buffer of the same composition, but at higher concentration, such that when the sample ions reach the capillary buffer with a lower electric field, they stack into a concentrated zone. Sample stacking can increase detection by one to three orders of magnitude. Other methods of concentration, such as isotachopheresis, may also be used.
- 15 High-performance liquid chromatography (HPLC) is a chromatographic separation technique that separates compounds in solution. HPLC instruments consist of a reservoir of mobile phase, a pump, an injector, a separation column, and a detector. Compounds are separated by injecting an aliquot of the sample mixture onto the column. The different components in the mixture pass through the column at different
- 20 rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase. IP-RO-HPLC on non-porous PS/DVB particles with chemically bonded alkyl chains can also be used to analyze nucleic acid molecules on the basis of size (Huber *et al.* (1993) *Anal. Biochem.* 121:351; Huber *et al.* (1993) *Nuc. Acids Res.* 21:1061; Huber *et al.* (1993) *Biotechniques* 16:898).
- 25 In each of these analysis techniques, the amplified fragments are detected. A variety of labels can be used to assist in detection. Such labels include, but are not limited to, radioactive molecules (*e.g.*, <sup>35</sup>S, <sup>32</sup>P, <sup>33</sup>P) fluorescent molecules, and mass spectrometric

-19-

tags. The labels may be attached to the oligonucleotide primers or to nucleotides that are incorporated during DNA synthesis, including amplification.

Radioactive nucleotides may be obtained from commercial sources; radioactive primers may be readily generated by transfer of label from  $\gamma$ - $^{32}\text{P}$ -ATP to a 5'-OH group  
5 by a kinase (*e.g.*, T4 polynucleotide kinase). Detection systems include autoradiograph, phosphor image analysis and the like.

Fluorescent nucleotides may be obtained from commercial sources (*e.g.*, ABI, Foster city, CA) or generated by chemical reaction using appropriately derivatized dyes.

Oligonucleotide primers can be labeled, for example, using succinimidyl esters to  
10 conjugate to amine-modified oligonucleotides. A variety of florescent dyes may be used, including 6 carboxyfluorescein, other carboxyfluorescein derivatives, carboxyrhodamine derivatives, Texas red derivatives, and the like. Detection systems include photomultiplier tubes with appropriate wave-length filters for the dyes used. DNA sequence analysis systems, such as produced by ABI (Foster City, CA), may be  
15 used.

After separation of the amplified cDNA fragments, cDNA fragments which correspond to differentially expressed mRNA species are isolated, reamplified and sequenced according to standard procedures. For instance, bands corresponding the cDNA fragments can be cut from the electrophoresis gel, reamplified and subcloned  
20 into any available vector, including pCRscript using the PCR script cloning kit (Stratagene). The insert is then sequenced using standard procedures, such as cycle sequencing on an ABI sequencer.

An additional means of analysis comprises hybridization of the amplified fragments to one or more sets of oligonucleotides immobilized on a solid substrate. Historically, the  
25 solid substrate is a membrane, such as nitrocellulose or nylon. More recently, the substrate is a silicon wafer or a borosilicate slide. The substrate may be porous (Beattie *et al.* WO 95/11755) or solid. Oligonucleotides are synthesized in situ or synthesized prior to deposition on the substrate. Various chemistries are known for attaching

-20-

oligonucleotide. Many of these attachment chemistries rely upon functionalizing oligonucleotides to contain a primary amine group. The oligonucleotides are arranged in an array form, such that the position of each oligonucleotide sequence can be determined.

- 5 The amplified fragments, which are generally labeled according to one of the methods described herein, are denatured and applied to the oligonucleotides on the substrate under appropriate salt and temperature conditions. In certain embodiments, the conditions are chosen to favor hybridization of exact complementary matches and disfavor hybridization of mismatches. Unhybridized nucleic acids are washed off and
- 10 the hybridized molecules detected, generally both for position and quantity. The detection method will depend upon the label used. Radioactive labels, fluorescent labels and mass spectrometry label are among the suitable labels.

The present invention as set forth in the specific embodiments, includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a

15 granulocyte population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.

In general, the method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte population to a pathogen, comprises the steps of preparing

20 a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to a pathogen, treating the exposed granulocyte population with the agent, preparing a third gene expression profile of the treated granulocyte population, comparing the first, second and third gene expression profiles and identifying agents that modulate the response of a granulocytic

25 population to the pathogen.

In another format, the method is used to identify a therapeutic agent that modulates the expression of genes in a granulocyte population found in a subject having a sterile inflammatory disease. The general method comprises the steps of preparing a first gene

-21-

- expression profile of a granulocyte population in a subject having a sterile inflammatory disease, treating the granulocyte population with the agent, preparing a second gene expression profile of the treated granulocyte population, comparing the first and second gene expression profile with the gene expression profile of a normal granulocyte
- 5 preparation and identifying agents that modulate the expression of genes whose transcription levels are altered in the granulocyte population of the subject as compared with normal granulocyte population.

- While the above methods for identifying a therapeutic agent comprise the comparison of gene expression profiles from treated and not-treated granulocytic cells, many other
- 10 variations are immediately envisioned by one of ordinary skill in the art. As an example, as a variation of a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocytic population to a pathogen, the second gene expression profile of a granulocyte population exposed to a pathogen and the third gene expression profile of the treated granulocyte population can each be independently
- 15 normalized using the first gene expression profile prepared from a quiescent granulocyte population. Normalization of the profiles can easily be achieved by scanning autoradiographs corresponding to each profile, and subtracting the digitized values corresponding to each band on the autoradiograph from quiescent granulocytic cells from the digitized value for each corresponding band on autoradiographs
- 20 corresponding to the second and third gene expression profiles. After normalization, the second and third gene expression profiles can be compared directly to detect cDNA fragments which correspond to mRNA species which are differentially expressed upon exposure of the granulocyte population to the agent to be tested.

### **Specific Embodiments**

#### **25 Example 1**

*Production of gene expression profiles generated from cDNAs made with RNA isolated from neutrophils exposed to virulent and avirulent bacteria.*

-22-

Expression profiles of RNA expression levels from neutrophils exposed to various bacteria offer a powerful means of identifying genes that are specifically regulated in response to bacterial infection. As an example, the production of expression profiles from neutrophils exposed to virulent and avirulent *E. coli* and *Y. pestis* allow the

5 identification of neutrophil genes that are specifically regulated in response to bacterial infection.

Neutrophils were isolated from normal donor peripheral blood following the LPS-free method. Peripheral blood was isolated using a butterfly needle and a syringe containing 5 cc ACD, 5 cc of 6% Dextran (in normal saline). After 30 minutes of

10 settling, plasma was collected and HBSS (without  $\text{Ca}^{++}$  or  $\text{Mg}^{++}$ ) was added to a total volume of 40 ml. The plasma was centrifuged (1500 rpm, for 15 m at 4°C), the supernatant decanted and cold HBSS added to resuspend the cells. The cell suspension was then layered onto a cold Ficoll Hypaque, centrifuged at 500xg for 30m at 4°C. The pellet contains polymorphonuclear neutrophils. Neutrophils can also be isolated by

15 other commonly used methods such as those disclosed in *Current Protocols of Immunology* (John Wiley & Sons, Inc.), Babior *et al.* (1981) In: *Leukocyte Function*, Cline, M.J. Ed., p.1-38 (Church Livingstone, NY), and Haslett *et al.* (1985) *Am. J. Pathol.* 119:101-110.

Following isolation, neutrophils were incubated with *E. coli* or *Y. pestis*. Before

20 incubation, bacteria are harvested and washed in phosphate buffered saline and opsonized either autologous human serum or complement factor C7 deficient human serum (SIGMA). Incubation was at a ratio of approximately a PMN:bacteria ratio of 1:20 in RPMI 1640 (HEPES buffered) with heat inactivated Fetal Bovine Serum at 37°C with gentle mixing in a rotary shaker bath

25 As controls, neutrophils were incubated with either bacterial lipopolysaccharide (LPS) or latex beads. LPS was added to approximately  $3.38 \times 10^8$  cells in 100 ml of RPMI containing 6% autologous serum to a final concentration of 1 ng/ml to 1 µg/l. Incubation proceeded for 30 or 120 minutes with gentle rotation in disposable



-23-

polycarbonate Erlenmeyer flasks at 37°C. After incubation, the cells were spun down and washed once with HBSS.

Total cellular RNA was prepared from untreated and treated neutrophils as described above using the procedure of Newburger *et al.* (1981) *J. Biol. Chem.* 266(24): 16171-7 and Newburger *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5215-5219. Ten micrograms of total RNA, the amount obtainable from about  $3 \times 10^6$  neutrophils, is sufficient for a complete set of cDNA expression profiles.

Synthesis of cDNA was performed as previously described by Prashar *et al.* in WO 97/05286 and in Prashar *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663. Briefly, cDNA was synthesized according to the protocol described in the GIBCO/BRL kit for cDNA synthesis. The reaction mixture for first-strand synthesis included 6 µg of total RNA, and 200 ng of a mixture of 1-base anchored oligo(dT) primers with all three possible anchored bases (ACGTAATACGACTCACTATAGGGCGAATTGGGTCGACTTTTTTTTTTTTTTTT Tn1 wherein n1=A/C or G) along with other components for first-strand synthesis reaction except reverse transcriptase. This mixture was incubated at 65°C for 5m, chilled on ice and the process repeated. Alternatively, the reaction mixture may include 10 µg of total RNA, and 2 pmol of 1 of the 2-base anchored oligo(dT) primers a heel such as RP5.0 (CTCTCAAGGATCTTACCGCTT<sub>18</sub>AT), or RP6.0 (TAATACCGCGCCACATAGCAT<sub>18</sub>CG), or RP9.2 (CAGGGTAGACGACGCTACGCT<sub>18</sub>GA) along with other components for first-strand synthesis reaction except reverse transcriptase. This mixture was then layered with mineral oil and incubated at 65°C for 7 min followed by 50°C for another 7 min. At this stage, 2 µl of Superscript reverse transcriptase (200 units/µl; GIBCO/BRL) was added quickly and mixed, and the reaction continued for 1 hr at 45-50°C. Second-strand synthesis was performed at 16°C for 2 hr. At the end of the reaction, the cDNAs were precipitated with ethanol and the yield of cDNA was calculated. In our experiments, ≈200 ng of cDNA was obtained from 10 µg of total RNA.

-24-

The adapter oligonucleotide sequences were  
A1 (TAGCGTCCGGCGCAGCGACGGCCAG) and  
A2 (GATCCTGGCCGTCGGCTGTCTGTCGGCGC). One microgram of  
oligonucleotide A2 was first phosphorylated at the 5' end using T4 polynucleotide  
5 kinase (PNK). After phosphorylation, PNK was heated denatured, and 1  $\mu$ g of the  
oligonucleotide A1 was added along with 10 $\times$  annealing buffer (1 M NaCl/100 mM  
Tris-HCl, pH8.0/10 mM EDTA, pH8.0) in a final vol of 20  $\mu$ l. This mixture was then  
heated at 65°C for 10 min followed by slow cooling to room temperature for 30 min,  
resulting in formation of the Y adapter at a final concentration of 100 ng/ $\mu$ l. About 20  
10 ng of the cDNA was digested with 4 units of *Bgl* II in a final vol of 10  $\mu$ l for 30 min at  
37°C. Two microliters ( $\approx$ 4 ng of digested cDNA) of this reaction mixture was then  
used for ligation to 100 ng ( $\approx$ 50-fold) of the Y-shaped adapter in a final vol of 5  $\mu$ l for  
16 hr at 15°C. After ligation, the reaction mixture was diluted with water to a final vol  
of 80  $\mu$ l (adapter ligated cDNA concentration,  $\approx$ 50 pg/ $\mu$ l) and heated at 65°C for 10  
15 min to denature T4 DNA ligase, and 2- $\mu$ l aliquots (with  $\approx$ 100 pg of cDNA) were used  
for PCR.

The following sets of primers were used for PCR amplification of the adapter  
ligated 3' -end cDNAs:

TGAAGCCGAGACGTCGGTCG(T)<sub>18</sub> n1, n2 (wherein n1, n2 = AA, AC, AG AT  
20 CA CC CG CT GA GC GG and GT) as the 3' primer with A1 as the 5' primer or  
alternatively

RP 5.0, RP 6.0, or RP 9.2 used as 3' primers with primer A1.1 serving as the 5' primer.  
To detect the PCR products on the display gel, 24 pmol of oligonucleotide A1 or A1.1  
was 5' -end-labeled using 15  $\mu$ l of [ $\gamma$ -<sup>32</sup>P]ATP (Amersham; 3000 Ci/mmol) and PNK  
25 in a final volume of 20  $\mu$ l for 30 min at 37°C. After heat denaturing PNK at 65°C for  
20 min, the labeled oligonucleotide was diluted to a final concentration of 2  $\mu$ M in 80  
 $\mu$ l with unlabeled oligonucleotide A1.1. The PCR mixture (20  $\mu$ l) consisted of 2  $\mu$ l  
( $\approx$ 100 pg) of the template, 2  $\mu$ l of 10 $\times$  PCR buffer (100 mM Tris-HCl, pH 8.3/500 mM

-25-

- KCl), 2  $\mu$ l of 15 mM  $MgCl_2$  to yield 1.5 mM final  $Mg^{2+}$  concentration optimum in the reaction mixture, 200  $\mu$ M dNTPs, 200 nM each 5' and 3' PCR primers, and 1 unit of Amplitaq Gold. Primers and dNTPs were added after preheating the reaction mixture containing the rest of the components at 85°C. This "hot start" PCR was done to avoid
- 5 artefactual amplification arising out of arbitrary annealing of PCR primers at lower temperature during transition from room temperature to 94°C in the first PCR cycle. PCR consisted of 5 cycles of 94°C for 30 sec, 55°C for 2 min, and 72°C for 60 sec followed by 25 cycles of 94°C for 30 sec, 60°C for 2 min, and 72°C for 60 sec. A higher number of cycles resulted in smeary gel patterns. PCR products (2.5 $\mu$ l) were
- 10 analyzed on 6% polyacrylamide sequencing gel. For double or multiple digestion following adapter ligation, 13.2  $\mu$ l of the ligated cDNA sample was digested with a secondary restriction enzyme(s) in a final vol of 20  $\mu$ l. From this solution, 3 $\mu$ l was used as template for PCR. This template vol of 3  $\mu$ l carried  $\approx$  100 pg of the cDNA and 10 mM  $MgCl_2$  (from the 10 $\times$  enzyme buffer), which diluted to the optimum of 1.5 mM
- 15 in the final PCR vol of 20  $\mu$ l. Since  $Mg^{2+}$  comes from the restriction enzyme buffer, it was not included in the reaction mixture when amplifying secondarily cut cDNA. Bands were extracted from the display gels as described by Liang *et al.* (1995 *Curr. Opin. Immunol.* 7:274-280), reamplified using the 5' and 3' primers, and subcloned into pCR-Script with high efficiency using the PCR-Script cloning kit from Stratagene.
- 20 Plasmids were sequenced by cycle sequencing on an ABI automated sequencer.

Figure 1 presents an autoradiogram of the expression profile generated from cDNAs made from RNA isolated from control (untreated) neutrophils (lanes 1, 5, 10, 13, 14 and 16), neutrophils incubated with avirulent *E. coli* K12 (lanes 2 and 11), virulent *Y. pestis* (lane 3), avirulent *Y. pestis* (lane 4), *Y. pestis yopB* (lane 6), *Y. pestis yopE* (lane 7), *Y. pestis yopH* (lane 8), latex beads (lanes 9 and 19), virulent Enterohemorrhagic *E. coli* (EHEC) (lane 12), LPS (lane 15), 1 ng/ml LPS for 30 minutes (lane 17), and LPS for 120 minutes (lane 18). The anchoring oligo d(T)18 n1, n2 has A and C at the n1 and n2 positions, respectively. The cDNAs were digested with *Bgl*III.

25

-26-

## Example 2

*Production of gene expression profiles generated from cDNAs made with RNA isolated from neutrophils exposed to virulent and avirulent bacteria and neutrophils exposed to cytokines.*

- 5     Neutrophils were isolated from normal donor peripheral blood following the LPS-free method as set forth in Example 1.

Neutrophils were incubated with virulent and avirulent *E. coli* or *Y. pestis*, LPS at 1ng/ml, GM-CSF at 100 units/ml, TNF $\alpha$  at 1000 units/ml, or  $\gamma$ IFN at 100 units/ml. The bacterial cells, LPS or cytokines were added to approximately  $3.38 \times 10^8$  cells in  
10 100 ml of RPMI containing 6% H1 autologous serum. Incubation proceeded for 2 to 4 hours, preferably 2 hours, with gentle rotation in disposable polycarbonate Erlenmeyer flasks at 37°C. After incubation, the cells were spun down and washed once with HBSS.

After incubation of the neutrophils, RNA was extracted and the cDNA profiles  
15 prepared as described in Example 1. Figure 2 is an autoradiogram of the expression profiles generated from cDNAs made with RNA isolated from control (untreated) neutrophils (lanes 1, 5, 10 and 14), neutrophils incubated with avirulent *E. coli* K12 (lanes 2 and 11), virulent *Y. pestis* (lanes 3 and 12), avirulent *Y. pestis* (lanes 4 and 13), 1ng/ml LPS (lanes 6 and 15), 100 units/ml GM-CSF (lanes 7 and 16), 1000 units/ml  
20 TNF $\alpha$  (lanes 8 and 17) and 100 units/ml  $\gamma$ IFN (lanes 9 and 18). The anchoring oligo d(T)18n1, n2 has A and C at the n1 and n2 positions for lanes 1-9 and G and G at the n1 and n2 for lanes 10-18. The cDNAs were digested with *Bgl*III.

As exhibited by Figure 2, the differential expression of mRNA species (as exhibited by cDNA fragments) in neutrophils exposed to virulent and avirulent *E. coli* and *Y.*  
25 *pestis* is not equivalent to the differential expression of mRNA species in neutrophils exposed to the various cytokines.

## Example 3

-27-

*Production of gene expression profiles generated from cDNAs made with RNA isolated from neutrophils exposed to bacteria using all 12 possible anchoring oligo d(T) n1,n2.*

Neutrophils were isolated from normal donor peripheral blood following the LPS-free method.

5     Neutrophils were incubated with *E. coli* or *Y. pestis*.

After incubation of the neutrophils, RNA was extracted and the cDNA profiles prepared as described in Example 1. Figure 3 is an autoradiogram of the expression profiles generated from cDNAs made with RNA isolated from control (untreated) neutrophils (lane 1), neutrophils incubated with avirulent *E. coli* K12 (lane 2), virulent  
10   *Y. pestis* (lane 3) , avirulent *Y. pestis* (lane 4). The anchoring oligo d(T)18 n1 and n2 positions are indicated at the top of the figure. The cDNAs were digested with *Bgl*III.

Figure 4 represents a summary of genes which are differentially expressed in neutrophils upon exposure to virulent and avirulent *E. coli* and *Y. pestis*. Expression patterns are determined by visual examination of the autoradiography gels comparing  
15 band intensity between neutrophils exposed to the various bacteria. The autoradiography gels can also be scanned using commonly available equipment, such as a UMAX D-1L scanner. Bands which exhibit altered intensities in gene expression profiles from neutrophils exposed to the various bacteria when compared to the gene expression profile prepared from normal nonexposed neutrophils are then extracted  
20 from the display gel as previously described by in Example 1. The isolated fragments are then reamplified using 5' and 3' primers, subcloned into pCR-Script (Stratagene) and sequenced using an ABI automated sequencer.

Tables 1 and 2 represent a summary of cDNA bands which are differentially expressed in response to exposure to *E. coli*.

-28-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
846	Up	0	0	+-	2+	4+	AA	Yale	K02286	Urokinase Gene
847	Up	+-	+-	+-	+	2-3+	AA	Yale		
848	Up	+-	+-	0	+-	2+	AA	Yale		
849	Up	+-	+-	+-	+-	1-2+	AA	Yale		
850	Down	+	0	0	0	0	AA	Yale		
851	Up	0	0	0	0	+	AA	Yale		
852	Down	+	+	+-	+	0	AA	Yale		
853	Up	0	0	+-	+-	1-2+	AA	Yale		
854	Down	2+	+	+-		0/0 +-	AA	Yale	AF039715	C. elegans cosmidR0 6A10
T103	Up	3+	3+	3-4+	4-5+	4-5+	AA	Yale	M77693	HUMAN SSAT
855	Up	+-	+-	+-	+-	2+	AA	Yale	G29248	Human STS SHGC 17036
856	Up	+-	+-	+-	+-	2+	AA	Yale	AI038932	ox96ho8.x l soares senescent Fibroblast s
T104	Up	+	+	+-	+	2+	AA	Yale	AA931109	HUMAN CGAP KID3
T105		3-4+	3-4+	3-4+	3+	3+	AA	Yale	M11354	HUMAN H3.3 HISTONE
857		+	+	2+	+	+-	AA	Yale		
T107	Down	2-3+	2-3+	2-3+	2-3+	2+	AA	Yale	AA936257	on43e12 Sincl CGAP co8
858	Down	2+	2+	2+	2+	++	AA	Yale		
859	Up	+-	+-	+-	2+	1-2+	AA	Yale	AC004987	DJ117312 0 Clone
860	Down	2-3+	2-3+	2+	2+	+-	AA	Yale		
861	Down	+	+	1-2+	+-	+-	AA	Yale		
862		2-3+	2-3+	2-3+	2-3+	2-3+	AA	Yale		
863	Down	2+	+	+-	+	+	AA	Yale	H26311	Cystic Fibrosis Antigen
864	Up	2+	2+	2+	2-3+	2-3+	AA	Yale		
865	Up	+	+	2+	2-3+	2+	AA	Yale		

SUBSTITUTE SHEET (RULE 26)

-29-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
866	Up	+-	+-	+	+	2+	AA	Yale	G06511	Human STS WI - 7311
867	Down	2+	2+	2+	2+	1-2+	AA	Yale		
868		+-	+-	+	2+	+-	AA	Yale		
869	Up	+	+-	+-	+-	2+	AC	Yale		
870	Up	0	0	0	+-	1-2+	AC	Yale		
871	Down	1-2+	1-2+	1-2+	+	+-	AC	Yale	AI026899	ov42do7.x I Soares testis nht
872		+	+	+-	+	+	AC	Yale	AA916304	on22do4.s i NCI CGAP Lu5
873	Up	+-	+-	+-	+-	2+	AC	Yale		
874	Up	1-2+	1-2+	1-2+	+	3+	AC	Yale	AI012139	EST 206590 (Rat Placenta)
875	Up	1-2+	1-2+	+	+	2-3+	AC	Yale		
876	Down	+	1-2+	2+	+	+-_0	AC	Yale	AI031728	ow39a05. xl Soares parathyroi d tumor NGHPA
877	Down	2-3+	2+	2+	+	+-	AC	Yale		
878	Down	2-3+	2-3+	2+	1-2+	0_+-	AC	Yale	AB002384	human mRNA for KIAA0386 gene
879		+	+-	0	0	+	AC	Yale		
880	Down	1-2+	+-	+-	+-	0	AC	Yale	AI016473	Transcripti on Factor BTF3
881	Down	+	+	1-2+	+	+-	AC	Yale	U82275	Human immunogl obulin-like transcript
882	Up	2+	2+	3+	3-4+	4+	AC	Yale	AI016664	Diamineac etyl Transferase

SUBSTITUTE SHEET (RULE 26)

-30-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
883	Down	1-2+	+	+	+	+-	AC	Yale	AA909168	.SI Soares NFLT GBC.SI
884	Down	+	+-	0	0	0	AC	Yale	AI039973	ox88e09.s i Soares senescent fibroblasts
885	Up	2+	1-2+	1-2+	2+	2-3+	AC	Yale	AI026998	ow41d06. si Soares parathyroid tumor NB4PA
886		0	+-	+-	+-	0	AC	Yale		
887	Up	+-	0	0	+-	+	AC	Yale		
888	Up	0	0	0	+-	+	AC	Yale		
T7	Down	2+	1-2+	1-2+	+	+-	AC	Yale		
889	Up	+-	0	+-	+-	1-2+	AC	Yale		
T8	Down	2-3+	2+	2+	2+	1-2+	AC	Yale	G06680	HUMAN STS
890	Up	2+	2+	1-2+	+	+-	AC	Yale		
891	Down	+	+	+-	0	0	AC	Yale		
T76	Down	2-3+	2+	2+	1-2+	+-	AC	Yale	S73591	HUMAN H HCPA78 HOMOLOG
892	Down	3+	3+	3+	2+	+-	AC	Yale		
893		2+	+	1-2+	2+	2+	AC	Yale		
T98	Down	2-3+	2-3+	2-3+	2-3+	+-	AC	Yale	G06788	HUMAN STS
894	Down	2+	1-2+	1-2+	1-2+	+	AC	Yale	AF039656	Neuronal tissue-enriched acidic protein
895	Down	2-3+	2-3+	2-3+	2+	+-	AC	Yale	AI016303	ot72d07. si soares total Fetus Nb3hf8
896	Down	2+	2+	1-2+	+-	0	AC	Yale	AC004987	DJ 1173120 clone

SUBSTITUTE SHEET (RULE 26)



Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
T81	Up	0	0	0	0	3+	AC	Yale	AA926999	om26do7 si Soares NFLTG3c 1s1
T82	Up	+	+	+	+-	2-3+	AC	Yale	AA926999	om26do7 .SI NFL TG3cSi
T83	Down	2+	2+	1-2+	1-2+	1-2+	AC	Yale		
T84		2-3+	2+	2-3+	3+	2-3+	AC	Yale		
T85	Down	+	+-	+-_0	+-_0	0	AC	Yale	O89052	HUMAN PROTON- ATPASE
897	Down	2+	1-2+	1-2+	+	+-	AC	Yale		
898		2+	2+	2+	2+	2+	AC	Yale		
899	Up	0	0	+-	+	3+	AC	Yale		
900	Down	1-2+	1-2+	+-	1-2+	0	AC	Yale		
901	Up	1-2+	+	1-2+	2+	2-3+	AC	Yale		
902	Down	2+	+	1-2+	1-2+	+	AC	Yale		
903	Down	2+	2+	3+	3-4+	+-	AC	Yale		
904		+	+	+-	+-	+	AC	Yale		
905	Up	0	+-	0	+	3-4+	AG	Yale	KO2286	Human urokinase gene 3' end
906	Up	0	0	+-	+-	1-2+	AG	Yale		
T111		+-_+	2+	+-	+-	+-	AG	Yale		
907		+-	+	+	2+	+-	AG	Yale		
908	Down	2+	2+	1-2+	2+	+-	AG	Yale		
909		+-	+-	+	2+	+-_0	AG	Yale		
910	Down	+	1-2+	0	+-	+-	AG	Yale	AC002091	Genomic Sequence Human 17, complete sequence
911	Down	2+	2+	2+	+	-	AG	Yale		
T113	Down	2+	2-3+	2+	2+	1-2+	AG	Yale	AI039523	ox371002. si Soares total fetus NB22HF8
912	Down	+-	+-	+-	-	-	AG	Yale		
913	Down	3+	3+	2-3+	2-3+	2+	AG	Yale		
914	Up	-	+-	-	-	+	AG	Yale		

-32-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
915	Up	+	1-2+	+	1-2+	2+	AG	Yale	AI038932	'ox96ho8. xi Soares senescent fibroblasts
T115		2+	2+	2+	2+	2+	AG	Yale		
916	Up	+	+	+	+	2+	AG	Yale	AC005038	Homosapi ens clone NH 048666I22 HTGS phase 1
917	Down	+-	+-	-	-	-	AG	Yale		
918	Down	+	+	+	+	+-	AG	Yale		
919		+	+	-	+	+	AG	Yale		
920	Down	+	2+	+	+-	+-	AG	Yale		
T116	Down	3-4+	3-4+	3+	3+	3+	AG	Yale	M11353 H	Histone H3.3 (human)
T117	Up	+	+	+	2+	2+	AG	Yale		
921	Up	1-2+	2+	+	1-2+	2-3+	AG	Yale	AA912471	NCI CGAP GC4 Homo Sapiens
922	Down	1-2+	2+	+	1-2+	0+-?	AG	Yale		
923	Down	+-	+-	-	+-	-	AG	Yale		
924	Up	0	0	0	+-	2+	AG	Yale		
925	Down	+-	+	0	0	0	AG	Yale		
926	Down	1-2+	1-2+	+	+-	2+	AG	Yale		
927	Up	+	?	?	2+	2+	AG	Yale	AA917380	0180a04.s i NCI CGAP KIDS
928	Up	0	0	0	0	2+	AG	Yale	AA926999	Homo Soares NFL TGBC si
929	Down	+	-	+	+	-	AG	Yale		

SUBSTITUTE SHEET (RULE 26)

-33-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
930	Up	0	0	0	+-	2+	AG	Yale	CH29R28051	AD000864 Homo Sapiens DNA from chromosome 19 cosmid R28051
931	Down	2+	2+	1-2+	1-2+	+	AG	Yale		
932	Up	+	+	+	+	2+	AG	Yale		
933	Down	4+	4+	3+	3+	3+	AG	Yale	m81637	Human grancalan mRNA
934		-	-	+-	+	+-	AG	Yale		
935	Down	+-	+	+	+	-	AG	Yale		
936		+	+-	+-	+	+	AG	Yale		
937	Up	+-	+-	+-	+-	+	AG	Yale		
938	Up	+-	+-	+-	+	2+	AT	Yale		
939	Up	0	0	+-	+-	2+	AT	Yale	AA916304	NCI CGAP LU5 HOMO SAPIENS
940		+	+	2+	2-3+	+	AT	Yale		
941	Up	+	+	+	+	2-3+	AT	Yale		
942	Up	+	+	+-	0	1-2+	AT	Yale		
943	Down	+-	+-	+-	+	-	AT	Yale		
944	Down	2+	+	+	+-	0	AT	Yale		
945	Up	+	+-	+	+-	+	2+	AT	AA928171	ON86HO3 SOARES NFL TGBC SI
946	Down	+	+	+	-	-	AT	Yale		
947		0	0	+	2+	0	AT	Yale		
948	Down	+	+	+	+-	-	AT	Yale		
949	Up	0	0	0	0	1-2+	AT	Yale	AI038932	HOMO SAPIENS SOARES SENESCENT FIBROBLASTS
950	Down	2-3+	2-3+	2-3+	2-3+	+	AT	Yale		
951	Up	+-	+-	+-	+-	+	AT	Yale		

SUBSTITUTE SHEET (RULE 26)

-34-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
952	Up	0	0	0	+-	1-2+	AT	Yale	ACC004551	HOMO SAPIENS HTGS PHASE 1
953	Down	1-2+	+	1-2+	+-	0	AT	Yale		
954	Up	+	+	+	1-2+	2-3+	AT	Yale	AI026998	HOMO SPAIENS SOARES PARATHYROID TUMOR
955	Down	+	+	+	+	0	AT	Yale		
956	Up	+-	+-	+-	+-	+	AT	Yale		
957	Down	2+	2+	2+	2+	+	AT	Yale		
958	Up	+	+	+	+-	2+	AT	Yale		
T123	Up	+-	+-	+	2+	3+	AT	Yale	HSO27467	HUMAN BCL-2 RELATED (BF1-1) MRNA
959		+	+-	2+	+	+	AT	Yale		
960	Down	2+	+	+	+	+-	AT	Yale		
961		0	+-	2+	+-	0	AT	Yale		
962	Up	0	0	0	0	2+	AT	Yale		
T124	Up	3+	3+	3+	3-4+	3-4+	AT	Yale		
963	Down	2+	2+	2+	2+	+	AT	GLI		
964		+-	1-2+	+	+	+-	AT	GLI		
965	Up	0	0	+-	2+	1-2+	AT	GLI		
966	Down	+	+	+	1-2+	+-	AT	GLI		
967	Down	3+	3+	3+	3+	+-	AT	GLI	M60830	Human gene EVI2B#P
968	Down	+	+	2+	1-2+	+-	AT	GLI		
969	Up	0	0	0	+-	2+	AT	GLI		
970		0	0	0	2+	0	AT	GLI		
971	Down	+	+	2+	1-2+	+-	AT	GLI		
972	Down	+	+	+	+	-	AT	GLI		
973	Up	-	-	-	-	+	AT	GLI		
974	Up	+	+	2+	3+	2+	CA	Yale		
975		+	+-	1-2+	2+	?	CA	Yale	GBM77693	HUMAN DIAMINE ACETYLT RANSFER ASE

SUBSTITUTE SHEET (RULE 26)

-35-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
976		1-2+	1-2+	2-3+	3+	?	CA	Yale	Z14136	HOMO SAPIENS GENE SPERMID INE/SPER MINE N1- ACETYLT RANSFER ASE
T132							CA			
T133							CA			
977	Up	+	+	1-2+	2-3+	1-2+	CA	Yale		
T135							CA			
978	Down	2+	2+	2+	2+	-	CA	GLI	G05563	Human STS WI- 7246
979	Down	+	+	+	+	-	CA	GLI		
980		-	-	-	+	-	CA	GLI		
981	Down	+	+	+	+	-	CA	GLI	473168	Human cosmid LUCA22
982		-	-	-	+	-	CA	GLI	M55542	Human granulyte binding M55542 protein Isoform I
983		-	-	-	+	-	CA	GLI		
984		2+	2+	3+	3-4+	2+	CC	Yale	HS167A1 4	Z94721 HUMAN DNA SEQ- PAC167A 14 CHROM6 927
T139	Up	+	+	+	-	2+	CC	GLI		
985	Down	+	+	+	2+	+	CC	Yale		
T140	Up	+	+	+	+	2+	CC	GLI		

SUBSTITUTE SHEET (RULE 26)

-36-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
986	Down	2+	2+	1-2+	1-2+	+-	CC	Yale	AI015836	0V51H11. SI SOARES TESTIS NHT HOMO SAPIENS
987		2-3+	2+	2+	3-4+	3+	CC	Yale		

SUBSTITUTE SHEET (RULE 26)

-37-

TABLE 2

Cln	Sequence
846	<p>1 TCTCAGTGAG CTGAGATCAC ACCACTGCAC TCCAAGTGG CGACAGAGCA</p> <p>51 AG</p>
854	<p>1 CACTTCCCC AAATTCTTTT GCCATAGTTC ACTCTCTACT GATAAGGCCA</p> <p>51 C</p>
855	<p>1 GGGAAAGTGG TGGGGTGGTG AGGGTCAATG TGCAGAAAAT CGATGTAAC</p> <p>51 TGTAATACAG TTGAGTCAAC TGTGTGTTCA CAACAACTCT GAGAGTTAAC</p> <p>101 ACCATTCTA C</p>
856	<p>1 ATCTAAATAT TTTCATACC GAGTTATTAA GGAGTCAGTA GTCTGTGCTA</p> <p>51 CAATGCTGCA AAAAGCATCA CGTGGAAGAA TGGGAACAT GCGTACTTTA</p> <p>101 TGAAGTGATG TATAACACAA TGAAGTCTGT TTTACAAC CAGTGCTGCA</p> <p>151 TTCAATTATC TTCCAT</p>

SUBSTITUTE SHEET (RULE 26)

-38-

859	<p>1 AAGCTCTGTA TACAAAAGTT ATTTATTAG ATGTTGAGG CATGTCTCTC</p> <p>51 CTCACCTGTA AACTAACTGT TTTATAACAG CTTGTATCAC ATGTGTGAAG</p> <p>101 TTAATGAATG TAATACTCCA ACAAGCCATT CATCAGATTG GCCAACAGCT</p> <p>151 AGGATACAGT TAAATAATGG CGACCAGGTT GACAAGTCAT AATTGCGGTT</p> <p>201 TGGGGGACCG TAGTTGCACC TCACCTAGAC CAACGTACGC ATGGCACTCG</p> <p>251 ACCCAGGCGA ACAAATTA T</p>
-----	---

SUBSTITUTE SHEET (RULE 26)



-39-

863	1 TTTCTCAAGA AGAGATAAGA ATGAAAAGTC ATAGAACACA TCATGGAGGA
	51 CCTGGACACA AATGCAGACA AGCAGCTGAG CTTCGAGGAG TTCATCATGC
	101 TGATGGCGAG GCTAACCTGG GCCTCCCACG AGAAGATGCA CGAGGGTGAC
	151 GATGGCCCTG GCCACCACCA TAAGCCAGGC CTCGGGGAGG GCACCCCCTA
	201 AGACCACAGT GGACAAGATC ACAGTGGCCA CGGACACGGC CACAGTCATG
	251 GTGGCCACGG CCACAGCCAC TAATCAGGAG GCCAGGCCAC CCTGCCTCTA
	301 CCCAACCAGG GCCCCGGGGC CTGTTATGTC AAAGTGTCTT GGCTGTGGGG

SUBSTITUTE SHEET (RULE 26)

-40-

866	<p>1 NGATCTTTCT AGGAGGGAGA CACTGGCCNC TCAAATCGTC CAGCGACCTT</p> <p>51 CCTCATCCAC CCCATCCCTC CCCAGTTCAT TGCACTTTGA TTAGCAGCGG</p> <p>101 AACAAAGGAGT CAGACATTTT AAGATGGTGG CAGTAGAGGC TATGGACAGG</p> <p>151 GCATGCCACG TGGGCTCATA TGGGGCTGGG AGTAGTTGTC TTTCCTGGCA</p> <p>201 CTAACGTTGA GCCCCTGGAG GCACTGAAGT GCTTAGTGTA CTTGGAGTAT</p> <p>251 TGGGGTCTGA CCCCAAACAC CTTCCAGCTC CTGTAACATA CTGGCCTGGA</p> <p>301 CTGTTTTCTC TCGGCTCCCC ATGTGTCCTG GTTCCCGTTT CTCCACCTAG</p> <p>351 ACTGTGAACC TCTCGAGGGC AGGGACCACA CCCTGTACTG TTCTGTGTCT</p> <p>401 TTCACAGCTC CTCCCACAAT GCTGAATATA CAGCAGGTGC TCAATAAATG</p> <p>451 ATTCT</p>
871	1 GCAAGTGTGT TGTGTTACAG TGTCACAACA CCGAG
872	<p>1 GATCTCTCCC TACGCAAAAC GTATTGTAGT GAAAGGGTCT TCTTTACTAC</p> <p>51 CTTAATAAAA CAGCTAGTGT G</p>
874	<p>1 GATCTAAATA CAAAGGATAT ACAGTCTTGA ATCTAAAATA ATTTGCTAAC</p> <p>51 TATTTTGATT CTTCAGAGAG AACTACTA</p>

SUBSTITUTE SHEET (RULE 26)

-41-

876	1 GATCTAGTCC GGACATGCTG TGTATATTGT AACGTTAAAT GAAAAAAGAA 51 CCCCCCTTTG TATTATAGTC ATGCGGTCTT ATGTATGATA AACAGTTG
878	1 GATCTTTTGT AGTCACCTCT GTATCTTATG TCTGGTTGAG GGGTGCTTTT 51 ACTTGTCTGG CATTTGCATT CAATGATCTT TCAGTCATGT CAGTTAGACT 101 AAAAATTATT TCTG
880	1 CCCAAGCCCC TTGGACACTG CAGCTCTTTT CAGTTTTTGC TTACACACAA 51 TTCATTCTTT GCAGCTAATT AAGCCGAAGA AGCGTGGGAA TCAAGTTTGG 101 AACAGAGATT AAAAAAGTTC TT
881	1 GCTCTGGAGG ACAATCCAGG AACTACATTA CCTGGACTGT ATGCTGGTCA 51 TTTCTACAGA CAGCATTAG TATTTGAGTG TACGGTAACT GTCTGGGGTG 101 ATTCCTATAA GATCATTATA CTG
882	1 GATCTTTCTC CTTGAATATC TTTCGATAAA CAACAAGGTG GTGTGATCTT 51 AATATATTTG AAAAAAAGTT CATTCTCGTG AGTCATTAA ATGTGTACAA 101 TGTACACACT GGTACTTAGA GTTTCTGTTT GATTCTTTTT TAATAAACTA 151 C
883	1 TGTCACTCAT GCCCTGGGAC TGCTTCTCCA GCCAGGCGGG CGCCATACGT 51 CCCACACTAG TGAAGGTCAA TGTCTCAGAA CAACACCTCT AT

SUBSTITUTE SHEET (RULE 26)

-42-

884	<p>1 GATCTGGCCT GTTCCTGCGT CTGCGGAGCA GGCCTTGTCT CCCAGCTATC</p> <p>51 TATAACCTTA CCTAGAGTGT CGACTTGTGG GTTCCTGTTG CTGAGACTTC</p> <p>101 CTGGATGGAG CCGCCCTCAC CGCCGGACCC GTAGCACTGC GCGGAACTGT</p> <p>151 GTCCAATAAA GT</p>
885	<p>1 GATCTGATTT GCTAGTTCTT CCTTGTAAG TTATAAATGG AAAGATTACA</p> <p>51 CTATCTGATT AATAGTTTCT TCATACTCTG CATATAATTT GTGGCTGCAG</p> <p>101 AATATTGTAA TTTGTTGCAC ACTATGTAAC AAAACAAC TG AAGATATGTT</p> <p>151 TAATAAATAT TGTACT</p>
894	<p>1 GATCTTTATG AGAGCAGTAT TTTCTGTGTT TTCTTTTAA TTTACAGCCT</p> <p>51 TTCTTATTTT GATATTTTTT TAATGTTGTG GATGAATGCC AGCTTTCAGA</p> <p>101 CAGAGCCAC TTAGCTTGTC CACATGGATC TCAATGCCAA TCCTCCATTC</p> <p>151 TTCCTCTCCA GATATTTTTG GGAGTGACAA ACATTCTCTC ATCCTACTTA</p> <p>201 GCCTACCTAG ATTTCTCATG ACGAGTTAAT GCATGTCCGT GGTTGGGTGC</p> <p>251 ACCTGTAGTT CTGTTTATTG GTCA</p>

SUBSTITUTE SHEET (RULE 26)

-43-

895	<p>1 GATCTAAGTT AGTCCAAAAG CTAAATGATT TAAAGTCAAG TTGTAATGCT</p> <p>51 AGGCATAAGC ACTCTATAAT ACATTAAATT ATAGGCCGAG CAATTAGGGA</p> <p>101 ATGTTTCTGA AACATTAAAC TTGTATTTAT GTCACTAAAA TTCTAACACA</p> <p>151 AACTTAAAAA ATGTGTCTCA TACATATGCT GTACTAGGCT TCATCATGCA</p> <p>201 TTTCTAAATT TGTGTATGAT TTGAATATAT GAAAGAATTT ATACACGAGT</p> <p>251 GTTATTTAAA ATTATTAAAA ATAAATGTA</p>
896	<p>1 GATCTTATAG GCCTGTCTCA TCAGGTTGGT GTCAGCCCAG CTAGGATTAG</p> <p>51 GCAGAATTGG GTGGGGGCTG TAGTGCACCTT TTGGCACAGC ATGTACCTGT</p> <p>101 CTGACTAATT CTCTGTCTTT TCTTTCCTGT TGCAATTCAT GGGTCTTAGC</p> <p>151 ATCTTCTGAA TGGTGTTTAG TAGGTCATCC TGTTGATTTT CTGCTAGGGA</p> <p>201 GTAGCATACT CTGGCTCTGT ACCACTGGCC AAGGGACTTA AGGATAGATG</p> <p>251 AAGGGCTGCA GTTTTGTTAA ATGGAACAAT ATGAAGAGA</p>
T10 3	<p>1 GATCTTCTC CTTGAGTATC TTTCGATAAA CAACAAAGTG GTGTGATCTT</p> <p>51 AATATATTTG AAAAAAACTT CATTCTCGTG AGTCATTIAA ATGTGTACAA</p> <p>101 TGTACACACT GGTACTTAGA GTTCTGTTT GATTCTTTTT TAATAAACTA</p> <p>151 C</p>

SUBSTITUTE SHEET (RULE 26)

-44-

T10 4	<p>1 GATCTCTGCT CATAGAATGC ATGGGGAGCC TTCCAGCTCA CTCTCCCTGA</p> <p>51 GGACTGGCTT GACAGGGGCT ATGGGTTTGC TTTGG</p>
T10 5	<p>1 GATCTGCGCT TCCAGAGCGC AGCTATCGGT GCTTTGCAGG AGGCAAGTGA</p> <p>51 GGCCTATCTG GTTGGCCTTT TTGAAGACAC CAACCTGTGT GCTATCCATG</p> <p>101 CCAAACGTGT AACAATTATG CCAAAAGACA TCCAGCTAGC ACGCCGCATA</p> <p>151 CGTGGAGAAC GTGCTTAAGA ATCCACTATG ATGGGAAACA</p>
T10 7	<p>1 GATCTAAATG TGAACAGTTT ACTAATGCAC TACTGAAGTT TAAATCTGTG</p> <p>51 GCACAATCAA TGTAAGCATG GGGTTTGTTC CTCTAAATTG ATTTGTAATC</p> <p>101 TGAAATTACT GAACAACTCC TATTCCCATT TTTGCTAAAC TCAATTTCTG</p> <p>151 GTTTTGGTAT ATATCCATTC CAGCTTAATG CCTCTAATTT TAATGCCAAC</p> <p>201 AAAATTGGTT GTAATCAAAT TTAAAATAA TAATAATTTG GC</p>
T76	<p>1 GCCTTTTCGA TAGTTTCGGG TCAGGTAAAA ATGGCCTCCT GCGTAAGCT</p> <p>51 TTTCAAGGTT TTTTGGAGGC TTTTGTAAA TTGTGATAGG AACTTTGGAC</p> <p>101 CTTGAACTTA CGTATCATGT GGAGAAGAGC CAATTTAACA AACTAGGAAG</p> <p>151 ATGAAAAGGG AAATTGTGGC CAAAACTTTG GGAAAAGGAG GTTCTTAAAA</p> <p>201 TCAGTGTTTC CCCTTT</p>

SUBSTITUTE SHEET (RULE 26)

-45-

T8	<p>1 GATCTATGCA CAAGAACCCC TTTACCCCAT GACCAACATC GCAGACACAT</p> <p>51 GTGCTGGCCA CCTGCTGAGC CCCAAGTGGA ACGAGACAAG CAGCCCTTAG</p> <p>101 CCCTTCCCCT CTGCAGCTTC CAGGCTGGCG TGCAGCATCA GCATCCCTAG</p> <p>151 AAAGCCATGT GCAGCCACCA GTCCATTGGG CAGGCAGATG TTCCTAATAA</p> <p>201 AGCT</p>
T81	<p>1 GATCTTTCCT CCTGGTTACT GTGAAGCCTG TTGGTTTGCT GCTGTCGTTT</p> <p>51 TTGAGGAGGG CCCATGGGGG TAGGAGCAGT TGAACCTGGG AACAAACCTC</p> <p>101 ACTTGAGCTG TGCCTAGACA ATGTGAATTC CTGTGTTGCT AACAGAAGTG</p> <p>151 GCCTGTAAGC TCCTGTGCTC CGGAGGGAAG CATTTCCTGG TAGGCTTTGA</p> <p>201 TTTTCTGTG TGTAAAGAA ATTCAATCTA CTCATGATGT GTTATGCATA</p> <p>251 AAACATTTCT GGAACATGGA TTTGTGTTCA CCTTAAATGT GAAAATAAAT</p> <p>301 CCTA</p>

SUBSTITUTE SHEET (RULE 26)

-46-

T82	1 ATCTTTCCTC CTGGTTACTG TGAAGCCTGT TGGTTTGCTG CTGTCGTTTT
	51 TGAGGAGGGC CCATGGGGGT AGGAGCAGTT GAACCTGGGA ACAAACCTCA
	101 CTTGAGCTGT GCCTAGACAA TGTGAATTCC TGTGTTGCTA ACAGAAGTGG
	151 CCTGTAAGCT CCTGTGCTCC GGAGGGAAGC ATTCCTGGT AGGCTTTGAT
	201 TTTTCTGTGT GTTAAAGAAA TTCAATCTAC TCATGATGTG TTATGCATAA
	251 AACATTTCTG GAACATGGAT TTGTGTTTAC CTAAATGTG AAAATAAATC
	301 CTATTTTCTA TG

SUBSTITUTE SHEET (RULE 26)



-47-

T85	<p>1 GATCTTTGGC AGCGCCATTG GACTCTTTGG GGTATCGTC GCAATTCTTC</p> <p>51 ATACCTCCAG AGTGAAGATG GGTGACTAGA TGATATGTGT GGGTGGGGCC</p> <p>101 GTGCCTCACT TTTATTTATT GCTGGTTTTTCTG GGGACAGC TGGAGCTGTG</p> <p>151 TCCCTTAACC TTTCAGAGGC TTGGTGTTCA GGGCCCTCCC TGCCTCCCC</p> <p>201 TCTTGCTGCG TGTTGATTTG GAGGCACTGC AGTCCAGGCC GAGTCCTCAG</p> <p>251 TCGGGGGAGC AGGCTGCTGC TGCTGACTCT GTGCAGCTGC GCACCTGTGT</p> <p>301 CCCCCACCTC CACCCTCAAC CCATCTTCCT AGTGTTTGTG AAATAAACTT</p> <p>351 GGTAT</p>
T98	<p>1 GATCTTCCAC GTCTCCATCT CAGTACACAA TCATTTAATA TTCCCTGTC</p> <p>51 TTACCCCTAT TCAAGCAACT AGAGGCCAGA AAATGGGCAA ATTATCACTA</p> <p>101 ACAGGTCTTT GACTCAGGTT CCAGTAGTTC ATTCTAATGC CTAGATTCTT</p> <p>151 TTGTGGTTGT TGCTGGCCCA ATGAGTCCCT AGTCACATCC CCTGCCAGAG</p> <p>201 GGAGTTCTTC TTTTGTGAGA GACACTGTAA ACGACACAAG AGAACAAGAA</p> <p>251 TAAAA</p>

SUBSTITUTE SHEET (RULE 26)

-48-

933	1	TTATATATTT TTCTTAAATA TGTTTTATTG TCTTCTCTAA GCAAAAAGTT
	51	CTTAATAAAC ATAGTATTTT TCTCTGCGTC CTATTTTCATT AGTGAAGACA
	101	TAGTTCACCT AAAATGGCAT CCTGCTCTGA ATCTAGACTT TTAGAAATG
	151	GCATATGTTT TTGATGATAT GTCAACATTC AAAATAGTCC TAATTAAATT
	201	GTTGGTTAAA TGTAATGTCA ACTCTTTATA AACTTAAATA TAAACAAGTA
	251	ATTAACCACT CTAAGTAATA AAACACATTT CACCTGTGTT CTGAGTGTA

SUBSTITUTE SHEET (RULE 26)

-49-

967	1 ATGAATCCTT GCCACCTCCA CCTGCAGAAC TGTATAAAT ATTACAACCTT
	51 GCTTTTTCAGC TGATCTTCCA TCCTCAAATG ACTCTTTTTT CTTTATATGT
	101 TAACATATAT AAAATGGCAA CTGATAGTCA ATTTTGATTT TTATTCAGGA
	151 ACTATCTGAA ATCTGCTCAG AGCCTATGTG CATAGATGAA ACTTTTTTTT
	201 AAAAAAAGTT ATTTAACAGT AATCTATTTA CTAATTATAG TACCTATCTT
	251 TAAAGTATAG TACATTTTAC ATATGTAAAT GGTATGTTTC AATAATTTAA
	301 GAACTCTGAA ACAATCTACA TATACTTATT ACCCAGTACA GTTTTTTTTC
	351 CCCTGAAAAG CTGTGTATAA AATTATGGTG AATAAACTTT TATGTTTCCA
	401 TTTCAAAGAC CAGGGTGGAG AGGAATAAGA GACTAAGTAT
	ATGCTTCAAG
	451 TTTTAAATTA ATACCTCAGG TATTAAAATA AATATTCCAA GTTTGTGGGA
	501 AATGGGGAGA TTAAAATG

SUBSTITUTE SHEET (RULE 26)

-50-

978	1 TTATGTGGCC TTAGGTAGCT GGTTGTACAT CTTCCCTAA ATCGATCCAT
	51 GTTACCACAT AGTAGTTTTA GTTTAGGATT CAGTAACAGT GAAGTGTTTA
	101 CTATGTGCAA CGGTATTGAA GTTCTTATGA CCACAGATCA TCAGTACTGT
	151 TGTCTCATGT AATGCTAAAA CTGAAATGGT CCGTGTTTGC ATTGTTAAAA
	201 ATGATGTGTG AAATAGAATG AGTGCTATGG TGTGAAAAC TGCAGTGTCC
	251 GTTATGAGTG CCAAAAATCT GTCTTGAAGG CAGCTACACT TTGAAGTGGT
	301 CTTTGAATAC TTTTAATAAA TTTATTTTGA TA

SUBSTITUTE SHEET (RULE 26)

-51-

981	1 TAGGTGAACC CTTATTCTGC AGGGTTCTCC CTCCACCTT AAAGAAGTTC
	51 CCCTTATGTG GGTGCCTGG TGAATGGCCT TCCTCCCGC CAGAGGGCTT
	101 GTGAACAGAC CGGAGAGGAC AGTGGATTGT TTATACTCCA GTGTACATAG
	151 TGTAATGTAG CGTGTTTACA TGTGTAGCCT ATGTTGTGGT CCATCAGCCC
	201 CTCACATTCC TAGGGGTTTG AGATGCTGTA CGTGGTATGT GACACCAAAG
	251 CCACCTCTGT CATTGTGTG TATGTCTTTT CTGGCAAAA GCCTTGTGTA
	301 TATTGTATA TTACACATTT GTACAGAATT TTGGAAGATT TTCAGTCTAG
	351 TTGCCAAATC TGGCTCCTTT ACAAAG

SUBSTITUTE SHEET (RULE 26)

-52-

982	1 AGAATCTCTT ATGTTCTCAG AGGAAGGTGG AAGAAACCAT GGGCAGGAGT  51 AGGAATTGAG TGATAAACAA TTGGGCTAAT GAAGAAAAC TCTCTTATTG  101 TTCAGTTCAT CCAGATTATA ACTTCAATGG GACACTTTAG ACCATTAGAC  151 AATTGACACT GGATTAAACA AATTCACATA ATGCCAAATA CACAATGTAT  201 TTATAGCAAC GTATAATTTG CAAAGATGGA CTTTAAAAGA TGCTGTGTAA  251 CTAAACTGAA ATAATTCAAT TACTTATTAT TTAGAATGTT AAAGCTTATG  301 ATAGTCTTTT CTAATTCTTA ACACTCATAC TTGAAATCTT TCTGAGTTTC  351 CCCAGAAGAG AATATGGGAT TTTTTTTGAC ATTTTGGACT CATTTAATAA  401 TGCTCTTG TG TTTACCTAGT ATATGTAGAC TTTGTCTTAT GTGTCAAAAG  451 TCCTAGGAAA GTGGTTGATG TTTCTTATAG CAATTAAAAA TTATT
-----	--

905	1 ATCTCAGTGA GCTGAGATCA CACCACTGCA CTCCAAC TGG GCGACAGAGC  51 AAGA
910	1 GATCTGTAAT TCAGGTGTTT TCTGTACAGC CATACGTAGA TAATGAAGCC  51 AAAAGGCTTT TAATTACACC ATGGCCTAAA ATAAATTCAT CA

SUBSTITUTE SHEET (RULE 26)

-53-

915	<p>1 TATTTTTCAG CTGAGTTATT AGGGAGTCAT TATTCTGTGG TACAATGCTG</p> <p>51 CAAAAAGCAT CATGTGGAAG AATGGGAACT ATGCTTACAT TATGAAGTGA</p> <p>101 TGTATAACAC AATGCAAATC TG</p>
916	<p>1 GATCTTTTTT CATTAAAAAA TGTTC AATTA TCAGGCCGGG TGCAGTGGGG</p> <p>51 CTCATGCCTG TAATCCCAAC ACTTTGGGAG GCCGATGCAG GCGGATCACT</p> <p>101 AGGTCAGCAG ATCGAGACCA TCCTGGCTAA CACAGTGAAA CCT</p>
921	<p>1 GATCTTTTATT TTTAGCCATG CACTGTTGTG AGGAAAATTA CCTGTCTTGA</p> <p>51 CTGCCATGTG TTCATCATCT TAAGTATTGT AAGCTGCTAT GTATGGATTT</p> <p>101 AAACCGTAAT CATATCTTTT TCCTATCTAT CTGAGGCACT GGTGGAATAA</p> <p>151 AGAACCTGTA TATTTTACTT TGTTCAGAT AGTCTTGCCG CATCTTGCA</p> <p>201 AGTTGCAGAG A</p>

SUBSTITUTE SHEET (RULE 26)

-54-

927	<p>1 GATCTTCGTG AAGACCTGAC TGGTAAGACC ATCACCTCG AGGTGGAGCC</p> <p>51 CAGTGACACC ATCGAGAATG TCAAGGCAAA GATCCAAGAT AAGGAAGGCA</p> <p>101 TCCCTCCTGA TCAGCAGAGG TTGATCTTTG CTGGGAAACA GCTGGAAGAT</p> <p>151 GGACGCACCC TGTCTGACTA CAACATCCAG AAAGAGTCCA CTCTGCACTT</p> <p>201 GGTCTGCGC TTGAGGGGGG GTGTCTAAGT TTCCCCTTTT AAGGTTTCAA</p> <p>251 CAAATTCAT TGCACCTTCC TTTCAATAAA GTTG</p>
928	<p>1 GATCTTTCCT CCTGGTACT GTGAAGCCTG TTGGTTTGCT GCTGTCGTTT</p> <p>51 TTGAGGAGGG CCCATGGGGG TAGGAGCAGT TGAACCTGGG AACAAACCTC</p> <p>101 ACTTGAGCTG TGCCTAGACA ATGTGAATTC CTGTGTTGCT AACAGAAGTG</p> <p>151 GCCTGTAAGC TCCTGTGCTC CGGAGGGAAG CATTCCTGG TAGGCTTTGA</p> <p>201 TTTTCTGTG TGTAAAGAA ATTCAATCTA CTCATGATGT GTTATGCATA</p> <p>251 AAACATTTCT GGAACATGGA TTTGTGTTCA CCTTAAATGT GAAAATAAAT</p>

SUBSTITUTE SHEET (RULE 26)



-55-

930	<p>1 GATCTTTCGG GTTCTCTCTC CTAACCTCAGC TCTTCGTTCC CAGAAACCCA</p> <p>51 GATGTAATCC CCCTACGTGG TGCTTGGGGC ATCCCGATAC CATCTCAGTA</p> <p>101 AATCTCCTAC ATTGGCCTCC TCACCCTCCC CGGGACCCAC ACCCTTCAGG</p> <p>151 TCCTCACCTT GAGACAGGAG GGACCCTCTG AGATCAGGGA CCCTTAGGTC</p> <p>201 TCACTGCTCT CTGATTCATA GCTCAACTGG GCCCCAGTT CCATACCCCA</p> <p>251 GCATTCCCGG TCACTCCCTC CCTAATCTGA GCATCACTCA AGCTCTTTAT</p> <p>301 TAAACTC</p>
939	<p>1 ATCTCTCTCC CTACGCAAAA CCCTATTGTA GTAAAAAAGT CTCTTTACT</p> <p>51 ATCTTAATAA AACAGATATT GTG</p>
945	<p>1 ATCTATTCTT GTAGATTTTT TTTGTGTGGG TCTATGTTT ATTCACTGC</p> <p>51 TTTCAGGCTG GATTTATAAC AAGCAGAACT TTAAAAACG</p>
949	<p>1 GATCTAAATA TTTTTCAGCT GAGTTATTAC GGAGTCATTA TTCTGTGGTA</p> <p>51 CAATGCTGCA AAAAGCATCA TGTGGAAGAA TGGGAAGTAT GCTTACTTTA</p> <p>101 TGAAGTGATG TATAACACAA TGAAA</p>
952	<p>1 CTACCCCGTG ACTCAGTTAC CTCCCACTGG GTCCCTCCCA CATCATGTGG</p> <p>51 GAATTGTAGG AGCTACAATT CAAGATGAGA TTTGGATGGG GTCACAGCCA</p> <p>101 AACCATATCA CTGAGGTATC AAGGAGATTC TT</p>

SUBSTITUTE SHEET (RULE 26)

-56-

954	<p>1 GATCTGATTT GCTAGTTCCTT CCTTGTAGAG TTATAAATGG AAAGATTACA</p> <p>51 CTATCTGATT AATAGTTTCT TCATACTCTG CATATAATTT GTGGCTGCAG</p> <p>101 AATATTGTAA TTTGTTGCAC ACTATGTAAC AAAACAACCTG AAGATATGTT</p> <p>151 TAATAAATAT TGTACTTATT G</p>
975	<p>1 NGATCTTTCT CCTTGAATAT CTTTCGATAA ACAACAAGGT GGTGTGATCT</p> <p>51 TAATATATTT GAAAAAACT TCATTCTCGT GAGTCATTTA AATGTGTACA</p> <p>101 ATGTACACAC TGGTACTTAG AGTTTCTGTT TGATTCTTTT TTAATAAA</p>
976	<p>1 GATCTGCTAG AAGATGGTTT TGGAGAGCAC CCCTTTTACC ACTGCCTGGT</p> <p>51 TGCAGAAGTG CCGAAAGAGC ACTGGACTCC GGAAGGTAAC CCCTCGCCCT</p> <p>101 TTCCAGAAGC CAGAGAGACC AAGTGTTATG TAAGAAGTAG TGTCGGCTGT</p> <p>151 GTAGAACCAC TGA CTACACA GGCCGAAGTT ACTGAGAACT TGGACAGAAA</p> <p>201 AAATAGCCAG CAAGTGTT</p>
984	<p>1 CATTACACA TTAAACCTCC TTCCATACCA AATCTT</p>
986	<p>1 GATCTGGACA GCAGAATGTT ATAACGCAAG TTCATGTGTT GCTCCCAACT</p> <p>51 CCATTCTCTT TTCTCTCGTG CAACCAGTTT GCCCATTCTC TTCCTATTAC</p> <p>101 TTGCTC</p>

SUBSTITUTE SHEET (RULE 26)

-57-

T11 3	1 TCAGAGATTT GCAAAGACTC ACGTTTTTGT TGTTTTCTCA TCATTCCATT  51 GTGATACTAA GAAACTAAGA AGCTTAATGA AAAGAAATAA AATGCCTATG
T11 6	1 GATCTGCGCT TCCAGAGCGC AGCTATCGGT GCTTTGCAGG AGGCAAGTGA  51 GGCCTATCTG GTTGGCCTTT TTGAAGACAC CAACCTGTGT GCTATCCATG  101 CCAAACGTGT AACAATTATG CCAAAAGACA TCCAGCTAGC ACGCCGCATA  151 CGTGGAGAAC GTGCTTAAGA ATCCACTATG ATGGGAAACA
T12 3	1 GATCTGTGAA ATGCTATCTC TCCTGAAGCA ATACTGTTGA CCAGAAAGGA  51 CACTCCATAT TGTGAAACCG GCCTAATTTT TCTGACTGAT ATGGAAACGA  101 TTGCCAACAC ATACTTCTAC TTITAAATAA ACAACTTTGA TGATGTA ACT  151 TGACCTTCCA GAGTTATGGA AATTTTGTCC CCATGTAATG AATAAATTGT  201 ATGTAT

#### Example 4

*Production of expression profiles generated from cDNAs made with RNA isolated from neutrophils isolated from a subject with a sterile inflammatory disease.*

Neutrophils are isolated from normal donor peripheral blood following the LPS-free  
5 method or from subjects exhibiting the symptoms of a sterile inflammatory disease.  
RNA is extracted and the gene expression profiles prepared as described in Example 1.

-58-

To determine the identity of genes (cDNAs) which are differentially expressed in the neutrophils isolated from a subject exhibiting the symptoms of a sterile inflammatory disease, the cDNA profiles prepared from neutrophils from said subject are compared to profiles prepared from neutrophils isolated from the normal donor.

- 5 Bands which exhibit altered intensities when compared between the gene expression profiles prepared from neutrophils from said subject and profiles prepared from neutrophils isolated from the normal donor are then extracted from the display gel as previously described in Example 1. The isolated fragments are then reamplified using 5' and 3' primers, subcloned into pCR-Script (Stratagene) and sequenced using an ABI  
10 automated sequencer.

Once sequences are obtained which correspond to the bands of interest, the sequences can be compared to known nucleic acid sequences in the available data bases.

#### Example 5.

- Method to identify a therapeutic or prophylactic agent that modulates the response of a*  
15 *granulocyte population to a pathogen*

- The methods set forth in Example 1 offer a powerful approach for identifying therapeutic or prophylactic agents that modulate the expression of neutrophils or other granulocytic cells to a pathogen. For instance, profiles of normal granulocytes and neutrophils or other granulocytes exposed to pathogens such as *E. coli*, *Y. pestis* or other  
20 pathogenic bacteria are prepared as set forth in Example 1. A profile is also prepared from a granulocyte population that has been exposed to the pathogen in the presence of the agent to be tested. By examining for differences in the intensity of individual bands between the three profiles, agents which up or down regulate genes of interest in the pathogen exposed granulocytes can be identified.

- 25 As a specific example, screening for agents which up or down regulate the expression of human pre-B cell enhancing factor (PBEF) can be identified by

-59-

examining the differences in band intensity between profiles produced from normal granulocytes, granulocytes exposed to the pathogen and granulocytes exposed to the pathogen in the presence of the agent to be tested. As shown in Figure 4, PBEF is expressed at high levels when exposed to avirulent bacteria, including *E. coli* K12 and  
5 avirulent *Y. pestis* but is not expressed at high levels in granulocytes exposed to pathogenic *Y. pestis*. Agents that up regulate PBEF expression as demonstrated by increased band density in the profile produced from granulocytic cells exposed to virulent *Y. pestis* in the presence of the agent may be useful in modulating the response of neutrophils to bacterial infection.

-60-

## Example 6

*Method to identify a therapeutic or prophylactic agent that modulates the expression of genes in a granulocyte cell population found in a subject having a sterile inflammatory disease.*

- 5       The methods set forth in Example 4 offer a powerful approach for identifying therapeutic or prophylactic agents that modulate the expression of neutrophils or other granulocytic cells in subjects exhibiting the symptoms of a sterile (non-infectious) inflammatory disease. For instance, gene expression profiles of normal granulocytes and granulocytes from a subject exhibiting the symptoms of a sterile inflammatory
- 10   disease are prepared as set forth in Examples 1 and 4. A profile is also prepared from a granulocyte population from a subject exhibiting the symptoms of a sterile inflammatory disease that have been exposed to the agent to be tested. By examining these profiles for differences in the intensity of band between the three profiles, agents which up or down regulate genes of interest in a granulocytic population from a subject
- 15   exhibiting the symptoms of a sterile inflammatory disease can be identified. Agents that up-regulate a gene or genes that are expressed at abnormally low levels in a granulocytic cell population from a subject exhibiting the symptoms of a sterile inflammatory disease compared to a normal granulocytic cell population as well as agents that down regulate a gene or genes that are expressed at abnormally high levels
- 20   in a granulocytic cell population from a subject exhibiting the symptoms of a sterile inflammatory disease are contemplated.

## Example 7

- Production of solid support compositions comprising groupings of nucleic acids that correspond to the genes whose expression levels are modulated in a granulocytic*
- 25   *population that has been exposed to a pathogen or nucleic acids that correspond to the genes whose expression levels are modulated in a granulocytic cell population from a subject having a sterile inflammatory disease.*

-61-

As set forth in Examples 1-4, expression profiles from granulocytic cells exposed to a pathogen or granulocytic cells from a subject having a sterile inflammatory disease yield the identity of genes whose expression levels are modulated compared to normal, quiescent granulocytic cells.

- 5       Solid supports can be prepared that comprise immobilized representative groupings of nucleic acids corresponding to the genes or fragments of said genes from granulocytic cells whose expression levels are modulated in response to exposure to a pathogen or in a subject having a sterile inflammatory disease. For instance, representative nucleic acids can be immobilized to any solid support to which nucleic
- 10 acids can be immobilized, such as positively charged nitrocellulose or nylon membranes (see Sambrook *et al.* (1989) *Molecular Cloning: a laboratory manual* 2nd., Cold Spring Harbor Laboratory) as well as porous glass wafers such as those disclosed by Beattie (WO 95/11755). Nucleic acids are immobilized to the solid support by well established techniques, including charge interactions as well as attachment of
- 15 derivatized nucleic acids to silicon dioxide surfaces such as glass which bears a terminal epoxide moiety. A solid support comprising a representative grouping of nucleic acids can then be used in standard hybridization assays to detect the presence or quantity of one or more specific nucleic acid species in a sample (such as a total cellular mRNA sample or cDNA prepared from said mRNA) which hybridize to the nucleic acids
- 20 attached to the solid support. Any hybridization methods, reactions, conditions and/or detection means can be used, such as those disclosed by Sambrook *et al.* (1989) *Molecular Cloning: a laboratory manual* 2nd., Cold Spring Harbor Laboratory, Ausbel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience or Beattie (WO 95/11755).
- 25       One of ordinary skill in the art may determine the optimal number of genes that must be represented by nucleic acid fragments immobilized on the solid support to effectively differentiate between samples, *e.g.* neutrophils exposed to various pathogens or neutrophils isolated from a patient to be tested for a sterile inflammatory disease.

-62-

Preferably, at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population will be present in the gene expression profile or array affixed to a solid support. More preferably, such profiles or arrays will contain a sufficient representative number of mRNA species whose expression levels are modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In most instances, a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100 in number and will be represented by the nucleic acid molecules or fragments of nucleic acid molecules immobilized on the solid support. For example, nucleic acids encoding all or a fragment of one or more of the known genes or previously reported ESTs that are identified in Fig.4 and Tables 1 and 2 may be so immobilized. The skilled artisan will be able to optimize the number and particular nucleic acids for a given purpose, i.e., screening for modulating agents, identifying activated granulocytes, etc.

#### 15 Example 9.

##### *Method of diagnosing exposure of a subject to a pathogen.*

Expression profiles of RNA expression levels from neutrophils exposed to various bacteria, such as those disclosed in Examples 1 and 3, offer a powerful means to diagnose exposure of a subject to a pathogen. As set forth in Examples 1 and 3, the display patterns generated from cDNAs made with RNA isolated from neutrophils exposed to pathogenic and nonpathogenic *E. coli* and *Y. pestis* exhibit unique patterns of cDNA species corresponding to neutrophil mRNA species (genes) whose expression levels are modulated in response to contact of the neutrophils with the bacteria. The contacting of neutrophils with different species of pathogens may result in the production of expression profiles that are unique to each pathogen species or strain. These unique expression profiles are useful in diagnosing whether a subject has been exposed to or is infected with a given pathogen.



-63-

Briefly, expression profiles are produced as set forth in Example 1 using neutrophil samples exposed to various pathogens, such as pathogenic strains of *E. coli*, *Y. pestis*, Staphylococci, Streptococci or any other bacterial species. Neutrophils are then isolated from the subject to be tested for exposure to a pathogen and an expression profile

5 prepared from the subject's neutrophils by the methods set forth in Example 1. The expression profile prepared from the subject neutrophils can then be compared to the expression profiles prepared from neutrophils exposed to the various pathogen species or strains to determine which expression profile most closely matches the expression profile prepared from the subject, thereby, diagnosing exposure of the subject to a

10 pathogen.

#### Example 10

##### *Method of diagnosing a sterile inflammatory disease in a subject*

Expression profiles of RNA expression levels from neutrophils isolated from a subject having a sterile inflammatory disease, such as those disclosed in Example 4,

15 offer a powerful means to diagnose inflammatory diseases such as psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and periodontal disease. As set forth in Example 4, the gene expression profiles generated from cDNAs made with RNA isolated from

20 neutrophils from subjects having various sterile inflammatory diseases may exhibit unique patterns of cDNA species corresponding to neutrophil mRNA species (genes) whose expression levels are modulated during the inflammatory process. These unique expression profiles are useful in diagnosing whether a subject has a sterile inflammatory disease.

25 Briefly, expression profiles are produced as set forth in Examples 1 and 4 using neutrophil samples isolated from patients with various sterile inflammatory diseases. Neutrophils are then isolated from the subject to be tested and an expression profile

-64-

prepared from the subject's neutrophils by the methods set forth in Example 1. The expression profile prepared from the subject neutrophils can then be compared to the expression profiles prepared from neutrophils isolated from patients with various sterile inflammatory diseases to determine which expression profile most closely matches the  
5 expression profile prepared from the subject, thereby, diagnosing whether the subject has a sterile inflammatory disease.

It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It therefore should be apparent to those of ordinary skill in the art that various modifications and equivalents can be  
10 made without departing from the spirit and scope of the invention. All articles, patents and texts that are identified above are incorporated by reference in their entirety.

-65-

**What is Claimed Is:**

1. A method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte population to a pathogen, comprising the steps of:
  - preparing a first gene expression profile of a quiescent granulocyte  
5 population;
  - preparing a second gene expression profile of a granulocyte population exposed to the pathogen;
  - treating the exposed granulocyte population with the agent;
  - preparing a third gene expression profile of the treated granulocyte  
10 population;
  - comparing the first, second and third gene expression profiles; and
  - identifying agents that modulate the response of a granulocytic population to the pathogen.
- 15 2. The method of claim 1, wherein the granulocyte population is selected from the group consisting of a population of neutrophils, basophils and eosinophils.
3. The method of claim 1, wherein the pathogen is selected from the group consisting of bacteria, viruses, fungi and parasites.
4. The method of claim 3 wherein the pathogen is selected from the group  
20 consisting of Gram positive and Gram negative bacteria.
5. The method of claim 3, wherein the pathogen is selected from the group consisting of Staphylococci, Streptococci, Clostridia, Neisseria, Enterobacteriaceae, Helicobacter, Vibrio, Campylobacter, Pseudomonas, Haemophilus, Bordetella,

-66-

Mycoplasma, Ureaplasma, Legionella, Spirochetes, Mycobacteria, Actinomyces, Nocardia, Chlamydia, Rickettsia, Coxiella, Ehrlichia, Rochalimaea, Brucella, Yersinia, Francisella, and Pasteurella.

6. A method to identify a therapeutic agent that modulates the expression of at least one gene in a granulocyte population found in a subject having a sterile inflammatory disease; comprising the steps of:

preparing a first gene expression profile of a granulocyte population in a subject having the sterile inflammatory disease;

treating the granulocyte population with the agent;

10 preparing a second gene expression profile of the treated granulocyte population;

comparing the first and second gene expression profiles with the gene expression profile of a normal granulocyte preparation; and

15 identifying an agent that modulates the expression of at least one gene whose transcription levels are altered in the granulocyte population of the subject as compared with normal granulocyte population.

7. The method of claim 6, wherein the granulocyte population is selected from the group consisting of a population of neutrophils, basophils and eosinophils.

8. The method of claim 6, wherein the sterile inflammatory disease is selected from the group consisting of psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and periodontal disease.

-67-

9. A composition comprising a grouping of nucleic acids that correspond to the genes or fragments of genes whose expression levels are modulated in a granulocyte population that has been exposed to a pathogen affixed to a solid support.

10. A composition comprising a grouping of nucleic acids that correspond to the  
5 genes or fragments of genes whose expression levels are modulated in a granulocyte population found in a subject having a sterile inflammatory disease affixed to a solid support.

11. A method of diagnosing exposure of a subject to a pathogen, comprising the steps of:

10 preparing a first gene expression profile of a granulocyte population from the subject;

comparing the first gene expression profile to a second gene expression profile of a granulocyte population exposed to the pathogen and to a third gene expression profile of a normal granulocyte preparation; and

15 determining if the subject was exposed to a pathogen.

12. A method of diagnosing a sterile inflammatory disease in a subject, comprising the steps of:

preparing a first gene expression profile of a granulocyte population from the subject;

20 comparing the first gene expression profile to at least one second gene expression profile from a granulocyte population from a subject having a sterile inflammatory disease and to a third gene expression profile of a normal granulocyte population; and

determining if the subject has a sterile inflammatory disease.

-68-

13. The method of claim 12, wherein the sterile inflammatory disease is glomerulo-nephritis.




FIG. 1






FIG. 2



FIG. 3



1) Neutrophils alone    2) Neutrophils + *E.coli*    3) Neutrophils + V



phils + Virulent *y. pestis* 4) Neutrophils + Avirulent *y. pestis*

Differential Display							Summary of Results (I)	Known Genes
No.	Clones	NIN2	Expression Patterns				Gene Bank Search and Analysis	
			Control	E. coli	Virulent	Avirulent		
1	NP102-3	AA	0	+	0	+	NADH-ubiquinone oxidoreductase ASH1 subunit	
2	IN12-B12	AC	+	+++	++	++++	human ubiquitin/polyubiquitin	
3	NP104-5	AA	+	+++	++	++	MAP kinase kinase 3b	
4	NP131-3	CA	++	+	++++	++++	cdc2/CDC28-like protein kinase (clk1)	
5	B20-4	AC	+++	++	±	+	human cyclin-dependent kinase inhibitor	
6	NP119-1	AG	0	+	0	++	bcl-2 related (bfl-1) mRNA	
7	NP126-3	AT	0	+++	+	+++	human B-cell lymphoma 3-encoded protein bcl-3 mRNA	
8	NP124-3	AT	++	+++	++	+++	helix-loop-helix basic phosphoprotein (GOS8)	
9	B14-3	AC	++	+++	0	+	human nucleolar phosphoprotein B23 (nucleophosmin)	
10	IN23-E11	AC	±	+++	+	+++	LD78 β (human homolog of mouse MIP1α)	
11	NP125-2	AT	0	++	±	++	LD78 receptor (HM74)	
12	NP149-1	CG	+++	+	++	++	vacuolar H+ pumping ATPase (16KD proteolipid subunit)	
13	B23-2	AC	++	+++	+	++	vacuolar H+ pumping ATPase (56KD subunit)	
14	NP139-1	CC	±	++	+	+++	plasma membrane Ca2+ pumping ATPase (56KD subunit)	
15	NP105-1	AA	++++	±	+	++	human H3.3 gene exon 4	
16	NP128-3	CA	0	+	++	++++	ribosomal protein S19	

FIG. 4

Differential Display							Summary of Results (I)	Known Genes
No.	Clones	NIN2	Expression Patterns				Gene Bank Search and Analysis	
			Control	E. coli	Virulent	Avirulent		
17	IN20-E8	AC	+	±	++	±	ribosomal protein S20	
18	NP127-2	AT	+	+	±	+	poly(A) binding protein II	
19	NP103-3	AA	++	+++	+	++++	Spermidine/Spermine N1-acetyltransferase	
20	NP132-2	CA	+	±0	+	++	human GDP-dissociation inhibitor (LY-GDI)	
21	B4-1	AC	+++	+++	+	+	bovine GTP binding regulatory protein $\gamma$ -6 subunit	
22	NP107-2	AA	++++	++	+++	+++	human B4-2 protein	
23	NP156-1	CG	++	+	++	++	ras-related protein p23/Rab-7	
24	B5-4	AC	±	+++	+	++	mouse ras-related YTP1 protein/Rab-1A	
25	B14-4	AC	+	+++	+	++++	human pre-B cell enhancing factor (PBEF)	
26	B22-2	AC	++	+++	+	++	human complement decay accelerating factor	
27	Bam1	AC	+	++	++++	++	TNF $\alpha$ inducible protein B94	

FIG. 4 (Cont.)

Differential Display										Summary of Results (I)		EST Sequences	
No	Clones	NIN2	Expression Patterns				Gene Bank Search and Analysis						
			Control	E. coli	Virulent	Avirulent							
1	NP101-3	AA	++	++	0	++	EST (GB/L81699/HSL81699)						
2	NP108-3	AA	++	+	+	++	EST (GB/R09487/R09487)						
3	NP113-2	AG	++	+	++	+	EST (GB/U79267/HSU79267)						
4	NP114-2	AG	+++	+	++	+++	EST (GB/N26756/N26756)						
5	NP115-3	AG	++	+	+++	+++	EST (GB/L49761/HUM78188)						
6	NP116-3	AG	+	+	++	+	EST (EMB/F10736/HSC3JC022)						
7	NP117-2	AG	±	++++	++	+++	EST (GB/AA004905/AA004905)						
8	NP120-3	AG	±	+	++	+	EST (GB/R16810/R16810)						
9	NP121-2	AG	±	++	+	++	EST (GB/AA159075/AA159075)						
10	NP122-1	AT	0	+	±	++	EST (GB/AA016979/AA016979)						
11	NP133-1	CA	+++	++	+++	+++	EST (GB/AA190718/AA190718)						
12	NP134-2	CA	0	±	++	+	EST (GB/T29287/T29287)						
13	NP138-1	CC	+	++	+	+++	EST (GB/T58520/T58520)						
14	NP150-1	CG	+	+++	+++	+++	EST (GB/AC001223/HSAC001223)						
15	B7-1	AC	++	+	+	0	EST (DJB/D60083/HUM084H05A)						
16	B8-1	AC	+++	+	++	0	EST (GB/R37008/R37008)						

FIG. 4 (Cont.)

Differential Display Summary of Results (I) EST Sequences						
No.	Clones	N1N2	Expression Patterns			Gene Bank Search and Analysis
			Control	E. coli	Virulent	Avirulent
17	B10-1	AC	+++	++	0	+
18	B12-2	AC	++	+++	+	+
19	B13-4	AC	+++	++	+	+
20	B15-2	AC	+++	±	++	±
21	B17-2	AC	++++	+++	++	+
22	B18-2	AC	++++	++	+++	+
23	B19-5	AC	+	++	+	±
24	B21-3	AC	+++	+++	+	++
25	IN10-B10	AC	+	+++	+	+++
26	IN19-E7	AC	0	+++	0	+
27	IN21-E9	AC	+	+++	+	++
28	IN22-E10	AC	++++	++	+++	+
29	Bcl	AC	+++	+++	+	++
						EST (GB/W67981/W67981)
						EST (GB/N24729/N24729)
						EST (GB/N23012/N23012)
						EST (GB/R49664/R49664)
						EST (GB/T34605/T34605)
						EST (GB/AA055573/AA055573)
						EST (GB/AA076421/AA076421)
						EST (GB/AA150905/AA150905)
						EST (GB/N21073/N21073)
						EST (GB/AA044087/AA044087)
						EST (GB/H44997/H44997)
						EST (GB/N50114/N50114)
						EST (EMB/Z39133/HSC11B122)

FIG. 4 (Cont.)

Differential Display										Summary of Results (I)		Unknown Sequences	
No	Clones	N1N2	Expression Patterns				Gene Bank Search and Analysis						
			Control	E coli	Virulent	Avirulent							
1	NP109-5	AA	+++	±	±	±	Unknown						
2	NP110-2	AA	±	++	+	++	Unknown						
3	NP111-2	AG	++	±	+	+	Unknown						
4	NP112-1	AG	0	0	0	++	Unknown						
5	NP118-1	AG	+++	+	+++	+	Unknown						
6	NP129-3	CA	±	+	+	+++	Unknown						
7	NP137-1	CC	0	+	0	++	Unknown						
8	NP140-1	CC	±	++	±	++	Unknown						
9	NP143-3	CC	+	++	++	±	Unknown						
10	P144-1	CC	+	+++	+	+++	Unknown						
11	NP146-2	CC	++	+++	+++	+++	Unknown						
12	NP157-1	CT	0	+	+	++	Unknown						

FIG. 4 (Cont.)

BamH1gel.JPG




FIG. 5



BamH1gel2.JPG





FIG. 5 (Cont.)



1. Neutrophils alone
2. Neutrophils + *E.coli*
3. Neutrophils + Virulent *y. pestis*
3. Neutrophils + Avirulent *y. pestis*

FIG. 6

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/17284

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) C12Q 1/68; C07H 21/04; C12P 19/34

US CL. 435/6, 91.2; 536/24.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/24.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97/05286 A1 (YALE UNIVERSITY) 13 February 1997, see entire document.	1-13
Y	TAM, F.W.K., et al., Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis. Kidney Internat. 1996, Vol. 49, pages 715-721, see especially the abstract, page 716, col. 1, and Figure 1.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 NOVEMBER 1998

Date of mailing of the international search report

22 DEC 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARY TUNG

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17284

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

MEDLINE, SCISEARCH, CANCERLIT, BIOSIS, EMBASE, WPIDS, USPATFULL, APS

**search terms:** glomerulonephritis, neutrophil, polymorphonucleocyte, granulocyte, bacteria, virus, fungus, parasite, gene, DNA, nucleic acid, inflammation, gene expression



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68, C07H 21/04, C12P 19/34</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/10536</b> <b>(43) International Publication Date:</b> 4 March 1999 (04.03.99)
<b>(21) International Application Number:</b> PCT/US98/17284 <b>(22) International Filing Date:</b> 21 August 1998 (21.08.98)  <b>(30) Priority Data:</b> 60 056,844      22 August 1997 (22.08.97)      US  <b>(71) Applicant (for all designated States except US):</b> YALE UNIVERSITY [US US]; 451 College Street, New Haven, CT 06520 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YERRAMILLI, Subrahmanyam, V. [IN US]; Apartment 103, 18453 Lost Knife Circle, Montgomery Village, MD 20886 (US). PRASHAR, Yatindra [IN US]; 15 Mountain Lake Court, Germantown, MD 20874 (US). NEWBURGER, Peter [US/US]; 165 Winsor Road, Waban, MA 02468 (US). GOGUEN, Jon [US/US]; 237 Brattle Street, Holden, MA 01520 (US). WEISSMAN, Sherman, M. [US US]; 459 Saint Ronan Street, New Haven, CT 06511 (US).  <b>(74) Agent:</b> ADLER, Reid, G., Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).		<b>(81) Designated States:</b> AU, CA, IL, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN GRANULOCYTIC CELLS  <b>(57) Abstract</b> <p>The present invention comprises a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen or in a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen or isolated from a subject having a sterile inflammatory disease and comparing that profile to a profile prepared from quiescent granulocytic cells. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules. The invention also includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a granulocyte population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.</p>		

\*(Referred to in PCT Gazette No. 20/1999, Section II)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

## A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN GRANULOCYTIC CELLS

This application is related to application serial No. 08/510,032, serial No. 60/056,844 and application serial No. 08/688,514, all of which are herein incorporated by reference in their entirety. All published articles, patents and other publications cited throughout this application are herein incorporated by reference in their entirety.

### 5 Technical Field

This invention relates to compositions and methods useful to identify agents that modulate the response of granulocytes to inflammatory and infectious conditions.

### Background of the Invention

Granulocytes (*i.e.*, neutrophils, eosinophils and basophils) are involved in the  
10 immune response elicited by inflammation and infection.

#### *Inflammation*

Inflammation is a localized protective response elicited by injury or destruction of tissues which serves to destroy, dilute or wall off both the injurious agent and the injured tissue. It is characterized by fenestration of the microvasculature, leakages of  
15 the elements of blood into the interstitial spaces, and migration of leukocytes into the inflamed tissue. On a macroscopic level, this is usually accompanied by the familiar clinical signs of erythema, edema, tenderness (hyperalgesia), and pain. During this complex response, chemical mediators such as histamine, 5-hydroxytryptamine, various chemotactic factors, bradykinin, leukotrienes, and prostaglandins are released locally.  
20 Phagocytic cells migrate into the area, and cellular lysosomal membranes may be ruptured, releasing lytic enzymes. All of these events may contribute to the inflammatory response.

-2-

Inflammation is initiated by, among other things, trauma, tissue necrosis, infection or immune reactions. The immediate response is temporary vasoconstriction. Vasoconstriction is followed within seconds by the acute vascular response resulting in increased blood flow (hyperemia) and edema. The acute phase is also characterized by

5 the margination of polymorphonuclear white blood cells (neutrophils) next to endothelial cells, followed by emigration of neutrophils into the adjacent tissue. Margination is recognized by the lining up of neutrophils along the endothelium of vessels. Emigration occurs by passage of the inflammatory cells between endothelial cells.

#### 10 *Neutrophils*

Neutrophils are the first wave of cellular attack on invading organisms and are the characteristic cells of acute inflammation. The appearance of neutrophils in areas of inflammation may be caused by chemicals released from bacteria, factors produced nonspecifically from necrotic tissue or antibody reacting with antigen. Neutrophils use

15 an actin-rich cytoskeleton to move in a directed manner along a chemotactic gradient from the bloodstream to an inflammatory site where they ingest particles (*e.g.*, bacteria) and immune complexes bearing IgG (via FcR) and/or breakdown products of the complement component C3.

Neutrophils belong to a category of white blood cells known as

20 polymorphonuclear white blood cells. The blood cells with single nuclei (mononuclear cells) form the white blood cell population that includes macrophages, T and B cells. White blood cells that contain segmented nuclei are broadly classified as polymorphonuclear. Polymorphonuclear white blood cells (or "granulocytes") are further subdivided into three major populations on the basis of the staining properties of

25 their cytoplasmic granules in standard hematologic smears or tissue preparations: neutrophils staining pink, eosinophils staining red and basophils staining blue.



-3-

Neutrophils (also referred to as polymorphonuclear neutrophils-PMNs) make up 50% to 70% of the white blood cells (WBCs) of the peripheral blood and may be found scattered diffusely in many tissues, although they are most frequently found in areas of acute inflammation or acute necrosis. Like other WBCs, neutrophils are produced from precursor cells in the bone marrow and released into the blood when mature. After entering the circulation, neutrophils are thought to last only 1 or 2 days.

Neutrophils are characterized by numerous cytoplasmic granules that contain highly destructive enzymes that must be kept isolated from the cytoplasm. These granules contain a number of oxygen-independent enzymes as well as oxygen-dependent mechanisms of killing. Upon attraction to sites of inflammation, neutrophils attempt to engulf and digest bacteria coated with antibody and complement. Phagocytosis by neutrophils is also usually accompanied by release of the lysosomal enzymes into the tissue spaces, particularly if the organism is difficult for the neutrophil to digest

At least three cytoplasmic granules are identifiable in neutrophils: specific granules containing lactoferrin, B cytochrome, the complement receptor CR3 and  $\beta_2$ -integrin; azurophilic granules containing acid hydrolases and other enzymes; and a third granule containing gelatinase.

In addition to the role neutrophils and other granulocytic cells play in immune response to pathogens, including bacterial infection, neutrophils and other granulocytic cells play an unwanted role in many chronic inflammatory diseases. There are many disease states in which excessive or unregulated granulocytic cell infiltration and activation are implicated in exacerbating and/or causing the disease. For instance, many inflammatory diseases are characterized by massive neutrophil infiltration, such as psoriasis, inflammatory bowel disease, Crohn's disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, rheumatoid arthritis, thrombosis and glomerulonephritis. All of these diseases are associated with increased IL-8

-4-

production which may be responsible for the chemotaxis of neutrophils into the inflammatory site.

While the role of neutrophil infiltration and activation in inflammation is well known, the biosynthetic responses of neutrophils to pathogens, chemotactic agents, 5 proinflammatory molecules, etc. are not as well understood. Neutrophils were once thought to be in a state of terminal differentiation, thereby lacking biosynthetic ability. This view is consistent with the relative scarcity in mature circulating neutrophils of ribosomes and endoplasmic reticulum and with the ability of neutrophils to ingest particles when RNA and/or protein synthesis has been inhibited. More recently it has 10 been demonstrated that neutrophils perform more active roles in their response to environmental stimuli.

It has thus recently been established that neutrophils synthesize *de novo* important macromolecules including, but not limited to interleukin (IL) 1, IL-6, IL-8, tumor necrosis factor (TNF $\alpha$ ), granulocyte and macrophage colony-stimulating factors, 15 interferon  $\alpha$  (IFN $\alpha$ ), intercellular adhesion molecule (ICAM-1) and membrane and cytoskeletal molecules, such as major histocompatibility class I antigens and actin (Beaulieu et al (1992) *J. Biolog. Chem.* 267(1):426-432; Arnold et al. (1993) *Infect. Immun.* 61(6):2545-2552; and Elsner et al. (1995) *Immunobiol* 193:456-464). No study, however, has taken a systematic approach to assess the transcriptional response 20 during neutrophil activation via contact with a pathogen or from neutrophils isolated from a subject with a sterile inflammatory disease.

#### *Eosinophils and Basophils*

Eosinophils are another granulocytic or polymorphonuclear white blood cell that are involved in the inflammatory response. Eosinophils are found predominately in 25 two types of inflammation: allergy and parasite infections.

The role of eosinophils in the host response to parasites is thought to be mediated through the components of the eosinophilic granules. Eosinophils are

-5-

cytotoxic to schistosome larvae through an antibody-dependent cell-mediated mechanism. Eosinophil cationic proteins are highly toxic for schistosomes and may be responsible for binding of eosinophils to parasitic worms as well as fragmentation of the parasite.

5        The role of eosinophils in acute inflammation is not fully understood. On one  
hand, there is evidence that enzymes in eosinophils may serve to limit the extent of  
inflammation by neutralizing mediators of anaphylaxis, such as LTC<sub>4</sub> , histamine and  
platelet-activating factor. On the other hand, there is increasing evidence that cationic  
proteins in eosinophilic granules are mediators of acute inflammation. Eosinophil  
10    activation is associated with acute tissue injury and cause an intense vasoconstriction in  
lung microvasculature, followed by increased pulmonary vascular permeability and  
pulmonary edema.

Basophils or mast cells are the other major cell type characterized as a granulocytic or polymorphonuclear white blood cell. Mast cells contain granules with a variety of biologically active agents which, when released extracellularly (degranulation), cause dilation of the smooth muscle of arterioles (vasodilation), increased blood flow, and contraction of endothelial cells, thereby opening up vessel walls to permit egress of antibodies, complement or inflammatory cells into tissue spaces.

## 20 Summary of the Invention

While the role of neutrophils and other granulocytic cells in inflammation and/or the immunological response to infection has been the subject of intense study, little is known about the global transcriptional response of granulocytes during cell activation. The present inventors have devised an approach to systematically assess the transcriptional response from granulocytic cells activated through contact with a pathogen or from granulocytic cells isolated from a subject with a sterile inflammatory disease.

-6-

The present invention includes a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen and comparing that profile to a profile prepared from quiescent granulocytic cells. cDNA species, and  
5 therefore genes, which are expressed *de novo* upon neutrophil contact with a pathogen are thereby identified. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules.

The present invention also includes a method to identify granulocytic cell genes  
10 that are differentially expressed in response to a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population isolated from a subject exhibiting the symptoms of a sterile inflammatory disease and comparing that profile to a profile prepared from granulocytic cells isolated from a normal granulocytic cell population. cDNA species, and therefore genes, which are differentially expressed  
15 in the granulocytic cells of a subject exhibiting the symptoms of a sterile inflammatory disease are thereby identified.

The present invention also includes a method to identify granulocytic cell genes that are differentially expressed upon exposure of a granulocytic cell population to an agonist (pro-inflammatory molecule) by preparing a gene expression profile of a  
20 granulocytic cell population contacted with an agonist and comparing that profile to a profile prepared from noncontacted granulocytic cells, thereby identifying cDNA species, and therefore genes, which are expressed *de novo* in the granulocytic cells contacted with the agonist are thereby identified.

The present invention further includes a method to identify a therapeutic or  
25 prophylactic agent that modulates the response of a granulocyte population to a pathogen, comprising the steps of preparing a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to a pathogen, treating said exposed granulocyte

-7-

population with the agent, preparing a third gene expression profile of the treated granulocyte population, comparing the first, second and third gene expression profiles and identifying agents that modulate the response of a granulocyte population to the pathogen.

Another aspect of the invention is a method to identify a therapeutic agent that modulates the expression of genes in a granulocyte population found in a subject having

Another aspect of the invention includes a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte cell population in a subject having a sterile inflammatory disease, comprising the steps of preparing a first gene expression profile of a granulocyte population in a subject having a sterile inflammatory disease, treating the granulocyte population with the agent, preparing a second gene expression profile of the treated granulocyte population, comparing the first and second gene expression profiles with the gene expression profile of a normal granulocyte population and identifying agents that modulate the expression of genes whose transcription levels are altered in the granulocyte population of the subject as compared with normal granulocyte population.

A further aspect of the present invention is a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocytic population to an agonist (pro-inflammatory molecule), comprising the steps of preparing a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to an agonist, treating the exposed granulocyte population with the agent, preparing a third gene expression profile of the treated granulocyte population, comparing the first, second and third gene expression profiles and identifying agents that modulate the response of a granulocytic population exposed to an agonist.

The present invention also includes a method of diagnosing the exposure of a subject to a pathogen, comprising the steps of preparing a first gene expression profile of a granulocyte population from the subject, comparing the first gene expression

-8-

profile to a second gene expression profile of a granulocyte population exposed to that pathogen and to a third gene expression profile of a normal granulocyte preparation and diagnosing whether the subject has been exposed to a pathogen.

Another aspect of the invention includes a method of diagnosing a sterile inflammatory disease in a subject, comprising the steps of preparing a first gene expression profile of a granulocyte population from the subject, comparing the first gene expression profile to at least one second gene expression profile from a granulocyte population from a subject having a sterile inflammatory disease and to a third gene expression profile of a normal granulocyte preparation and thereby determining if the subject has a sterile inflammatory disease.

The present invention also includes a method of identifying new bacterial virulence factor genes by preparing a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to a virulent or avirulent bacterial strain, preparing a third gene expression profile from a granulocyte population exposed to a bacterial strain with a mutation in a putative bacterial virulence factor gene, comparing the first, second and third gene expression profiles and identifying a bacterial virulence factor gene.

Another aspect of the invention is a composition comprising a grouping of nucleic acids that correspond to at least a part of one or more of the genes whose expression levels are modulated in a granulocyte population that has been exposed to a pathogen, these nucleic acids being affixed to a solid support.

Lastly, an aspect of the invention is a composition comprising a grouping of nucleic acids that correspond to at least part of one or more genes whose expression levels are modulated in a granulocyte population found in a subject having a sterile inflammatory disease, these nucleic acids being affixed to a solid support.

#### **Brief Description of the Drawings**

-9-

Fig. 1 Figure 1 is an autoradiogram of the expression profile generated from cDNAs made with RNA isolated from neutrophils exposed to avirulent *Escherichia coli* and virulent and avirulent *Yersinia pestis*.

Fig. 2 Figure 2 is an autoradiogram of the expression profile generated from  
5 cDNAs made with RNA isolated from neutrophils exposed to virulent and avirulent *E. coli*, virulent and avirulent *Y. pestis*, LPS, GM-CSF, TNF $\alpha$ , or  $\gamma$ IFN.

Fig. 3 Figure 3 is an autoradiogram of the expression profile generated from cDNAs made with RNA isolated from neutrophils exposed to avirulent *E. coli* and virulent and avirulent *Y. pestis*. All possible 12 anchoring oligo d(T)n1, n2 were used  
10 to generate a complete expression profile for the enzyme *Bgl*III.

Fig. 4 Figure 4 represents a summary of genes which are differentially expressed in neutrophils upon exposure to virulent and avirulent *E. coli* and *Y. pestis*.

Fig. 5 Figure 5 is an autoradiogram of the expression profile generated from cDNAs made with RNA isolated from neutrophils exposed to avirulent *E. coli* and  
15 virulent and avirulent *Y. pestis*. All possible 12 anchoring oligo d(T)n1, n2 were used to generate a complete expression profile for the enzyme *Bam*HI.

Fig. 6 is a section of an autoradiogram showing the differences in band intensity for 2 mRNA species when neutrophils are exposed to avirulent *E. coli* and virulent and avirulent *Y. pestis*.

## 20 Modes of Carrying Out the Invention

### General Description

The response of neutrophils to pathogens, including bacterial pathogens, is a subject of primary importance in view of the need to find ways to modulate the immune response to infection. Similarly, the response of neutrophils to agonists (pro-  
25 inflammatory molecules) is a subject of primary importance in view of the need to find better ways of controlling inflammation in various disease states. One means of assessing the response of neutrophils to pathogens and agonists is to measure the ability

-10-

of neutrophils to synthesize specific RNA *de novo* upon contact with the pathogen or agonist.

The following discussion presents a general description of the invention as well definitions for certain terms used herein.

## 5 Definitions

Granulocytic cells, also known as polymorphonuclear white blood cells, include neutrophils, also known as polymorphonuclear neutrophils or peripheral blood neutrophils, eosinophils, and basophils, also referred to as mast cells.

The term "pathogen" refers to any infectious organism including bacteria, viruses,  
10 parasites, mycoplasma, protozoans, and fungi (including molds and yeast). Pathogenic bacteria include, but are not limited to Staphylococci (e.g. aureus), Streptococci (e.g. pneumoniae), Clostridia (e.g. perfringens), Neisseria (e.g. gonorrhoeae), Enterobacteriaceae (e.g. coli as well as Klebsiella, Salmonella, Shigella, Yersinia and Proteus), Helicobacter (e.g. pylori), Vibrio (e.g. cholerae), Campylobacter (e.g. jejuni),  
15 Pseudomonas (e.g. aeruginosa), Haemophilus (e.g. influenzae), Bordetella (e.g. pertussis), Mycoplasma (e.g. pneumoniae), Ureaplasma (e.g. urealyticum), Legionella (e.g. pneumophila), Spirochetes (e.g. Treponema, Leptospira and Borrelia), Mycobacteria (e.g. tuberculosis, smegmatis), Actinomyces (e.g. israelii), Nocardia (e.g. asteroides), Chlamydia (e.g. trachomatis), Rickettsia, Coxiella, Ehrlichia, Rochalimaea,  
20 Brucella, Yersinia, Francisella, and Pasteurella.

The term "sterile inflammatory disease" refers to any inflammatory disease caused by immune or nonimmune mechanisms not directly linked to infection (see Stewart *et al.*). Examples of sterile inflammatory diseases include, but are not limited to psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury,  
25 thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and periodontal disease.



-11-

The phrase "solid support" refers to any support to which nucleic acids can be bound or immobilized, including nitrocellulose, nylon, glass, other solid supports which are positively charged and nanochannel glass arrays disclosed by Beattie (WO 95/1175).

The phrase "gene expression profile", also referred to as a "differential expression profile" or "expression profile" refers to any representation of the expression of at least one mRNA species in a cell sample or population. For instance, a gene expression profile can refer to an autoradiograph of labeled cDNA fragments produced from total cellular mRNA separated on the basis of size by known procedures. Such procedures include slab gel electrophoresis, capillary gene electrophoresis, high performance liquid chromatography, and the like. Digitized representations of scanned electrophoresis gels are also included as are two and three dimensional representations of the digitized data.

While a gene expression profile encompasses a representation of the expression level of at least one mRNA species, in practice, the typical gene expression profile represents the expression level of multiple mRNA species. For instance, a gene expression profile useful in the methods and compositions disclosed herein represents the expression levels of at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population. Particularly preferred are gene expression profiles or arrays affixed to a solid support that contain a sufficient representative number of mRNA species whose expression levels are modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In some instances a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100.

Gene expression profiles can be produced by any means known in the art, including, but not limited to the methods disclosed by: Liang *et al.* (1992) *Science* 257:967-971; Ivanova *et al.* (1995) *Nucleic Acids Res.* 23:2954-2958; Guilfoyl *et al.* (1997) *Nucleic Acids Res.* 25(9):1854-1858; Chee *et al.* (1996) *Science* 274:610-614; Velculescu *et al.* (1995) *Science* 270:484-487; Fischer *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92(12):5331-5335; and Kato (1995) *Nucleic Acids Res.* 23(18):3685-3690. Preferably,

-12-

gene expression profiles are produced by the methods of Prashar *et al.* (WO 97/05286) and Prashar *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663.

As an example, gene expression profiles as described herein are made to identify one or more genes whose expression levels are modulated in a granulocytic cell population 5 exposed to a pathogen or isolated from a subject having a sterile inflammatory disease. The assaying of the modulation of gene expression via the production of a gene expression profile generally involves the production of cDNA from polyA RNA (mRNA) isolated from granulocytes as described below.

The mRNAs are isolated from a granulocytic cell source. The cells may be obtained 10 from an *in vivo* source, such as a peripheral blood. As is apparent to one skilled in the art, any granulocytic cell type may be used, however, neutrophils are preferred. Furthermore, the peripheral blood cells that are initially obtained may be subjected to various separation techniques (*e.g.*, flow cytometry, density gradients).

mRNAs are isolated from cells by any one of a variety of techniques. Numerous 15 techniques are well known (*see e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Approach*, Cold Spring harbor Press, NY, 1987; Ausubel *et.*, *Current Protocols in Molecular Biology*, Greene Publishing Co. NY, 1995). In general, these techniques first lyse the cells and then enrich for or purify RNA. In one such protocol. Cells are lysed in a Tris-buffered solution containing SDS. The lysate is extracted with 20 phenol/chloroform, and nucleic acids are precipitated. Purification of poly(A)-containing RNA is not a requirement. The mRNAs may, however, be purified from crude preparations of nucleic acids or from total RNA by chromatography, such as binding and elution from oligo(dT)-cellulose or poly(U)-Sephadex®. As stated above, other protocols and methods for isolation of RNAs may be substituted.

25 The mRNAs are reverse transcribed using an RNA-directed DNA polymerase, such as reverse transcriptase isolated from AMV, MoMuLV or recombinantly produced. Many commercial sources of enzyme are available (*e.g.*, Pharmacia, New England Biolabs, Stratagene Cloning Systems). Suitable buffers, cofactors, and conditions are well

-13-

known and supplied by manufacturers (*see also*, Sambrook *et al.*, *supra*; Ausubel *et al.*, *supra*).

Various oligonucleotides are used in the production of cDNA. In particular, the methods utilize oligonucleotide primers for cDNA synthesis, adapters, and primers for  
5 amplification. Oligonucleotides are generally synthesized as single strands by standard chemistry techniques, including automated synthesis. Oligonucleotides are subsequently de-protected and may be purified by precipitation with ethanol, chromatographed using a sized or reversed-phase column, denaturing polyacrylamide gel electrophoresis, high-pressure liquid chromatography (HPLC), or other suitable  
10 method. In addition, within certain preferred embodiments, a functional group, such as biotin, is incorporated preferably at the 5' or 3' terminal nucleotide. A biotinylated oligonucleotide may be synthesized using pre-coupled nucleotides, or alternatively, biotin may be conjugated to the oligonucleotide using standard chemical reactions. Other functional groups, such as fluorescent dyes, radioactive molecules, digoxigenin,  
15 and the like, may also be incorporated.

Partially-double stranded adaptors are formed from single stranded oligonucleotides by annealing complementary single-stranded oligonucleotides that are chemically synthesized or by enzymatic synthesis. Following synthesis of each strand, the two oligonucleotide strands are mixed together in a buffered salt solution (*e.g.*, 1 M NaCl,  
20 100 mM Tris-HCl pH.8.0, 10 mM EDTA) or in a buffered solution containing  $Mg^{2+}$  (*e.g.*, 10 mM  $MgCl_2$ ) and annealed by heating to high temperature and slow cooling to room temperature.

The oligonucleotide primer that primes first strand DNA synthesis comprises a 5' sequence incapable of hybridizing to a polyA tail of the mRNAs, and a 3' sequence that  
25 hybridizes to a portion of the polyA tail of the mRNAs and at least one non-polyA nucleotide immediately upstream of the polyA tail. The 5' sequence is preferably a sufficient length that can serve as a primer for amplification. The 5' sequence also preferably has an average G+C content and does not contain large palindromic

-14-

sequence; some palindromes, such as a recognition sequence for a restriction enzyme, may be acceptable. Examples of suitable 5' sequences are CTCTCAAGGATC:TACCGCT (SEQ ID No. \_\_\_\_), CAGGGTAGACGACGCTACGC (SEQ ID No. \_\_\_\_), and  
5 TAATACCGCGCCACATAGCA (SEQ ID No. \_\_\_\_).

The 5' sequence is joined to a 3' sequence comprising sequence that hybridizes to a portion of the polyA tail of mRNAs and at least one non-polyA nucleotide immediately upstream. Although the polyA-hybridizing sequence is typically a homopolymer of dT or dU, it need only contain a sufficient number of dT or dU bases to hybridize to polyA  
10 under the conditions employed. Both oligo-dT and oligo-dU primers have been used and give comparable results. Thus, other bases may be interspersed or concentrated, as long as hybridization is not impeded. Typically, 12 to 18 bases or 12 to 30 bases of dT or dU will be used. However, as one skilled in the art appreciates, the length need only be sufficient to obtain hybridization. The non-polyA nucleotide is A, C, or G, or a  
15 nucleotide derivative, such as inosinate. If one non-polyA nucleotide is used, then three oligonucleotide primers are needed to hybridize to all mRNAs. If two non-polyA nucleotides are used, then 12 primers are needed to hybridize to all mRNAs (AA, AC, AG, AT, CA, CC, CG, CT, GA, GC, GG, GT). If three non-poly A nucleotides are used then 48 primers are needed (3 X 4 X 4). Although there is no theoretical upper  
20 limit on the number of non-polyA nucleotides, practical considerations make the use of one or two non-polyA nucleotides preferable.

For cDNA synthesis, the MRNAs are either subdivided into three (if one non-polyA nucleotide is used) or 12 (if two non-polyA nucleotides are used) fractions, each containing a single oligonucleotide primer, or the primers may be pooled and contacted  
25 with a mRNA preparation. Other subdivisions may alternatively be used. Briefly, first strand cDNA is initiated from the oligonucleotide primer by reverse transcriptase (RTase). As noted above, RTase may be obtained from numerous sources and protocols are well known. Second strand synthesis may be performed by RTase

-15-

(Gubler and Hoffman, *Gene* 25: 263, 1983), which also has a DNA-directed DNA polymerase activity, with or without a specific primer, by DNA polymerase 1 in conjunction with RNaseH and DNA ligase, or other equivalent methods. The double-stranded cDNA is generally treated by phenol:chloroform extraction and ethanol  
5 precipitation to remove protein and free nucleotides.

Double-stranded cDNA is subsequently digested with an agent that cleaves in a sequence-specific manner. Such cleaving agents include restriction enzymes. Restriction enzyme digestion is preferred; enzymes that are relatively infrequent cutters (*e.g.*,  $\geq 5$  bp recognition site) are preferred and those that leave overhanging ends are  
10 especially preferred. A restriction enzyme with a six base pair recognition site cuts approximately 8% of cDNAs, so that approximately 12 such restriction enzymes should be needed to digest every cDNA at least once. By using 30 restriction enzymes, digestion of every cDNA is assured.

The adapters for use in the present invention are designed such that the two strands  
15 are only partially complementary and only one of the nucleic acid strands that the adapter is ligated to can be amplified. Thus, the adapter is partially double-stranded (*i.e.*, comprising two partially hybridized nucleic acid strands), wherein portions of the two strands are non-complementary to each other and portions of the two strands are complementary to each other. Conceptually, the adapter is "Y-shaped" or "bubble-  
20 shaped." When the 5' region is non-paired, the 3' end of other strand cannot be extended by a polymerase to make a complementary copy. The ligated adapter can also be blocked at the 3' end to eliminate extension during subsequent amplifications. Blocking groups include dideoxynucleotides or any other agent capable of blocking the 3'-OH. In this type of adapter ("Y-shaped"), the non-complementary portion of the  
25 upper strand of the adapters is preferably a length that can serve as a primer for amplification. As noted above, the non-complementary portion of the lower strand need only be one base, however, a longer sequence is preferable (*e.g.*, 3 to 20 bases; 3 to 15

-16-

bases; 5 to 15 bases; or 14 to 24 bases). The complementary portion of the adapter should be long enough to form a duplex under conditions of ligation.

For "bubble-shaped" adapters, the non-complementary portion of the upper strand is preferably a length that can serve as a primer for amplification. Thus, this portion is  
5 preferably 15 to 30 bases. Alternatively, the adapter can have a structure similar to the Y-shaped adapter, but has a 3' end that contains a moiety that a DNA polymerase cannot extend from.

Amplification primers are also used in the present invention. Two different amplification steps are performed in the preferred aspect. In the first, the 3' end  
10 (referenced to mRNA) of double stranded cDNA that has been cleaved and ligated with an adapter is amplified. For this amplification, either a single primer or a primer pair is used. The sequence of the single primer comprises at least a portion of the 5' sequence of the oligonucleotide primer used for first strand cDNA synthesis. The portion need only be long enough to serve as an amplification primer. The primer pair consists of a  
15 first primer whose sequence comprises at least a portion of the 5' sequence of the oligonucleotide primer as described above; and a second primer whose sequence comprises at least a portion of the sequence of one strand of the adapter in the non-complementary portion. The primer will generally contain all the sequence of the non-complementary portion, but may contain less of the sequence, especially when the non-  
20 complementary portion is very long, or more of the sequence, especially when the non-complementary portion is very short. In some embodiments, the primer will contain sequence of the complementary portion, as long as that sequence does not appreciably hybridize to the other strand of the adapter under the amplification conditions employed. For example, in one embodiment, the primer sequence comprises four bases  
25 of the complementary region to yield a 19 base primer, and amplification cycles are performed at 56°C (annealing temperature), 72°C (extension temperature), and 94°C (denaturation temperature). In another embodiment, the primer is 25 bases long and has 10 bases of sequence in the complementary portion. Amplification cycles for this

-17-

primer are performed at 68°C (annealing and extension temperature) and 94°C (denaturation temperature). By using these longer primers, the specificity of priming is increased.

The design of the amplification primers will generally follow well-known guidelines, such as average G-C content, absence of hairpin structures, inability to form primer-dimers and the like. At times, however, it will be recognized that deviations from such guidelines may be appropriate or desirable.

After amplification, the lengths of the amplified fragments are determined. Any procedure that separate nucleic acids on the basis of size and allows detection or identification of the nucleic acids is acceptable. Such procedures include slab gel electrophoresis, capillary gel electrophoresis, high performance liquid chromatography, and the like.

Electrophoresis is technique based on the mobility of DNA in an electric field. Negatively charged DNA migrates towards a positive electrode at a rate dependent on their total charge, size, and shape. Most often, DNA is electrophoresed in agarose or polyacrylamide gels. For maximal resolution, polyacrylamide is preferred and for maximal linearity, a denaturant, such as urea is present. A typical gel setup uses a 19:1 mixture of acrylamide:bisacrylamide and a Tris-borate buffer. DNA samples are denatured and applied to the gel, which is usually sandwiched between glass plates. A typical procedure can be found in Sambrook et al (*Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989) or Ausubel et al. (*Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995). Variations may be substituted as long as sufficient resolution is obtained.

Capillary electrophoresis (CE) in its various manifestations (free solution, isotachopheresis, isoelectric focusing, polyacrylamide gel. micellar electrokinetic "chromatography") allows high resolution separation of very small sample volumes. Briefly, in capillary electrophoresis, a neutral coated capillary, such as a 50 µm X 37 cm column (eCAP neutral, Beckman Instruments, CA), is filled with a linear

-18-

- polyacrylamide (*e.g.*, 0.2% polyacrylamide), a sample is introduced by high-pressure injection followed by an injection of running buffer (*e.g.*, 1X TBE). the sample is electrophoresed and fragments are detected. An order of magnitude increase can be achieved with the use of capillary electrophoresis. Capillaries may be used in parallel
- 5 for increased throughput (Smith *et al.* (1990) *Nuc. Acids. Res.* 18:4417; Mathies and Huang (1992) *Nature* 359:167). Because of the small sample volume that can be loaded onto a capillary, sample may be concentrated to increase level of detection. One means of concentration is sample stacking (Chien and Burgi (1992) *Anal. Chem* 64:489A). In sample stacking, a large volume of sample in a low concentration buffer is introduced to
- 10 the capillary column. the capillary is then filled with a buffer of the same composition, but at higher concentration, such that when the sample ions reach the capillary buffer with a lower electric field, they stack into a concentrated zone. Sample stacking can increase detection by one to three orders of magnitude. Other methods of concentration, such as isotachopheresis, may also be used.
- 15 High-performance liquid chromatography (HPLC) is a chromatographic separation technique that separates compounds in solution. HPLC instruments consist of a reservoir of mobile phase, a pump, an injector, a separation column, and a detector. Compounds are separated by injecting an aliquot of the sample mixture onto the column. The different components in the mixture pass through the column at different
- 20 rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase. IP-RO-HPLC on non-porous PS/DVB particles with chemically bonded alkyl chains can also be used to analyze nucleic acid molecules on the basis of size (Huber *et al.* (1993) *Anal. Biochem.* 121:351; Huber *et al.* (1993) *Nuc. Acids Res.* 21:1061; Huber *et al.* (1993) *Biotechniques* 16:898).
- 25 In each of these analysis techniques, the amplified fragments are detected. A variety of labels can be used to assist in detection. Such labels include, but are not limited to, radioactive molecules (*e.g.*,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{33}\text{P}$ ) fluorescent molecules, and mass spectrometric



-19-

tags. The labels may be attached to the oligonucleotide primers or to nucleotides that are incorporated during DNA synthesis, including amplification.

Radioactive nucleotides may be obtained from commercial sources; radioactive primers may be readily generated by transfer of label from  $\gamma$ -<sup>32</sup>P-ATP to a 5'-OH group  
5 by a kinase (*e.g.*, T4 polynucleotide kinase). Detection systems include autoradiograph, phosphor image analysis and the like.

Fluorescent nucleotides may be obtained from commercial sources (*e.g.*, ABI, Foster city, CA) or generated by chemical reaction using appropriately derivatized dyes. Oligonucleotide primers can be labeled, for example, using succinimidyl esters to  
10 conjugate to amine-modified oligonucleotides. A variety of florescent dyes may be used, including 6 carboxyfluorescein, other carboxyfluorescein derivatives, carboxyrhodamine derivatives, Texas red derivatives, and the like. Detection systems include photomultiplier tubes with appropriate wave-length filters for the dyes used. DNA sequence analysis systems, such as produced by ABI (Foster City, CA), may be  
15 used.

After separation of the amplified cDNA fragments, cDNA fragments which correspond to differentially expressed mRNA species are isolated, reamplified and sequenced according to standard procedures. For instance, bands corresponding the cDNA fragments can be cut from the electrophoresis gel, reamplified and subcloned  
20 into any available vector, including pCRscript using the PCR script cloning kit (Stratagene). The insert is then sequenced using standard procedures, such as cycle sequencing on an ABI sequencer.

An additional means of analysis comprises hybridization of the amplified fragments to one or more sets of oligonucleotides immobilized on a solid substrate. Historically, the  
25 solid substrate is a membrane, such as nitrocellulose or nylon. More recently, the substrate is a silicon wafer or a borosilicate slide. The substrate may be porous (Beattie *et al.* WO 95/11755) or solid. Oligonucleotides are synthesized in situ or synthesized prior to deposition on the substrate. Various chemistries are known for attaching

-20-

oligonucleotide. Many of these attachment chemistries rely upon functionalizing oligonucleotides to contain a primary amine group. The oligonucleotides are arranged in an array form, such that the position of each oligonucleotide sequence can be determined.

- 5 The amplified fragments, which are generally labeled according to one of the methods described herein, are denatured and applied to the oligonucleotides on the substrate under appropriate salt and temperature conditions. In certain embodiments, the conditions are chosen to favor hybridization of exact complementary matches and disfavor hybridization of mismatches. Unhybridized nucleic acids are washed off and
- 10 the hybridized molecules detected, generally both for position and quantity. The detection method will depend upon the label used. Radioactive labels, fluorescent labels and mass spectrometry label are among the suitable labels.

The present invention as set forth in the specific embodiments, includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a

15 granulocyte population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.

In general, the method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte population to a pathogen, comprises the steps of preparing

20 a first gene expression profile of a quiescent granulocyte population, preparing a second gene expression profile of a granulocyte population exposed to a pathogen, treating the exposed granulocyte population with the agent, preparing a third gene expression profile of the treated granulocyte population, comparing the first, second and third gene expression profiles and identifying agents that modulate the response of a granulocytic

25 population to the pathogen.

In another format, the method is used to identify a therapeutic agent that modulates the expression of genes in a granulocyte population found in a subject having a sterile inflammatory disease. The general method comprises the steps of preparing a first gene

-21-

expression profile of a granulocyte population in a subject having a sterile inflammatory disease, treating the granulocyte population with the agent, preparing a second gene expression profile of the treated granulocyte population, comparing the first and second gene expression profile with the gene expression profile of a normal granulocyte

- 5 preparation and identifying agents that modulate the expression of genes whose transcription levels are altered in the granulocyte population of the subject as compared with normal granulocyte population.

While the above methods for identifying a therapeutic agent comprise the comparison of gene expression profiles from treated and not-treated granulocytic cells, many other  
10 variations are immediately envisioned by one of ordinary skill in the art. As an example, as a variation of a method to identify a therapeutic or prophylactic agent that modulates the response of a granulocytic population to a pathogen, the second gene expression profile of a granulocyte population exposed to a pathogen and the third gene expression profile of the treated granulocyte population can each be independently  
15 normalized using the first gene expression profile prepared from a quiescent granulocyte population. Normalization of the profiles can easily be achieved by scanning autoradiographs corresponding to each profile, and subtracting the digitized values corresponding to each band on the autoradiograph from quiescent granulocytic cells from the digitized value for each corresponding band on autoradiographs  
20 corresponding to the second and third gene expression profiles. After normalization, the second and third gene expression profiles can be compared directly to detect cDNA fragments which correspond to mRNA species which are differentially expressed upon exposure of the granulocyte population to the agent to be tested.

### **Specific Embodiments**

#### **25 Example 1**

*Production of gene expression profiles generated from cDNAs made with RNA isolated from neutrophils exposed to virulent and avirulent bacteria.*

-22-

Expression profiles of RNA expression levels from neutrophils exposed to various bacteria offer a powerful means of identifying genes that are specifically regulated in response to bacterial infection. As an example, the production of expression profiles from neutrophils exposed to virulent and avirulent *E. coli* and *Y. pestis* allow the

5 identification of neutrophil genes that are specifically regulated in response to bacterial infection.

Neutrophils were isolated from normal donor peripheral blood following the LPS-free method. Peripheral blood was isolated using a butterfly needle and a syringe containing 5 cc ACD, 5 cc of 6% Dextran (in normal saline). After 30 minutes of

10 settling, plasma was collected and HBSS (without  $\text{Ca}^{++}$  or  $\text{Mg}^{++}$ ) was added to a total volume of 40 ml. The plasma was centrifuged (1500 rpm, for 15 m at 4°C), the supernatant decanted and cold HBSS added to resuspend the cells. The cell suspension was then layered onto a cold Ficoll Hypaque, centrifuged at 500xg for 30m at 4°C. The pellet contains polymorphonuclear neutrophils. Neutrophils can also be isolated by

15 other commonly used methods such as those disclosed in *Current Protocols of Immunology* (John Wiley & Sons, Inc.), Babior *et al.* (1981) In: *Leukocyte Function*, Cline, M.J. Ed., p.1-38 (Church Livingstone, NY), and Haslett *et al.* (1985) *Am. J. Pathol.* 119:101-110.

Following isolation, neutrophils were incubated with *E. coli* or *Y. pestis*. Before

20 incubation, bacteria are harvested and washed in phosphate buffered saline and opsonized either autologous human serum or complement factor C7 deficient human serum (SIGMA). Incubation was at a ratio of approximately a PMN:bacteria ratio of 1:20 in RPMI 1640 (HEPES buffered) with heat inactivated Fetal Bovine Serum at 37°C with gentle mixing in a rotary shaker bath

25 As controls, neutrophils were incubated with either bacterial lipopolysaccharide (LPS) or latex beads. LPS was added to approximately  $3.38 \times 10^8$  cells in 100 ml of RPMI containing 6% autologous serum to a final concentration of 1 ng/ml to 1 µg/l. Incubation proceeded for 30 or 120 minutes with gentle rotation in disposable

-23-

polycarbonate Erlenmeyer flasks at 37°C. After incubation, the cells were spun down and washed once with HBSS.

Total cellular RNA was prepared from untreated and treated neutrophils as described above using the procedure of Newburger *et al.* (1981) *J. Biol. Chem.* 266(24): 5 16171-7 and Newburger *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5215-5219. Ten micrograms of total RNA, the amount obtainable from about  $3 \times 10^6$  neutrophils, is sufficient for a complete set of cDNA expression profiles.

Synthesis of cDNA was performed as previously described by Prashar *et al.* in WO 97/05286 and in Prashar *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:659-663. Briefly, 10 cDNA was synthesized according to the protocol described in the GIBCO/BRL kit for cDNA synthesis. The reaction mixture for first-strand synthesis included 6 µg of total RNA, and 200 ng of a mixture of 1-base anchored oligo(dT) primers with all three possible anchored bases  
(ACGTAATACGACTCACTATAGGGCGAATTGGGTCGACTTTTTTTTTTTTTTTT  
15 TTn1 wherein n1=A/C or G) along with other components for first-strand synthesis reaction except reverse transcriptase. This mixture was incubated at 65°C for 5m, chilled on ice and the process repeated. Alternatively, the reaction mixture may include 10µg of total RNA, and 2 pmol of 1 of the 2-base anchored oligo(dT) primers as well such as RP5.0 (CTCTCAAGGATCTTACCGCTT<sub>18</sub>AT), or  
20 RP6.0 (TAATACCGCGCCACATAGCAT<sub>18</sub>CG), or RP9.2 (CAGGGTAGACGACGCTACGCT<sub>18</sub>GA) along with other components for first-strand synthesis reaction except reverse transcriptase. This mixture was then layered with mineral oil and incubated at 65°C for 7 min followed by 50°C for another 7 min. At this stage, 2µl of Superscript reverse transcriptase (200 units/µl; GIBCO/BRL) was  
25 added quickly and mixed, and the reaction continued for 1 hr at 45-50°C. Second-strand synthesis was performed at 16°C for 2 hr. At the end of the reaction, the cDNAs were precipitated with ethanol and the yield of cDNA was calculated. In our experiments, ~200 ng of cDNA was obtained from 10µg of total RNA.

-24-

The adapter oligonucleotide sequences were  
 A1 (TAGCGTCCGGCGCAGCGACGGCCAG) and  
 A2 (GATCCTGGCCGTCGGCTGTCTGTCTGGCGC). One microgram of  
 oligonucleotide A2 was first phosphorylated at the 5' end using T4 polynucleotide  
 5 kinase (PNK). After phosphorylation, PNK was heated denatured, and 1  $\mu$ g of the  
 oligonucleotide A1 was added along with 10 $\times$  annealing buffer (1 M NaCl/100 mM  
 Tris-HCl, pH8.0/10 mM EDTA, pH8.0) in a final vol of 20  $\mu$ l. This mixture was then  
 heated at 65°C for 10 min followed by slow cooling to room temperature for 30 min,  
 resulting in formation of the Y adapter at a final concentration of 100 ng/ $\mu$ l. About 20  
 10 ng of the cDNA was digested with 4 units of *Bgl* II in a final vol of 10  $\mu$ l for 30 min at  
 37°C. Two microliters ( $\approx$ 4 ng of digested cDNA) of this reaction mixture was then  
 used for ligation to 100 ng ( $\approx$ 50-fold) of the Y-shaped adapter in a final vol of 5  $\mu$ l for  
 16 hr at 15°C. After ligation, the reaction mixture was diluted with water to a final vol  
 of 80  $\mu$ l (adapter ligated cDNA concentration,  $\approx$ 50 pg/ $\mu$ l) and heated at 65°C for 10  
 15 min to denature T4 DNA ligase, and 2- $\mu$ l aliquots (with  $\approx$ 100 pg of cDNA) were used  
 for PCR.

The following sets of primers were used for PCR amplification of the adapter  
 ligated 3' -end cDNAs:

TGAAGCCGAGACGTCGGTCG(T)<sub>18</sub> n1, n2 (wherein n1, n2 = AA, AC, AG AT  
 20 CA CC CG CT GA GC GG and GT) as the 3' primer with A1 as the 5' primer or  
 alternatively

RP 5.0, RP 6.0, or RP 9.2 used as 3' primers with primer A1.1 serving as the 5' primer.  
 To detect the PCR products on the display gel, 24 pmol of oligonucleotide A1 or A1.1  
 was 5' -end-labeled using 15  $\mu$ l of [ $\gamma$ -<sup>32</sup>P]ATP (Amersham; 3000 Ci/mmol) and PNK  
 25 in a final volume of 20  $\mu$ l for 30 min at 37°C. After heat denaturing PNK at 65°C for  
 20 min, the labeled oligonucleotide was diluted to a final concentration of 2  $\mu$ M in 80  
 $\mu$ l with unlabeled oligonucleotide A1.1. The PCR mixture (20  $\mu$ l) consisted of 2  $\mu$ l  
 ( $\approx$ 100 pg) of the template, 2  $\mu$ l of 10 $\times$  PCR buffer (100 mM Tris-HCl, pH 8.3/500 mM

Figure 1 presents an autoradiogram of the expression profile generated from cDNAs made from RNA isolated from control (untreated) neutrophils (lanes 1, 5, 10, 13, 14 and 16), neutrophils incubated with avirulent *E. coli* K12 (lanes 2 and 11), virulent *Y. pestis* (lane 3), avirulent *Y. pestis* (lane 4), *Y. pestis yopB* (lane 6), *Y. pestis yopE* (lane 7), *Y. pestis yopH* (lane 8), latex beads (lanes 9 and 19), virulent Enterohemorrhagic *E. coli* (EHEC) (lane 12), LPS (lane 15), 1 ng/ml LPS for 30 minutes (lane 17), and LPS for 120 minutes (lane 18). The anchoring oligo d(T)18 n1, n2 has A and C at the n1 and n2 positions, respectively. The cDNAs were digested with *Bgl*II.

-26-

## Example 2

*Production of gene expression profiles generated from cDNAs made with RNA isolated from neutrophils exposed to virulent and avirulent bacteria and neutrophils exposed to cytokines.*

- 5 Neutrophils were isolated from normal donor peripheral blood following the LPS-free method as set forth in Example 1.

Neutrophils were incubated with virulent and avirulent *E. coli* or *Y. pestis*, LPS at 1ng/ml, GM-CSF at 100 units/ml, TNF $\alpha$  at 1000 units/ml, or  $\gamma$ IFN at 100 units/ml. The bacterial cells, LPS or cytokines were added to approximately  $3.38 \times 10^8$  cells in  
10 100 ml of RPMI containing 6% H1 autologous serum. Incubation proceeded for 2 to 4 hours, preferably 2 hours, with gentle rotation in disposable polycarbonate Erlenmeyer flasks at 37°C. After incubation, the cells were spun down and washed once with HBSS.

After incubation of the neutrophils, RNA was extracted and the cDNA profiles  
15 prepared as described in Example 1. Figure 2 is an autoradiogram of the expression profiles generated from cDNAs made with RNA isolated from control (untreated) neutrophils (lanes 1, 5, 10 and 14), neutrophils incubated with avirulent *E. coli* K12 (lanes 2 and 11), virulent *Y. pestis* (lanes 3 and 12), avirulent *Y. pestis* (lanes 4 and 13), 1ng/ml LPS (lanes 6 and 15), 100 units/ml GM-CSF (lanes 7 and 16), 1000 units/ml  
20 TNF $\alpha$  (lanes 8 and 17) and 100 units/ml  $\gamma$ IFN (lanes 9 and 18). The anchoring oligo d(T)18n1, n2 has A and C at the n1 and n2 positions for lanes 1-9 and G and G at the n1 and n2 for lanes 10-18. The cDNAs were digested with *Bgl*II.

As exhibited by Figure 2, the differential expression of mRNA species (as exhibited by cDNA fragments) in neutrophils exposed to virulent and avirulent *E. coli* and *Y.*  
25 *pestis* is not equivalent to the differential expression of mRNA species in neutrophils exposed to the various cytokines.

## Example 3



-27-

*Production of gene expression profiles generated from cDNAs made with RNA isolated from neutrophils exposed to bacteria using all 12 possible anchoring oligo d(T) n1,n2.*

Neutrophils were isolated from normal donor peripheral blood following the LPS-free method.

5 Neutrophils were incubated with *E. coli* or *Y. pestis*.

After incubation of the neutrophils, RNA was extracted and the cDNA profiles prepared as described in Example 1. Figure 3 is an autoradiogram of the expression profiles generated from cDNAs made with RNA isolated from control (untreated) neutrophils (lane 1), neutrophils incubated with avirulent *E. coli* K12 (lane 2), virulent  
10 *Y. pestis* (lane 3), avirulent *Y. pestis* (lane 4). The anchoring oligo d(T)18 n1 and n2 positions are indicated at the top of the figure. The cDNAs were digested with *Bgl*III.

Figure 4 represents a summary of genes which are differentially expressed in neutrophils upon exposure to virulent and avirulent *E. coli* and *Y. pestis*. Expression patterns are determined by visual examination of the autoradiography gels comparing  
15 band intensity between neutrophils exposed to the various bacteria. The autoradiography gels can also be scanned using commonly available equipment, such as a UMAX D-11L scanner. Bands which exhibit altered intensities in gene expression profiles from neutrophils exposed to the various bacteria when compared to the gene expression profile prepared from normal nonexposed neutrophils are then extracted  
20 from the display gel as previously described by in Example 1. The isolated fragments are then reamplified using 5' and 3' primers, subcloned into pCR-Script (Stratagene) and sequenced using an ABI automated sequencer.

Tables 1 and 2 represent a summary of cDNA bands which are differentially expressed in response to exposure to *E. coli*.

-28-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
846	Up	0	0	+-	2+	4+	AA	Yale	K02286	Urokinase Gene
847	Up	+-	+-	+-	+	2-3+	AA	Yale		
848	Up	+-	+-	0	+-	2+	AA	Yale		
849	Up	+-	+-	+-	+-	1-2+	AA	Yale		
850	Down	+	0	0	0	0	AA	Yale		
851	Up	0	0	0	0	+	AA	Yale		
852	Down	+	+	+-	+	0	AA	Yale		
853	Up	0	0	+-	+-	1-2+	AA	Yale		
854	Down	2+	+	+-		0 0 +-	AA	Yale	AF039715	C. elegans cosmid R06A10
T103	Up	3+	3+	3-4+	4-5+	4-5+	AA	Yale	M77693	HUMAN SSAT
855	Up	+-	+-	+-	+-	2+	AA	Yale	G29248	Human STS SHGC 17036
856	Up	+-	+-	+-	+-	2+	AA	Yale	A1038932	ox96ho8.x l soares senescent Fibroblasts
T104	Up	+	+	+-	+	2+	AA	Yale	AA931109	HUMAN CGAP KID3
T105		3-4+	3-4+	3-4+	3+	3+	AA	Yale	M11354	HUMAN H3.3 HISTONE
857		+	+	2+	+	+-	AA	Yale		
T107	Down	2-3+	2-3+	2-3+	2-3+	2+	AA	Yale	AA936257	on43e12 Sinel CGAP co8
858	Down	2+	2+	2+	2+	+-	AA	Yale		
859	Up	+-	+-	+-	2+	1-2+	AA	Yale	AC004987	DJ117312 0 Clone
860	Down	2-3+	2-3+	2+	2+	+-	AA	Yale		
861	Down	+	+	1-2+	+-	+-	AA	Yale		
862		2-3+	2-3+	2-3+	2-3+	2-3+	AA	Yale		
863	Down	2+	+	+-	+	+	AA	Yale	H26311	Cystic Fibrosis Antigen
864	Up	2+	2+	2+	2-3+	2-3+	AA	Yale		
865	Up	+	+	2+	2-3+	2+	AA	Yale		

SUBSTITUTE SHEET (RULE 26)

-29-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
866	Up	+-	+-	+	+	2+	AA	Yale	G06511	Human STS WI - 7311
867	Down	2+	2+	2+	2+	1-2+	AA	Yale		
868		+-	+-	+	2+	+-	AA	Yale		
869	Up	+	+-	+-	+-	2+	AC	Yale		
870	Up	0	0	0	+-	1-2+	AC	Yale		
871	Down	1-2+	1-2+	1-2+	+	+-	AC	Yale	AI026899	ov42do7.x I Soares testis nht
872		+	+	+-	+	+	AC	Yale	AA916304	on22do4.s i NCI CGAP Lu5
873	Up	+-_+	+-_+	+-_+	+-_+	2+	AC	Yale		
874	Up	1-2+	1-2+	1-2+	+	3+	AC	Yale	AI012139	EST 206590 (Rat Placenta)
875	Up	1-2+	1-2+	+	+	2-3+	AC	Yale		
876	Down	+	1-2+	2+	+	+-_0	AC	Yale	AI031728	ow39a05. xl Soares parathyroi d tumor NGHPA
877	Down	2-3+	2+	2+	+	+-	AC	Yale		
878	Down	2-3+	2-3+	2+	1-2+	0_+-	AC	Yale	AB002384	human mRNA for KIAA0386 gene
879		+	+-	0	0	+	AC	Yale		
880	Down	1-2+	+-	+-	+-	0	AC	Yale	AI016473	Transcripti on Factor BTF3
881	Down	+	+	1-2+	+	+-	AC	Yale	U82275	Human immunogl obulin-like transcript
882	Up	2+	2+	3+	3-4+	4+	AC	Yale	AI016664	Diamineac etyl Transferase

SUBSTITUTE SHEET (RULE 26)

-30-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
883	Down	1-2+	+	+	+	+-	AC	Yale	AA909168	.SI Soares NFLT GBC.SI
884	Down	+	+-	0	0	0	AC	Yale	AI039973	ox88e09.s i Soares senescent fibroblasts
885	Up	2+	1-2+	1-2+	2+	2-3+	AC	Yale	AI026998	ow41d06. si Soares parathyroi d tumor NB4PA
886		0	+-	+-	+-	0	AC	Yale		
887	Up	+-	0	0	+-	+	AC	Yale		
888	Up	0	0	0	+-	+	AC	Yale		
T7	Down	2+	1-2+	1-2+	+	+-	AC	Yale		
889	Up	+-	0	+-	+-	1-2+	AC	Yale		
T8	Down	2-3+	2+	2+	2+	1-2+	AC	Yale	G06680	HUMAN STS
890	Up	2+	2+	1-2+	+	+-	AC	Yale		
891	Down	+	+	+-	0	0	AC	Yale		
T76	Down	2-3+	2+	2+	1-2+	+-	AC	Yale	S73591	HUMAN H HCPA78 HOMOLO G
892	Down	3+	3+	3+	2+	+-	AC	Yale		
893		2+	+	1-2+	2+	2+	AC	Yale		
T98	Down	2-3+	2-3+	2-3+	2-3+	+-	AC	Yale	G06788	HUMAN STS
894	Down	2+	1-2+	1-2+	1-2+	+	AC	Yale	AF039656	Neuronal tissue- enricheda cidic protein
895	Down	2-3+	2-3+	2-3+	2+	+-	AC	Yale	AI016303	ot72d07.si soares total Fetus Nb3hf8
896	Down	2+	2+	1-2+	+-	0	AC	Yale	AC004987	DJ 1173I20 clone

SUBSTITUTE SHEET (RULE 26)

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
T81	Up	0	0	0	0	3+	AC	Yale	AA926999	om26do7 si Soares NFLTG3c 1s1
T82	Up	+	+	+	+-	2-3+	AC	Yale	AA926999	om26do7 .SI NFL TG3cSi
T83	Down	2+	2+	1-2+	1-2+	1-2+	AC	Yale		
T84		2-3+	2+	2-3+	3+	2-3+	AC	Yale		
T85	Down	+	+-	+-_0	+-_0	0	AC	Yale	O89052	HUMAN PROTON- ATPASE
897	Down	2+	1-2+	1-2+	+	+-	AC	Yale		
898		2+	2+	2+	2+	2+	AC	Yale		
899	Up	0	0	+-	+	3+	AC	Yale		
900	Down	1-2+	1-2+	+-	1-2+	0	AC	Yale		
901	Up	1-2+	+	1-2+	2+	2-3+	AC	Yale		
902	Down	2+	+	1-2+	1-2+	+	AC	Yale		
903	Down	2+	2+	3+	3-4+	+-	AC	Yale		
904		+	+	+-	+-	+	AC	Yale		
905	Up	0	+-	0	+	3-4+	AG	Yale	KO2286	Human urokinase gene 3' end
906	Up	0	0	+-	+-	1-2+	AG	Yale		
T111		+-_+	2+	+-	+-	+-	AG	Yale		
907		+-	+	+	2+	+-	AG	Yale		
908	Down	2+	2+	1-2+	2+	+-	AG	Yale		
909		+-	+-	+	2+	+-_0	AG	Yale		
910	Down	+	1-2+	0	+-	+-	AG	Yale	AC002091	Genomic Sequence Human 17, complete sequence
911	Down	2+	2+	2+	+	-	AG	Yale		
T113	Down	2+	2-3+	2+	2+	1-2+	AG	Yale	AI039523	ox371002. si Soares total fetus NB22HF8
912	Down	+-	+-	+-	-	-	AG	Yale		
913	Down	3+	3+	2-3+	2-3+	2+	AG	Yale		
914	Up	-	+-	-	-	+	AG	Yale		

-32-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
915	Up	+	1-2+	+	1-2+	2+	AG	Yale	AI038932	'ox96ho8. xi Soares senescent fibroblasts
T115		2+	2+	2+	2+	2+	AG	Yale		
916	Up	+	+	+	+	2+	AG	Yale	AC005038	Homosapi ens clone NH 048666122 HTGS phase 1
917	Down	+-	+-	-	-	-	AG	Yale		
918	Down	+	+	+	+	+-	AG	Yale		
919		+	+	-	+	+	AG	Yale		
920	Down	+	2+	+	+-	+-	AG	Yale		
T116	Down	3-4+	3-4+	3+	3+	3+	AG	Yale	M11353 H	Histone H3.3 (human)
T117	Up	+	+	+	2+	2+	AG	Yale		
921	Up	1-2+	2+	+	1-2+	2-3+	AG	Yale	AA912471	NCI CGAP GC4 Homo Sapiens
922	Down	1-2+	2+	+	1-2+	0-+-?	AG	Yale		
923	Down	+-	+-	-	+-	-	AG	Yale		
924	Up	0	0	0	+-	2+	AG	Yale		
925	Down	+-	+	0	0	0	AG	Yale		
926	Down	1-2+	1-2+	+	+-	2+	AG	Yale		
927	Up	+	?+	?+	2+	2+	AG	Yale	AA917380	0180a04.s i NCI CGAP KIDS
928	Up	0	0	0	0	2+	AG	Yale	AA926999	Homo Soares NFL TGBC si
929	Down	+	-	+	+	-	AG	Yale		

SUBSTITUTE SHEET (RULE 26)

-33-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
930	Up	0	0	0	+-	2+	AG	Yale	CH29R28051	AD000864 Homo Sapiens DNA from chromosome 19 cosmid R28051
931	Down	2+	2+	1-2+	1-2+	+	AG	Yale		
932	Up	+	+	+	+	2+	AG	Yale		
933	Down	4+	4+	3+	3+	3+	AG	Yale	m81637	Human grancalan mRNA
934		-	-	+-	+	+-	AG	Yale		
935	Down	+-	+	+	+	-	AG	Yale		
936		+	+-	+-	+	+	AG	Yale		
937	Up	+-	+-	+-	+-	+	AG	Yale		
938	Up	+-	+-	+-	+	2+	AT	Yale		
939	Up	0	0	+-	+-	2+	AT	Yale	AA916304	NCI CGAP LU5 HOMO SAPIENS
940		+	+	2+	2-3+	+	AT	Yale		
941	Up	+	+	+	+	2-3+	AT	Yale		
942	Up	+	+	+-	0	1-2+	AT	Yale		
943	Down	+-	+-	+-	+	-	AT	Yale		
944	Down	2+	+	+	+-	0	AT	Yale		
945	Up	+	+-	+	+-	+	2+	AT	AA928171	ON86HO3 SOARES NFL TGBC SI
946	Down	+	+	+	-	-	AT	Yale		
947		0	0	+	2+	0	AT	Yale		
948	Down	+	+	+	+-	-	AT	Yale		
949	Up	0	0	0	0	1-2+	AT	Yale	AI038932	HOMO SAPIENS SOARES SENESCENT FIBROBLASTS
950	Down	2-3+	2-3+	2-3+	2-3+	+	AT	Yale		
951	Up	+-	+-	+-	+-	+	AT	Yale		

SUBSTITUTE SHEET (RULE 26)

-34-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
952	Up	0	0	0	+	1-2+	AT	Yale	ACC0045 51	HOMO SAPIENS HTGS PHASE 1
953	Down	1-2+	+	1-2+	+	0	AT	Yale		
954	Up	+	+	+	1-2+	2-3+	AT	Yale	AI026998	HOMO SPAIENS SOARES PARATHY ROID TUMOR
955	Down	+	+	+	+	0	AT	Yale		
956	Up	+-	+-	+-	+-	+	AT	Yale		
957	Down	2+	2+	2+	2+	+	AT	Yale		
958	Up	+	+	+	+-	2+	AT	Yale		
T123	Up	+-	+-	+	2+	3+	AT	Yale	HSO2746 7	HUMAN BCL-2 RELATED (BF1-1) MRNA
959		+	+-	2+	+	+	AT	Yale		
960	Down	2+	+	+	+	+-	AT	Yale		
961		0	+-	2+	+-	0	AT	Yale		
962	Up	0	0	0	0	2+	AT	Yale		
T124	Up	3+	3+	3+	3-4+	3-4+	AT	Yale		
963	Down	2+	2+	2+	2+	+	AT	GLI		
964		+-	1-2+	+	+	+-	AT	GLI		
965	Up	0	0	+-	2+	1-2+	AT	GLI		
966	Down	+	+	+	1-2+	+-	AT	GLI		
967	Down	3+	3+	3+	3+	+-	AT	GLI	M60830	Human gene EVI2B#P
968	Down	+	+	2+	1-2+	+-	AT	GLI		
969	Up	0	0	0	+-	2+	AT	GLI		
970		0	0	0	2+	0	AT	GLI		
971	Down	+	+	2+	1-2+	+-	AT	GLI		
972	Down	+	+	+	+	-	AT	GLI		
973	Up	-	-	-	-	+	AT	GLI		
974	Up	+	+	2+	3+	2+	CA	Yale		
975		+	+-	1-2+	2+	?	CA	Yale	GBM7769 3	HUMAN DIAMINE ACETYLT RANSFER ASE

SUBSTITUTE SHEET (RULE 26)



-35-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
976		1-2+	1-2+	2-3+	3+	?	CA	Yale	Z14136	HOMO SAPIENS GENE SPERMID INE/SPER MINE N1- ACETYLT RANSFER ASE
T132							CA			
T133							CA			
977 Up		+	+	1-2+	2-3+	1-2+	CA	Yale		
T135							CA			
978 Down		2+	2+	2+	2+	-	CA	GLI	G05563	Human STS WI- 7246
979 Down		+	+	+	+	-	CA	GLI		
980		-	-	-	+	-	CA	GLI		
981 Down		+	+	+	+	-	CA	GLI	473168	Human cosmid LUCA22
982		-	-	-	+	-	CA	GLI	M55542	Human granulyte binding M55542 protein Isoform I
983		-	-	-	+	-	CA	GLI		
984		2+	2+	3+	3-4+	2+	CC	Yale	HS167A1 4	Z94721 HUMAN DNA SEQ- PAC167A 14 CHROM6 927
T139 Up		+	+	+	-	2+	CC	GLI		
985 Down		+	+	+	2+	+	CC	Yale		
T140 Up		+	+	+	+	2+	CC	GLI		

SUBSTITUTE SHEET (RULE 26)

-36-

Clones	mRNA Expression Pattern	Control	10'	30'	60'	120'	n1n2	Sequenced by	Closest Genbank Acc. #	Closest Homology
986	Down	2+	2+	1-2+	1-2+	+-	CC	Yale	AI015836	OV51H11. SI SOARES TESTIS NHT HOMO SAPIENS
987		2-3+	2+	2+	3-4+	3+	CC	Yale		

SUBSTITUTE SHEET (RULE 26)

-37-

TABLE 2

Cln	Sequence
846	<p>1 TCTCAGTGAG CTGAGATCAC ACCACTGCAC TCCAAGTGGG CGACAGAGCA</p> <p>51 AG</p>
854	<p>1 CACTTCCCC AAATTCTTTT GCCATAGTTC ACTCTCTACT GATAAGGCCA</p> <p>51 C</p>
855	<p>1 GGGAAAGTGG TGGGGTGGTG AGGGTCAATG TGCAGAAAAT CGATGTAACT</p> <p>51 TGTAATACAG TTGAGTCAAC TGTGTGTTCA CAACAACTCT GAGAGTTAAC</p> <p>101 ACCATTTCTA C</p>
856	<p>1 ATCTAAATAT TTTTCATACC GAGTTATTAA GGAGTCAGTA GTCTGTGCTA</p> <p>51 CAATGCTGCA AAAAGCATCA CGTGGAAGAA TGGGAACTAT GCGTACTTTA</p> <p>101 TGAAGTGATG TATAACACAA TGAAGTCTGT TTTACAACTA CAGTGCTGCA</p> <p>151 TTCAATTATC TTCCAT</p>

-38-

859	1 AAGCTCTGTA TACAAAAGTT ATTTATTTAG ATGTTGAGG CATGTCTCTC
	51 CTCACCTGTA AACTAACTGT TTTATAACAG CTTGTATCAC ATGTGTGAAG
	101 TTAATGAATG TAATACTCCA ACAAGCCATT CATCAGATTG GCCAACAGCT
	151 AGGATACAGT TAAATAATGG CGACCAGGTT GACAAGTCAT AATTGCGGTT
	201 TGGGGGACCG TAGTTGCACC TCACCTAGAC CAACGTACGC ATGGCACTCG
	251 ACCCAGGCGA ACAAATTAAT

SUBSTITUTE SHEET (RULE 26)

-39-

863	1 TTTCTCAAGA AGAGATAAGA ATGAAAAGTC ATAGAACACA TCATGGAGGA
	51 CCTGGACACA AATGCAGACA AGCAGCTGAG CTTCGAGGAG TTCATCATGC
	101 TGATGGCGAG GCTAACCTGG GCCTCCCACG AGAAGATGCA CGAGGGTGAC
	151 GATGGCCCTG GCCACCACCA TAAGCCAGGC CTCGGGGAGG GCACCCCCTA
	201 AGACCACAGT GGACAAGATC ACAGTGGCCA CGGACACGGC CACAGTCATG
	251 GTGGCCACGG CCACAGCCAC TAATCAGGAG GCCAGGCCAC CCTGCCTCTA
	301 CCCAACCAGG GCCCCGGGGC CTGTTATGTC AAAGTGTCTT GGCTGTGGGG

SUBSTITUTE SHEET (RULE 26)

-40-

866	<p>1 NGATCTTTCT AGGAGGGAGA CACTGGCCNC TCAAATCGTC CAGCGACCTT</p> <p>51 CCTCATCCAC CCCATCCCTC CCCAGTTCAT TGCACTTTGA TTAGCAGCGG</p> <p>101 AACAAAGGAGT CAGACATTTT AAGATGGTGG CAGTAGAGGC TATGGACAGG</p> <p>151 GCATGCCACG TGGGCTCATA TGGGGCTGGG AGTAGTTGTC TTTCCTGGCA</p> <p>201 CTAACGTTGA GCCCCTGGAG GCACTGAAGT GCTTAGTGTA CTTGGAGTAT</p> <p>251 TGGGGTCTGA CCCCAAACAC CTTCAGCTC CTGTAACATA CTGGCCTGGA</p> <p>301 CTGTTTTCTC TCGGCTCCCC ATGTGTCCTG GTTCCCGTTT CTCCACCTAG</p> <p>351 ACTGTGAACC TCTCGAGGGC AGGGACCACA CCCTGTACTG TTCGTGTCT</p> <p>401 TTCACAGCTC CTCCACAAT GCTGAATATA CAGCAGGTGC TCAATAAATG</p> <p>451 ATTCT</p>
871	1 GCAAGTGTGT TGTGTTACAG TGTCACAACA CCGAG
872	<p>1 GATCTCTCCC TACGCAAAAC GTATTGTAGT GAAAGGGTCT TCTTTACTAC</p> <p>51 CTTAATAAAA CAGCTAGTGT G</p>
874	<p>1 GATCTAAATA CAAAGGATAT ACAGTCTTGA ATCTAAAATA ATTTGCTAAC</p> <p>51 TATTTTGATT CTTCAGAGAG AACTACTA</p>

SUBSTITUTE SHEET (RULE 26)

-41-

876	1 GATCTAGTCC GGACATGCTG TGTATATTGT AACGTAAAT GAAAAAAGAA 51 CCCCCCTTTG TATTATAGTC ATGCGGTCTT ATGTATGATA AACAGTTG
878	1 GATCTTTTGT AGTCACCTCT GTATCTTATG TCTGGTTGAG GGGTGCTTTT 51 ACTTGTCTGG CATTTCATT CAATGATCTT TCAGTCATGT CAGTTAGACT 101 AAAAATTATT TCTG
880	1 CCCAAGCCCC TTGGACACTG CAGCTCTTTT CAGTTTTTGC TTACACACAA 51 TTCATTCTTT GCAGCTAATT AAGCCGAAGA AGCGTGCGGAA TCAAGTTTGG 101 AACAGAGATT AAAAAAGTTC TT
881	1 GCTCTGGAGG ACAATCCAGG AACTACATTA CCTGGACTGT ATGCTGGTCA 51 TTTCTACAGA CAGCATTCAG TATTTGAGTG TACGGTAACT GTCTGGGGTG 101 ATTCTATAA GATCATTATA CTG
882	1 GATCTTTCTC CTTGAATATC TTTCGATAAA CAACAAGGTG GTGTGATCTT 51 AATATATTTG AAAAAAACTT CATTCTCGTG AGTCATTTAA ATGTGTACAA 101 TGTACACACT GGTACTTAGA GTTTCTGTTT GATTCTTTTT TAATAAACTA 151 C
883	1 TGTCATCAT GCCCTGGGAC TGCTTCTCCA GCCAGGCGGG CGCCATACGT 51 CCCACACTAG TGAAGGTCAA TGTCTCAGAA CAACACCTCT AT

SUBSTITUTE SHEET (RULE 26)

-42-

884	<p>1 GATCTGGCCT GTTCCTGCGT CTGCGGAGCA GGCCTTGTCT CCCAGCTATC</p> <p>51 TATAACCTTA CCTAGAGTGT CGACTTGTGG GTTCCTGTTG CTGAGACTTC</p> <p>101 CTGGATGGAG CCGCCCTCAC CGCCGGACCC GTAGCACTGC GCGGAACTGT</p> <p>151 GTCCAATAAA GT</p>
885	<p>1 GATCTGATTT GCTAGTTCTT CCTTGTAGAG TTATAAATGG AAAGATTACA</p> <p>51 CTATCTGATT AATAGTTTCT TCATACTCTG CATATAATTT GTGGCTGCAG</p> <p>101 AATATTGTAA TTTGTTGCAC ACTATGTAAC AAAACAACTG AAGATATGTT</p> <p>151 TAATAAATAT TGTACT</p>
894	<p>1 GATCTTTATG AGAGCAGTAT TTTCTGTGTT TTCTTTTAA TTTACAGCCT</p> <p>51 TTCTTATTTT GATATTTTTT TAATGTTGTG GATGAATGCC AGCTTTCAGA</p> <p>101 CAGAGCCAC TTAGCTTGTC CACATGGATC TCAATGCCAA TCCTCCATTC</p> <p>151 TTCCTCTCCA GATATTTTTG GGAGTGACAA ACATTCTCTC ATCCTACTTA</p> <p>201 GCCTACCTAG ATTTCTCATG ACGAGTTAAT GCATGTCCGT GGTGGGTGC</p> <p>251 ACCTGTAGTT CTGTTTATTG GTCA</p>

SUBSTITUTE SHEET (RULE 26)



-43-

895	<p>1 GATCTAAGTT AGTCCAAAAG CTAAATGATT TAAAGTCAAG TTGTAATGCT</p> <p>51 AGGCATAAGC ACTCTATAAT ACATTAAATT ATAGGCCGAG CAATTAGGGA</p> <p>101 ATGTTTCTGA AACATTAAAC TTGTATTTAT GTCACTAAAA TTCTAACACA</p> <p>151 AACTTAAAAA ATGTGTCTCA TACATATGCT GTACTAGGCT TCATCATGCA</p> <p>201 TTTCTAAATT TGTGTATGAT TTGAATATAT GAAAGAATTT ATACACGAGT</p> <p>251 GTTATTTAAA ATTATTAAAA ATAAATGTA</p>
896	<p>1 GATCTTATAG GCCTGTCTCA TCAGGTGGT GTCAGCCCAG CTAGGATTAG</p> <p>51 GCAGAATTGG GTGGGGGCTG TAGTGCACTT TTGGCACAGC ATGTACCTGT</p> <p>101 CTGACTAATT CTCTGTCTTT TCTTTCCTGT TGCAATTCAT GGGTCTTAGC</p> <p>151 ATCTTCTGAA TGGTGTTTAG TAGGTCATCC TGTTGATTTC CTGCTAGGGA</p> <p>201 GTAGCATACT CTGGCTCTGT ACCACTGGCC AAGGGACTTA AGGATAGATG</p> <p>251 AAGGGCTGCA GTTTTGTTAA ATGGAACAAT ATGAAGAGA</p>
T10 3	<p>1 GATCTTCTC CTTGAGTATC TTTCGATAAA CAACAAAGTG GTGTGATCTT</p> <p>51 AATATATTTG AAAAAAATT CATTCCTGTG AGTCATTTAA ATGTGTACAA</p> <p>101 TGTACACACT GGTACTTAGA GTTCTGTTT GATTCTTTTT TAATAAACTA</p> <p>151 C</p>

SUBSTITUTE SHEET (RULE 26)

-44-

T10 4	<p>1 GATCTCTGCT CATAGAATGC ATGGGGAGCC TTCCAGCTCA CTCTCCCTGA</p> <p>51 GGACTGGCTT GACAGGGGCT ATGGGTTTGC TTTGG</p>
T10 5	<p>1 GATCTGCGCT TCCAGAGCGC AGCTATCGGT GCTTTGCAGG AGGCAAGTGA</p> <p>51 GGCCTATCTG GTTGGCCTTT TTGAAGACAC CAACCTGTGT GCTATCCATG</p> <p>101 CCAAACGTGT AACAATTATG CCAAAAGACA TCCAGCTAGC ACGCCGCATA</p> <p>151 CGTGGAGAAC GTGCTTAAGA ATCCACTATG ATGGGAAACA</p>
T10 7	<p>1 GATCTAAATG TGAACAGTTT ACTAATGCAC TACTGAAGTT TAAATCTGTG</p> <p>51 GCACAATCAA TGTAAGCATG GGGTTTGTTT CTCTAAATTG ATTTGTAATC</p> <p>101 TGAAATTACT GAACAACTCC TATTCCCATT TTTGCTAAAC TCAATTTCTG</p> <p>151 GTTTTGGTAT ATATCCATTC CAGCTTAATG CCTCTAATTT TAATGCCAAC</p> <p>201 AAAATTGGTT GTAATCAAAT TTAAAATAA TAATAATTTG GC</p>
T76	<p>1 GCCTTTTCGA TAGTTTCGGG TCAGGTAAAA ATGGCCTCCT GGCCTAAGCT</p> <p>51 TTTCAAGGTT TTTTGAGGC TTTTGTAAGG TTGTGATAGG AACTTTGGAC</p> <p>101 CTTGAACCTA CGTATCATGT GGAGAAGAGC CAATTTAACA AACTAGGAAG</p> <p>151 ATGAAAAGGG AAATTGTGGC CAAAACCTTG GGAAAAGGAG GTTCTTAAAA</p> <p>201 TCAGTGTTTC CCCTTT</p>

SUBSTITUTE SHEET (RULE 26)

-45-

T8	<p>1 GATCTATGCA CAAGAACCCC TTTACCCCAT GACCAACATC GCAGACACAT</p> <p>51 GTGCTGGCCA CCTGCTGAGC CCCAAGTGGA ACGAGACAAG CAGCCCTTAG</p> <p>101 CCCTTCCCCT CTGCAGCTTC CAGGCTGGCG TGCAGCATCA GCATCCCTAG</p> <p>151 AAAGCCATGT GCAGCCACCA GTCCATTGGG CAGGCAGATG TTCCTAATAA</p> <p>201 AGCT</p>
T81	<p>1 GATCTTTCCT CCTGGTACT GTGAAGCCTG TTGGTTTGCT GCTGTCGTTT</p> <p>51 TTGAGGAGGG CCCATGGGGG TAGGAGCAGT TGAACCTGGG AACAAACCTC</p> <p>101 ACTTGAGCTG TGCCTAGACA ATGTGAATTC CTGTGTTGCT AACAGAAGTG</p> <p>151 GCCTGTAAGC TCCTGTGCTC CGGAGGGAAG CATTTCTTGG TAGGCTTTGA</p> <p>201 TTTTCTGTG TGTTAAAGAA ATTCAATCTA CTCATGATGT GTTATGCATA</p> <p>251 AAACATTTCT GGAACATGGA TTTGTGTTCA CCTTAAATGT GAAAATAAAT</p> <p>301 CCTA</p>

SUBSTITUTE SHEET (RULE 26)

-46-

T82	1 ATCTTTCCTC CTGGTTACTG TGAAGCCTGT TGGTTTGCTG CTGTCGTTTT
	51 TGAGGAGGGC CCATGGGGGT AGGAGCAGTT GAACCTGGGA ACAAACCTCA
	101 CTTGAGCTGT GCCTAGACAA TGTGAATTCC TGTGTTGCTA ACAGAAGTGG
	151 CCTGTAAGCT CCTGTGCTCC GGAGGGAAGC ATTCCTGGT AGGCTTTGAT
	201 TTTTCTGTGT GTTAAAGAAA TTCAATCTAC TCATGATGTG TTATGCATAA
	251 AACATTTCTG GAACATGGAT TTGTGTTTAC CTAAATGTG AAAATAAATC
	301 CTATTTTCTA TG

SUBSTITUTE SHEET (RULE 26)

-47-

T85	<p>1 GATCTTTGGC AGCGCCATTG GACTCTTTGG GGTATCGTC GCAATTCTTC</p> <p>51 ATACCTCCAG AGTGAAGATG GGTGACTAGA TGATATGTGT GGGTGGGGCC</p> <p>101 GTGCCTCACT TTTATTTATT GCTGGTTTTTCTG GGGACAGC TGGAGCTGTG</p> <p>151 TCCCTTAACC TTTCAGAGGC TTGGTGTTCA GGGCCCTCCC TGCCTCCCC</p> <p>201 TCTTGCTGCG TGTGATTTG GAGGCACTGC AGTCCAGGCC GAGTCCTCAG</p> <p>251 TGCGGGGAGC AGGCTGCTGC TGCTGACTCT GTGCAGCTGC GCACCTGTGT</p> <p>301 CCCCCACCTC CACCCTCAAC CCATCTTCCT AGTGTTTGTG AAATAAACTT</p> <p>351 GGTAT</p>
T98	<p>1 GATCTTCCAC GTCTCCATCT CAGTACACAA TCATTTAATA TTTCCCTGTC</p> <p>51 TTACCCCTAT TCAAGCAACT AGAGGCCAGA AAATGGGCAA ATTATCACTA</p> <p>101 ACAGGTCTTT GACTCAGGTT CCAGTAGTTC ATTCTAATGC CTAGATTCTT</p> <p>151 TTGTGGTTGT TGCTGGCCCA ATGAGTCCCT AGTCACATCC CCTGCCAGAG</p> <p>201 GGAGTTCTTC TTTTGTGAGA GACACTGTAA ACGACACAAG AGAACAAGAA</p> <p>251 TAAAA</p>

-48-

933	1	TTATATATTT TTCTTAAATA TGTTTTATTG TCTTCTCTAA GCAAAAAGTT
	51	CTTAATAAAC ATAGTATTTT TCTCTGCGTC CTATTTCAAT AGTGAAGACA
	101	TAGTTCACCT AAAATGGCAT CCTGCTCTGA ATCTAGACTT TTTAGAAATG
	151	GCATATGTTT TTGATGATAT GTCAACATTC AAAATAGTCC TAATTAAATT
	201	GTTGGTTAAA TGTAATGTCA ACTCTTTATA AACTTAAATA TAAACAAGTA
	251	ATTAACCACT CTAAGTAATA AAACACATTT CACCTGTGTT CTGAGTGTA

SUBSTITUTE SHEET (RULE 26)

-49-

967	1 ATGAATCCTT GCCACCTCCA CCTGCAGAAC TGTATAAAT ATTACAACCTT
	51 GCTTTTITAGC TGATCTTCCA TCCTCAAATG ACTCTTTTTT CTTTATATGT
	101 TAACATATAT AAAATGGCAA CTGATAGTCA ATTTTGATTT TTATTCAGGA
	151 ACTATCTGAA ATCTGCTCAG AGCCTATGTG CATAGATGAA ACTTTTTTTT
	201 AAAAAAAGTT ATTTAACAGT AATCTATTTA CTAATTATAG TACCTATCTT
	251 TAAAGTATAG TACATTTTAC ATATGTAAAT GGTATGTTTC AATAATTTAA
	301 GAACTCTGAA ACAATCTACA TATACTTATT ACCCAGTACA GTTTTTTTTC
	351 CCCTGAAAAG CTGTGTATAA AATTATGGTG AATAAACTTT TATGTTTCCA
	401 TTTCAAAGAC CAGGGTGGAG AGGAATAAGA GACTAAGTAT
	ATGCTTCAAG
	451 TTTTAAATTA ATACCTCAGG TATTAAAATA AATATTCCAA GTTTGTGGGA
	501 AATGGGGAGA TTAAAATG

SUBSTITUTE SHEET (RULE 26)

-50-

978	1 TTATGTGGCC TTAGGTAGCT GGTGTACAT CTTCCCTAA ATCGATCCAT
	51 GTTACCACAT AGTAGTTTGA GTTAGGATT CAGTAACAGT GAAGTGTTA
	101 CTATGTGCAA CGGTATTGAA GTTCTTATGA CCACAGATCA
	TCAGTACTGT
	151 TGTCTCATGT AATGCTAAAA CTGAAATGGT CCGTGTTTGC ATTGTAAAA
	201 ATGATGTGTG AAATAGAATG AGTGCTATGG TGTTGAAAAC
	TGCAGTGTCC
	251 GTTATGAGTG CCAAAAATCT GTCTGAAGG CAGCTACACT
	TTGAAGTGGT
	301 CTTGAATAC TTTAATAAAA TTTATTTTGA TA

SUBSTITUTE SHEET (RULE 26)



-51-

981	1 TAGGTGAACC CTTATTCTGC AGGGTTCTCC CTCCCACCTT AAAGAAGTTC
	51 CCCTTATGTG GGTTCCTGG TGAATGGCCT TCCTTCCCGC CAGAGGGCTT
	101 GTGAACAGAC CGGAGAGGAC AGTGGATTGT TTATACTCCA GTGTACATAG
	151 TGTAATGTAG CGTGTTTACA TGTGTAGCCT ATGTTGTGGT CCATCAGCCC
	201 CTCACATTCC TAGGGGTTTG AGATGCTGTA CGTGGTATGT GACACCAAAG
	251 CCACCTCTGT CATTTGTTGT GATGTCITTT CTGGCAAAA GCCTTGTGTA
	301 TATTTGTATA TTACACATTT GTACAGAATT TTGGAAGATT TTCAGTCTAG
	351 TTGCCAAATC TGGCTCCTTT ACAAAG

SUBSTITUTE SHEET (RULE 26)

-52-

982	1 AGAATCTCTT ATGTTCTCAG AGGAAGGTGG AAGAAACCAT GGGCAGGAGT  51 AGGAATTGAG TGATAAACAA TTGGGCTAAT GAAGAAAACCT TCTCTTATTG  101 TTCAGTTCAT CCAGATTATA ACTTCAATGG GACACTTTAG ACCATTAGAC  151 AATTGACACT GGATTAAACA AATTCACATA ATGCCAAATA CACAATGTAT  201 TTATAGCAAC GTATAATTTG CAAAGATGGA CTTTAAAAGA TGCTGTGTAA  251 CTAAACTGAA ATAATTCAAT TACTTATTAT TTAGAATGTT AAAGCTTATG  301 ATAGTCTTTT CTAATTCTTA ACACTCATAC TTGAAATCTT TCTGAGTTTC  351 CCCAGAAGAG AATATGGGAT TTTTTTTGAC ATTTTGTACT CATTTAATAA  401 TGCTCTTGTG TTTACCTAGT ATATGTAGAC TTTGTCTTAT GTGTCAAAAG  451 TCCTAGGAAA GTGGTTGATG TTTCTTATAG CAATTAAAAA TTATT
-----	---

905	1 ATCTCAGTGA GCTGAGATCA CACCACTGCA CTCCAACCTGG GCGACAGAGC  51 AAGA
910	1 GATCTGTAAT TCAGGTGTTT TCTGTACAGC CATACGTAGA TAATGAAGCC  51 AAAAGGCTTT TAATTACACC ATGGCCTAAA ATAAATTCAT CA

-53-

915	<p>1 TATTTTTCAG CTGAGTTATT AGGGAGTCAT TATTCTGTGG TACAATGCTG</p> <p>51 CAAAAAGCAT CATGTGGAAG AATGGGAACT ATGCTTACAT TATGAAGTGA</p> <p>101 TGTATAACAC AATGCAAATC TG</p>
916	<p>1 GATCTTTTTT CATTAAAAAA TGTTCAATTA TCAGGCCGGG TGCAGTGGGG</p> <p>51 CTCATGCCTG TAATCCCAAC ACTTTGGGAG GCCGATGCAG GCGGATCACT</p> <p>101 AGGTCAGCAG ATCGAGACCA TCCTGGCTAA CACAGTGAAA CCT</p>
921	<p>1 GATCTTTATT TTTAGCCATG CACTGTTGTG AGGAAAATTA CCTGTCTTGA</p> <p>51 CTGCCATGTG TTCATCATCT TAAGTATTGT AAGCTGCTAT GTATGGATTT</p> <p>101 AAACCGTAAT CATATCTTTT TCCTATCTAT CTGAGGCACT GGTGGAATAA</p> <p>151 AGAACCTGTA TATTTTACTT TGTTGCAGAT AGTCTTGCCG CATCTTGGCA</p> <p>201 AGTTGCAGAG A</p>

SUBSTITUTE SHEET (RULE 26)

-54-

927	<p>1 GATCTTCGTG AAGACCTGAC TGGTAAGACC ATCACCTCG AGGTGGAGCC</p> <p>51 CAGTGACACC ATCGAGAATG TCAAGGCAAA GATCCAAGAT AAGGAAGGCA</p> <p>101 TCCCTCCTGA TCAGCAGAGG TTGATCTTTG CTGGGAAACA GCTGGAAGAT</p> <p>151 GGACGCACCC TGTCTGACTA CAACATCCAG AAAGAGTCCA CTCTGCACTT</p> <p>201 GGCCTGCGC TTGAGGGGGG GTGTCTAAGT TTCCCCTTTT AAGGTTTCAA</p> <p>251 CAAATTTTCAT TGCACTTTCC TTTCAATAAA GTTG</p>
928	<p>1 GATCTTTCCT CCTGGTTACT GTGAAGCCTG TTGGTTTGCT GCTGTCGTTT</p> <p>51 TTGAGGAGGG CCCATGGGGG TAGGAGCAGT TGAACCTGGG AACAAACCTC</p> <p>101 ACTTGAGCTG TGCCTAGACA ATGTGAATTC CTGTGTTGCT AACAGAAGTG</p> <p>151 GCCTGTAAGC TCCTGTGCTC CGGAGGGAAG CATTTCTTGG TAGGCTTTGA</p> <p>201 TTTTCTGTG TGTAAAGAA ATTCAATCTA CTCATGATGT GTTATGCATA</p> <p>251 AAACATTTCT GGAACATGGA TTTGTGTTCA CCTTAAATGT GAAAATAAAT</p>

SUBSTITUTE SHEET (RULE 26)

-55-

930	<p>1 GATCTTTCGG GTTCTCTCTC CTAATCAGC TCTTCGTTCC CAGAAACCCA</p> <p>51 GATGTAATCC CCCTACGTGG TGCTTGGGGC ATCCCGATAC CATCTCAGTA</p> <p>101 AATCTCCTAC ATTGGCCTCC TCACCCTCCC CGGGACCCAC ACCCTTCAGG</p> <p>151 TCCTCACCTT GAGACAGGAG GGACCCTCTG AGATCAGGGA CCCTTAGGTC</p> <p>201 TCACTGCTCT CTGATTCATA GCTCAACTGG GCCCCCAGTT CCATACCCCA</p> <p>251 GCATTCCCGG TCACTCCCTC CCTAATCTGA GCATCACTCA AGCTCTTTAT</p> <p>301 TAAACTC</p>
939	<p>1 ATCTCTCTCC CTACGCAAAA CCCTATTGTA GTAAAAAAGT CTTCTTTACT</p> <p>51 ATCTTAATAA AACAGATATT GTG</p>
945	<p>1 ATCTATTCTT GTAGATTTTT TTTGTGTGGG TCTATGTTTC ATTCATCTGC</p> <p>51 TTTCAGGCTG GATTTATAAC AAGCAGAACT TTTAAAACG</p>
949	<p>1 GATCTAAATA TTTTTCAGCT GAGTTATTAC GGAGTCATTA TTCTGTGGTA</p> <p>51 CAATGCTGCA AAAAGCATCA TGTGGAAGAA TGGGAAGTAT GCTTACTTTA</p> <p>101 TGAAGTGATG TATAACACAA TGAAA</p>
952	<p>1 CTACCCCGTG ACTCAGTTAC CTCCCACTGG GTCCCTCCCA CATCATGTGG</p> <p>51 GAATTGTAGG AGCTACAATT CAAGATGAGA TTTGGATGGG GTCACAGCCA</p> <p>101 AACCATATCA CTGAGGTATC AAGGAGATTC TT</p>

SUBSTITUTE SHEET (RULE 26)

-56-

954	<p>1 GATCTGATTT GCTAGTTCTT CCTTGTAGAG TTATAAATGG AAAGATTACA</p> <p>51 CTATCTGATT AATAGTTTCT TCATACTCTG CATATAATTT GTGGCTGCAG</p> <p>101 AATATTGTAA TTTGTTGCAC ACTATGTAAC AAAACAACTG AAGATATGTT</p> <p>151 TAATAAATAT TGTACTTATT G</p>
975	<p>1 NGATCTTTCT CCTTGAATAT CTTTCGATAA ACAACAAGGT GGTGTGATCT</p> <p>51 TAATATATTT GAAAAAACT TCATTCTCGT GAGTCATTTA AATGTGTACA</p> <p>101 ATGTACACAC TGGTACTTAG AGTTTCTGTT TGATTCTTTT TTAATAAA</p>
976	<p>1 GATCTGCTAG AAGATGGTTT TGGAGAGCAC CCCTTTTACC ACTGCCTGGT</p> <p>51 TGCAGAAGTG CCGAAAGAGC ACTGGACTCC GGAAGGTAAC CCCTCGCCCT</p> <p>101 TTCCAGAAGC CAGAGAGACC AAGTGTTATG TAAGAAGTAG TGTCGGCTGT</p> <p>151 GTAGAACCAC TGA CTACACA GGCCGAAGTT ACTGAGAACT TGGACAGAAA</p> <p>201 AAATAGCCAG CAAGTGTT</p>
984	<p>1 CATTACACA TTAACTTCC TTCCATACCA AATCTT</p>
986	<p>1 GATCTGGACA GCAGAATGTT ATAACGCAAG TTCATGTGTT GCTCCCAACT</p> <p>51 CCATTCTCTT TTCTCTCGTG CAACCAGTTT GCCCATCTCTC TTCCTATTAC</p> <p>101 TTGCTC</p>

SUBSTITUTE SHEET (RULE 26)

-57-

T11 3	1 TCAGAGATTT GCAAAGACTC ACGTTTTTGT TGTTTTCTCA TCATTCCATT  51 GTGATACTAA GAAACTAAGA AGCTTAATGA AAAGAAATAA AATGCCTATG
T11 6	1 GATCTGCGCT TCCAGAGCGC AGCTATCGGT GCTTTGCAGG AGGCAAGTGA  51 GGCCTATCTG GTTGGCCTTT TTGAAGACAC CAACCTGTGT GCTATCCATG  101 CCAAACGTGT AACAATTATG CCAAAAGACA TCCAGCTAGC ACGCCGCATA  151 CGTGGAGAAC GTGCTTAAGA ATCCACTATG ATGGGAAACA
T12 3	1 GATCTGTGAA ATGCTATCTC TCCTGAAGCA ATACTGTTGA CCAGAAAGGA  51 CACTCCATAT TGTGAAACCG GCCTAATTTT TCTGACTGAT ATGGAAACGA  101 TTGCCAACAC ATACTTCTAC TTTTAAATAA ACAACTTTGA TGATGTAAC 151 TGACCTTCCA GAGTTATGGA AATTTTGTCC CCATGTAATG AATAAATTGT  201 ATGTAT

**Example 4**

*Production of expression profiles generated from cDNAs made with RNA isolated from neutrophils isolated from a subject with a sterile inflammatory disease.*

Neutrophils are isolated from normal donor peripheral blood following the LPS-free  
5 method or from subjects exhibiting the symptoms of a sterile inflammatory disease.  
RNA is extracted and the gene expression profiles prepared as described in Example 1.

-58-

To determine the identity of genes (cDNAs) which are differentially expressed in the neutrophils isolated from a subject exhibiting the symptoms of a sterile inflammatory disease, the cDNA profiles prepared from neutrophils from said subject are compared to profiles prepared from neutrophils isolated from the normal donor.

- 5 Bands which exhibit altered intensities when compared between the gene expression profiles prepared from neutrophils from said subject and profiles prepared from neutrophils isolated from the normal donor are then extracted from the display gel as previously described in Example 1. The isolated fragments are then reamplified using 5' and 3' primers, subcloned into pCR-Script (Stratagene) and sequenced using an ABI  
10 automated sequencer.

Once sequences are obtained which correspond to the bands of interest, the sequences can be compared to known nucleic acid sequences in the available data bases.

#### Example 5.

- Method to identify a therapeutic or prophylactic agent that modulates the response of a*  
15 *granulocyte population to a pathogen*

The methods set forth in Example 1 offer a powerful approach for identifying therapeutic or prophylactic agents that modulate the expression of neutrophils or other granulocytic cells to a pathogen. For instance, profiles of normal granulocytes and neutrophils or other granulocytes exposed to pathogens such as *E. coli*, *Y. pestis* or other  
20 pathogenic bacteria are prepared as set forth in Example 1. A profile is also prepared from a granulocyte population that has been exposed to the pathogen in the presence of the agent to be tested. By examining for differences in the intensity of individual bands between the three profiles, agents which up or down regulate genes of interest in the pathogen exposed granulocytes can be identified.

- 25 As a specific example, screening for agents which up or down regulate the expression of human pre-B cell enhancing factor (PBEF) can be identified by



-59-

examining the differences in band intensity between profiles produced from normal granulocytes, granulocytes exposed to the pathogen and granulocytes exposed to the pathogen in the presence of the agent to be tested. As shown in Figure 4, PBEF is expressed at high levels when exposed to avirulent bacteria, including *E. coli* K12 and  
5 avirulent *Y. pestis* but is not expressed at high levels in granulocytes exposed to pathogenic *Y. pestis*. Agents that up regulate PBEF expression as demonstrated by increased band density in the profile produced from granulocytic cells exposed to virulent *Y. pestis* in the presence of the agent may be useful in modulating the response of neutrophils to bacterial infection.

-60-

## Example 6

*Method to identify a therapeutic or prophylactic agent that modulates the expression of genes in a granulocyte cell population found in a subject having a sterile inflammatory disease.*

- 5 The methods set forth in Example 4 offer a powerful approach for identifying therapeutic or prophylactic agents that modulate the expression of neutrophils or other granulocytic cells in subjects exhibiting the symptoms of a sterile (non-infectious) inflammatory disease. For instance, gene expression profiles of normal granulocytes and granulocytes from a subject exhibiting the symptoms of a sterile inflammatory
- 10 disease are prepared as set forth in Examples 1 and 4. A profile is also prepared from a granulocyte population from a subject exhibiting the symptoms of a sterile inflammatory disease that have been exposed to the agent to be tested. By examining these profiles for differences in the intensity of band between the three profiles, agents which up or down regulate genes of interest in a granulocytic population from a subject
- 15 exhibiting the symptoms of a sterile inflammatory disease can be identified. Agents that up-regulate a gene or genes that are expressed at abnormally low levels in a granulocytic cell population from a subject exhibiting the symptoms of a sterile inflammatory disease compared to a normal granulocytic cell population as well as agents that down regulate a gene or genes that are expressed at abnormally high levels
- 20 in a granulocytic cell population from a subject exhibiting the symptoms of a sterile inflammatory disease are contemplated.

## Example 7

- Production of solid support compositions comprising groupings of nucleic acids that correspond to the genes whose expression levels are modulated in a granulocytic*
- 25 *population that has been exposed to a pathogen or nucleic acids that correspond to the genes whose expression levels are modulated in a granulocytic cell population from a subject having a sterile inflammatory disease.*

-61-

As set forth in Examples 1-4, expression profiles from granulocytic cells exposed to a pathogen or granulocytic cells from a subject having a sterile inflammatory disease yield the identity of genes whose expression levels are modulated compared to normal, quiescent granulocytic cells.

- 5 Solid supports can be prepared that comprise immobilized representative groupings of nucleic acids corresponding to the genes or fragments of said genes from granulocytic cells whose expression levels are modulated in response to exposure to a pathogen or in a subject having a sterile inflammatory disease. For instance, representative nucleic acids can be immobilized to any solid support to which nucleic
- 10 acids can be immobilized, such as positively charged nitrocellulose or nylon membranes (see Sambrook *et al.* (1989) *Molecular Cloning: a laboratory manual* 2nd., Cold Spring Harbor Laboratory) as well as porous glass wafers such as those disclosed by Beattie (WO 95/11755). Nucleic acids are immobilized to the solid support by well established techniques, including charge interactions as well as attachment of
- 15 derivatized nucleic acids to silicon dioxide surfaces such as glass which bears a terminal epoxide moiety. A solid support comprising a representative grouping of nucleic acids can then be used in standard hybridization assays to detect the presence or quantity of one or more specific nucleic acid species in a sample (such as a total cellular mRNA sample or cDNA prepared from said mRNA) which hybridize to the nucleic acids
- 20 attached to the solid support. Any hybridization methods, reactions, conditions and/or detection means can be used, such as those disclosed by Sambrook *et al.* (1989) *Molecular Cloning: a laboratory manual* 2nd., Cold Spring Harbor Laboratory, Ausbel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience or Beattie (WO 95/11755).
- 25 One of ordinary skill in the art may determine the optimal number of genes that must be represented by nucleic acid fragments immobilized on the solid support to effectively differentiate between samples, *e.g.* neutrophils exposed to various pathogens or neutrophils isolated from a patient to be tested for a sterile inflammatory disease.

-62-

Preferably, at least about 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000 or more preferably, substantially all of the detectable mRNA species in a cell sample or population will be present in the gene expression profile or array affixed to a solid support. More preferably, such profiles or arrays will contain a sufficient representative  
5 number of mRNA species whose expression levels are modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In most instances, a sufficient representative number of such mRNA species will be about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100 in number and will be represented by the nucleic acid molecules or fragments of nucleic acid molecules immobilized on the solid  
10 support. For example, nucleic acids encoding all or a fragment of one or more of the known genes or previously reported ESTs that are identified in Fig.4 and Tables 1 and 2 may be so immobilized. The skilled artisan will be able to optimize the number and particular nucleic acids for a given purpose, i.e., screening for modulating agents, identifying activated granulocytes, etc.

#### 15 Example 9.

##### *Method of diagnosing exposure of a subject to a pathogen.*

Expression profiles of RNA expression levels from neutrophils exposed to various bacteria, such as those disclosed in Examples 1 and 3, offer a powerful means to diagnose exposure of a subject to a pathogen. As set forth in Examples 1 and 3, the  
20 display patterns generated from cDNAs made with RNA isolated from neutrophils exposed to pathogenic and nonpathogenic *E. coli* and *Y. pestis* exhibit unique patterns of cDNA species corresponding to neutrophil mRNA species (genes) whose expression levels are modulated in response to contact of the neutrophils with the bacteria. The contacting of neutrophils with different species of pathogens may result in the  
25 production of expression profiles that are unique to each pathogen species or strain. These unique expression profiles are useful in diagnosing whether a subject has been exposed to or is infected with a given pathogen.

-63-

Briefly, expression profiles are produced as set forth in Example 1 using neutrophil samples exposed to various pathogens, such as pathogenic strains of *E. coli*, *Y. pestis*, Staphylococci, Streptococci or any other bacterial species. Neutrophils are then isolated from the subject to be tested for exposure to a pathogen and an expression profile

5 prepared from the subject's neutrophils by the methods set forth in Example 1. The expression profile prepared from the subject neutrophils can then be compared to the expression profiles prepared from neutrophils exposed to the various pathogen species or strains to determine which expression profile most closely matches the expression profile prepared from the subject, thereby, diagnosing exposure of the subject to a

10 pathogen.

#### Example 10

##### *Method of diagnosing a sterile inflammatory disease in a subject*

Expression profiles of RNA expression levels from neutrophils isolated from a subject having a sterile inflammatory disease, such as those disclosed in Example 4,

15 offer a powerful means to diagnose inflammatory diseases such as psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and periodontal disease. As set forth in Example 4, the gene expression profiles generated from cDNAs made with RNA isolated from

20 neutrophils from subjects having various sterile inflammatory diseases may exhibit unique patterns of cDNA species corresponding to neutrophil mRNA species (genes) whose expression levels are modulated during the inflammatory process. These unique expression profiles are useful in diagnosing whether a subject has a sterile inflammatory disease.

25 Briefly, expression profiles are produced as set forth in Examples 1 and 4 using neutrophil samples isolated from patients with various sterile inflammatory diseases. Neutrophils are then isolated from the subject to be tested and an expression profile

-64-

prepared from the subject's neutrophils by the methods set forth in Example 1. The expression profile prepared from the subject neutrophils can then be compared to the expression profiles prepared from neutrophils isolated from patients with various sterile inflammatory diseases to determine which expression profile most closely matches the  
5 expression profile prepared from the subject, thereby, diagnosing whether the subject has a sterile inflammatory disease.

It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It therefore should be apparent to those of ordinary skill in the art that various modifications and equivalents can be  
10 made without departing from the spirit and scope of the invention. All articles, patents and texts that are identified above are incorporated by reference in their entirety.

-65-

**What is Claimed Is:**

1. A method to identify a therapeutic or prophylactic agent that modulates the response of a granulocyte population to a pathogen, comprising the steps of:  
preparing a first gene expression profile of a quiescent granulocyte  
5 population;  
preparing a second gene expression profile of a granulocyte population exposed to the pathogen;  
treating the exposed granulocyte population with the agent;  
preparing a third gene expression profile of the treated granulocyte  
10 population;  
comparing the first, second and third gene expression profiles; and  
identifying agents that modulate the response of a granulocytic population to the pathogen.
- 15 2. The method of claim 1, wherein the granulocyte population is selected from the group consisting of a population of neutrophils, basophils and eosinophils.
3. The method of claim 1, wherein the pathogen is selected from the group consisting of bacteria, viruses, fungi and parasites.
4. The method of claim 3 wherein the pathogen is selected from the group  
20 consisting of Gram positive and Gram negative bacteria.
5. The method of claim 3, wherein the pathogen is selected from the group consisting of Staphylococci, Streptococci, Clostridia, Neisseria, Enterobacteriaceae, Helicobacter, Vibrio, Campylobacter, Pseudomonas, Haemophilus, Bordetella,

-66-

Mycoplasma, Ureaplasma, Legionella, Spirochetes, Mycobacteria, Actinomyces, Nocardia, Chlamydia, Rickettsia, Coxiella, Ehrlichia, Rochalimaea, Brucella, Yersinia, Francisella, and Pasteurella.

6. A method to identify a therapeutic agent that modulates the expression of at least one gene in a granulocyte population found in a subject having a sterile inflammatory disease; comprising the steps of:

preparing a first gene expression profile of a granulocyte population in a subject having the sterile inflammatory disease;

treating the granulocyte population with the agent;

10 preparing a second gene expression profile of the treated granulocyte population;

comparing the first and second gene expression profiles with the gene expression profile of a normal granulocyte preparation; and

15 identifying an agent that modulates the expression of at least one gene whose transcription levels are altered in the granulocyte population of the subject as compared with normal granulocyte population.

7. The method of claim 6, wherein the granulocyte population is selected from the group consisting of a population of neutrophils, basophils and eosinophils.

8. The method of claim 6, wherein the sterile inflammatory disease is selected from the group consisting of psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and periodontal disease.



-67-

9. A composition comprising a grouping of nucleic acids that correspond to the genes or fragments of genes whose expression levels are modulated in a granulocyte population that has been exposed to a pathogen affixed to a solid support.

10. A composition comprising a grouping of nucleic acids that correspond to the  
5 genes or fragments of genes whose expression levels are modulated in a granulocyte population found in a subject having a sterile inflammatory disease affixed to a solid support.

11. A method of diagnosing exposure of a subject to a pathogen, comprising the steps of:

10 preparing a first gene expression profile of a granulocyte population from the subject;

comparing the first gene expression profile to a second gene expression profile of a granulocyte population exposed to the pathogen and to a third gene expression profile of a normal granulocyte preparation; and

15 determining if the subject was exposed to a pathogen.

12. A method of diagnosing a sterile inflammatory disease in a subject, comprising the steps of:


preparing a first gene expression profile of a granulocyte population from the subject;


20 comparing the first gene expression profile to at least one second gene expression profile from a granulocyte population from a subject having a sterile inflammatory disease and to a third gene expression profile of a normal granulocyte population; and


determining if the subject has a sterile inflammatory disease.

-68-


13. The method of claim 12, wherein the sterile inflammatory disease is **glomerulo-nephritis**.

**FIG. 1**

**FIG. 2**

**FIG. 3**

SUBSTITUTE SHEET (RULE 26)

**FIG. 3(Cont.)**

SUBSTITUTE SHEET (RULE 26)

Differential Display Summary of Results (I) Known Genes

No.	Clones	NIN2	Expression Patterns				Gene Bank Search and Analysis
			Control	E. coli	Virulent	Avirulent	
1	NP102-3	AA	0	+	0	+	NADH-ubiquinone oxidoreductase ASH subunit
2	IN12-B12	AC	+	+++	++	++++	human ubiquitin polyubiquitin
3	NP104-5	AA	+	+++	++	++	MAP kinase kinase 3b
4	NP131-3	CA	++	+	++++	++++	cdc2/CDC28-like protein kinase (clk1)
5	B20-4	AC	+++	++	±	+	human cyclin-dependent kinase inhibitor
6	NP119-1	AG	0	+	0	++	bcl-2 related (bfl-1) mRNA
7	NP126-3	AT	0	+++	+	+++	human B-cell lymphoma 3-encoded protein bcl-3 mRNA
8	NP124-3	AT	++	+++	++	+++	helix-loop-helix basic phosphoprotein (GOS8)
9	B14-3	AC	++	+++	0	+	human nucleolar phosphoprotein B23 (nucleophosmin)
10	IN23-E11	AC	±	+++	+	+++	LD78 β (human homolog of mouse MIP1α)
11	NP125-2	AT	0	++	±	++	LD78 receptor (HM74)
12	NP149-1	CG	+++	+	++	++	vacuolar H <sup>+</sup> pumping ATPase (16KD proteolipid subunit)
13	B23-2	AC	++	+++	+	++	vacuolar H <sup>+</sup> pumping ATPase (56KD subunit)
14	NP139-1	CC	±	++	+	+++	plasma membrane Ca <sup>2+</sup> pumping ATPase (56KD subunit)

FIG. 4

SUBSTITUTE SHEET (RULE 26)

## Differential Display Summary of Results (I) Known Genes

No.	Clones	N1N2	Expression Patterns				Gene Bank Search and Analysis
			Control	E. coli	Virulent	Avirulent	
15	NP105-1	AA	++++	±	+	++	human H3.3 gene exon 4
16	NP128-3	CA	0	+	++	++++	ribosomal protein S19
17	IN20-E8	AC	+	±	++	±	ribosomal protein S20
18	NP127-2	AT	+	+	±	+	poly(A) binding protein II
19	NP103-3	AA	++	+++	+	++++	Spermidine/Spermine N1-acetyltransferase
20	NP132-2	CA	+	±0	+	++	human GDP-dissociation inhibitor (LY-GDI)
21	B4-1	AC	+++	+++	+	+	bovine GTP binding regulatory protein $\gamma$ -6 subunit
22	NP107-2	AA	++++	++	+++	+++	human B4-2 protein
23	NP156-1	CG	++	+	++	++	ras-related protein p23/Rab-7
24	B5-4	AC	±	+++	+	++	mouse ras-related YTP1 protein/Rab-1A
25	B14-4	AC	+	+++	+	++++	human pre-B cell enhancing factor (PBEF)
26	B22-2	AC	++	+++	+	++	human complement decay accelerating factor
27	Bam1	AC	+	++	++++	++	TNF $\alpha$ inducible protein B94

FIG. 4 (CONT'D)



Differential Display Summary of Results (I) EST Sequences

No.	Clones	N1N2	Expression Patterns				Gene Bank Search and Analysis
			Control	E. coli	Virulent	Avirulent	
1	NP101-3	AA	++	++	0	++	EST (GB/L81699/HSL81699)
2	NP108-3	AA	++	+	+	++	EST (GB/R09487/R09487)
3	NP113-2	AG	++	+	++	+	EST (GB/U79267/HSU79267)
4	NP114-2	AG	+++	+	++	+++	EST (GB/N26756/N26756)
5	NP115-3	AG	++	+	+++	+++	EST (GB/L49761/HUM78188)
6	NP116-3	AG	+	+	++	+	EST (EMB/F10736/HSC3JC022)
7	NP117-2	AG	±	++++	++	++++	EST (GB/AA004905/AA004905)
8	NP120-3	AG	±	+	++	+	EST (GB/R16810/R16810)
9	NP121-2	AG	±	++	+	++	EST (GB/AA159075/AA159075)
10	NP122-1	AT	0	+	±	++	EST (GB/AA016979/AA016979)
11	NP133-1	CA	+++	++	+++	+++	EST (GB/AA190718/AA190718)
12	NP134-2	CA	0	±	++	+	EST (GB/T29287/T29287)
13	NP138-1	CC	+	++	+	+++	EST (GB/T58520/T58520)
14	NP150-1	CG	+	+++	+++	+++	EST (GB/AC001223/HSAC001223)
15	B7-1	AC	++	+	+	0	EST (DJB/D60083/HUM084H05A)


FIG. 4 (CONT'D)

Differential Display Summary of Results (I) EST Sequences

No.	Clones	N1N2	Expression Patterns				Gene Bank Search and Analysis
			Control	E. coli	Virulent	Avirulent	
16	B8-1	AC	+++	+	++	0	EST (GB/R37008/R37008)
17	B10-1	AC	+++	++	0	+	EST (GB/W67981/W67981)
18	B12-2	AC	++	+++	+	+	EST (GB/N24729/N24729)
19	B13-4	AC	+++	++	+	+	EST (GB/N23012/N23012)
20	B15-2	AC	+++	±	++	±	EST (GB/R49664/R49664)
21	B17-2	AC	++++	+++	++	+	EST (GB/T34605/T34605)
22	B18-2	AC	++++	++	+++	+	EST (GB/AA055573/AA055573)
23	B19-5	AC	+	++	+	±	EST (GB/AA076421/AA076421)
24	B21-3	AC	+++	+++	+	++	EST (GB/AA150905/AA150905)
25	IN10-B10	AC	+	+++	+	+++	EST (GB/N21073/N21073)
26	IN19-E7	AC	0	++++	0	+	EST (GB/AA044087/AA044087)
27	IN21-E9	AC	+	+++	+	++	EST (GB/H44997/H44997)
28	IN22-E10	AC	++++	++	+++	+	EST (GB/N50114/N50114)
29	Bcl	AC	+++	+++	+	++	EST (EMB/Z39133/HSC11B122)

FIG. 4 (CONT'D)


SUBSTITUTE SHEET (RULE 26)


**FIG. 5**

SUBSTITUTE SHEET (RULE 26)

**FIG. 5 (Cont.)**

AA GA CA AG GG CG  
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4



**FIG. 6**

1. Neutrophils alone
2. Neutrophils + *E.coli*
3. Neutrophils + Virulent *y. pestis*
3. Neutrophils + Avirulent *y. pestis*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/17284

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C07H 21/04; C12P 19/34

US CL : 435/6, 91.2; 536/24.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/24.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97/05286 A1 (YALE UNIVERSITY) 13 February 1997, see entire document.	1-13
Y	TAM, F.W.K., et al., Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis. Kidney Internat. 1996, Vol. 49, pages 715-721, see especially the abstract, page 716, col. 1, and Figure 1.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 10 NOVEMBER 1998	Date of mailing of the international search report <b>22 DEC 1998</b>
---	--

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARY TUNG

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17284

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

MEDLINE, SCISEARCH, CANCERLIT, BIOSIS, EMBASE, WPIDS, USPATFULL, APS

search terms: glomerulonephritis, neutrophil, polymorphonucleocyte, granulocyte, bacteria, virus, fungus, parasite, gene, DNA, nucleic acid, inflammation, gene expression

